Studies on human serum cholinesterases by King, John
Studies  on  Human  Serum  Cholinesterases. 
John  King,  Department  of  Pathological  Biochemistry, 
v 
Royal  Infirmary,  Glasgow. 
Thesis  submitted  for  the  Degree  of  Doctor  of  Philosophy 
in  the  Faculty  of  Medicine,  University  of  Glasgow, 
Scotland,  1974. ST  COPY 
AVAILA  L 
Variable  print  quality Contents  Lýjýze. 
1.  Introduction. 
(a)  Cholinesterase 
Molecular  properties  1 
Enzyme  characteristics  3 
Assay  procedures  5 
Physiological  function  9 
Clinical  significance  10 
Polymorphisni  14 
(b)  Multiple  Forms  of  Enzymes  19 
Nomenclature  21 
Methods  of  characterisation  24 
(c)  Effect  of  Heat  on  Isoenzymes.  30 
(d)  Aims  of  study  38 
Benzoylcholine  Hydrolysis. 
(a)  Temperature  studies  39 
Instrumentation,  Methods 
and  Materials  42 
Experimental  Results 
Denaturation  47 
Case  Reports  49 
Temperature  Coefficients  53 
Discussion  55 
(b)  Arrhenius  relationships  69 
Inhibition  so 
Instrumentation,  Methods 
and  Materials  81 
Experimental  results  82 
Discussion  84 Contents  (cont.  )  Page. 
2.  (d)  Effect  of  temperature  on  inhibition  93 
. 
Instrumentation,  Methods 
and  Materials  93 
Experimental  Results  94 
Discussion  94 
3.  Thiocholine  Ester  Hydrolysis.  103 
Instrumentation,  Methods 
and  Materials  104 
Experimental  Results  107 
Discussion  ill 
4.  Population  Survey. 
Scalpay  121 
Pregnancy  123 
5.  General  Discussion,  Conclusions  and 
Prospects.  127 
References  142 Acknowledgements 
I  thank  Professor  H.  G.  Morgan  for  the  use  of  the 
facilities  and  resources  of  his  Department  and  for  his 
personal  supervision,  advice  and  criticism.  I  am  also 
grateful  to  Professor  R.  M.  S.  Smellie  and  Dr.  A.  Fleck  for 
constructive  discussions  and  advice. 
The  practical  work  of  the  Population  Studies  section 
and  preliminary  studies  of  the  Thiocholine  Ester  Hydrolysis 
section  owes  much  to  the  patient  and  skilful  technical 
assistance  of  Miss  Dorothy  Griffin  and  Miss  Gillian  Ritchie 
respectively  which  is  gratefully  acknowledged. 
Support  in  the  form  of  essential  equipment  was 
generously  provided  by  the  Medical  Research  Council  (Project 
grant  G971/343/C)  and  by  the  New  Medical  Developments 
Committee  of  the  Scottish  Home  and  Health  Department.  With 
regard  to  equipment  it  is  a  pleasure  to  acknowledge  particularly 
the  help  of  Mr.  John  McGregor,  University  of  Glasfr 
,  ow  and 
Mr.  Eric  Leask,  Scotti.  sh  Home  and  Health  Department. 
My  thanks  are  also  due  to  the  many  anaesthetist 
colleagues  in  the  West  of  Scotlad  Region  who  have  referred 
cases  of  I'suxamethonium  sensitivity"  and  thereby  provided 
the  material  without  which  this  study  could  not  have  been 
undertaken. Summarv. 
The  molecular,  enzymic  and  physiological  characteristics, 
methods  of  assay  and  the  clinical  significance  of  human 
serum  cholinesterase  are  reviewed.  The  existence  of 
multiple  forms  of  enzymes  and  the  particular  inherited 
polymorphism  of  human  cholinesterase  which  results  in 
abnormal  responses  to  the  muscle  relaxant,  suxamethonium, 
are  summarised. 
The  effect  of  reaction  temperature  on  the  hydrolysis 
of  substrates  by  cholinesterases  has  been  investigated  and 
significant  differences  have  been  demonstrated.  The 
temperature/activity  relationships  have  been  found  to  reflect 
the  sensitivity  of  the  different  phenotypes  to  suxamethonium. 
At  the  physiological  temperature  of  37  0C  the  cholinesterases 
of  the  three  phenotypes  which  exhibit  an  abnormal  response 
to  the  drug  have  been  shown  to  undergo  a  pronounced 
reversible  Inactivation.  This  suggests  that  the  prolonged 
response  to  suxamethonium  in  these  cases  is  not  entirely 
due  to  the  reduced  enzymic  affinity  but'  is  in  some  part 
caused  by  the  Inactivation  of  the  enzyme  species  at  its 
functional  temperature.  This  in  turn'indicates  that  only 
by  conducting  assays  at  37  0C  is  a  valid  indication  of  serum 
cholinesterase  activity  obtained  and  also  explains  the 
anomalies  recorded  in  the  literature  concerning  activities 
obtained  at  different  temperatures. 
Thermodynamic  data  derived  from  these  studies  indicate 
that  both  genes  regulate  enzyme  synthesis  at  equal  rates, 
that  is,  heterozygous  sera  contain  equal  molecular  pro- 
portions  of  both  variants.  The  same  data  is  employed  to show  that  the  different  molecular  activities  of  the 
isoenzymes  on  this  equal  synthesis  basis  explain.  s  the 
skewed  distributions  of  inhibitions  in  heterozygote  sera. 
The  methods  of  dif.  ferentiating  the  allelic  isoenzymes 
of  human  serum  cholinesterase  by  inhibitions  have  been 
examined  and  extended.  The  use  of  succiny1dicholine  as  a 
differential  inhibitor  reveals  anomalies  in  the  limited 
number  of  allelic  variants  which  are  currently  recognised. 
It  is  postulated  that  a  larger  number  exists.  The  action 
of  some  non-depolarising  muscle  re  laxant  drugs  on  enzymic 
hydrolysis  has  also  been  investigated  in  vitro.  Of  these, 
pancuronium  has  been  shown  to  inhibit  not  only  human  serum 
cholinesterase  but  also  erythrocyte  acetylcholinesterase. 
The  effect  of  reaction  temperature  on  the  inhibition 
of  the  cholinestorase  isoenzymes  by  a  variety  of  agents 
hits  also  been  examined.  Variation  with  type  of  inhibitor 
and  allelic  variant  has  been  demonstrated  and  because  of 
t1lis  the  ability  to  precisely  categorise  a  phenotype  is 
only  possible  at  the  definition  temperature,  that  is, 
about  25  0  C.  he'anomalous  inhibitions  found  at  this 
temperature  for  the  "fluoride-resistant"  enzyme  are  explained 
by  temperature  sensitivity  and  at  37  0C  the  inhibitions 
accord  with  the  observed  drug  response  of  this  variant. 
By  means  of  inhibitions,  by  relative  substrate  hydrolysis 
rates  or  by  ratios  of  activities  at  two  reaction  temperatures, 
techniques  have  been  evolved,  employing  thiocholine  ester 
substrates  capable.  of  screening  large  numbers  for 
I'suxamethonium  sensitivity". 
Population  surveys  gave  no  direct  support  to  the postulate  of  numerous  cholinesterase  variants.  It  has 
been  found  however  that  there  is  an  apparent  modification 
of  the  "fluoride-resistant"*isoenzyme  during  pregnancy. 
This  indicates  how  readily  a  new  identifiable  variant  can 
be  produced  and  opens  avenues  for  further  elucidation  of 
the  changes  in  molecular  structure  which  result  in 
recognisable  polymorphism. 1.  Introduction. 
(a)  Cholinesterase. 0 
(a)  Cholinesterase  (E.  C.  3.1.1.8  Acylcholinc  acyl-hydrolase). 
The  term  "choline-esterasell  was  first  used  by  Stedman, 
Stedman  and  Easson  (1932)  to  describe  an  enzyme  which 
hydrolysed  acetylcholine  (Engblhart  and  Loewi 
' 
1930),  the 
substance  which  is  liberated  at  the  motor  end  plates 
during  a  nerve  impulse.  The  importance  of  the  enzyme  in 
the  physiology  of  the  nervous  system  was  readily  realised 
for  by  hydrolysing  the  acetylcholine  after  transmission  it 
permitted  the  nerve  fibre  to  accommodate  the  next  impulse. 
What  was  not  appreciated  until  the  studies  of  Alles  and 
Hawes  (1940)  was  that  there  are  two  enzymes  which  hydrolyse 
choline  esters  present  in  human  tissues. 
The  enzyme  predominating  in  nerve  tissue  and  present 
in  erythrocytes  has  variously  been  termed  "specific", 
"true",  Ilaceto-11  or  Ile-type"  cholinesterase  in  distinction 
to  the  "non-specific",  "pseudo-",  "butyro-11  or  I's-type" 
cholinesterase  found  in  blood  serum  and  synthesised  by 
the  liver.  These  hydrolases  have  wide  and  overlapping 
substrate  specificities  but  the  former  has  a  specificity 
directed  towards  acetyl  esters  and  is  correctly  termed 
acety1cholinesterase  (E.  C.  3.1.1.7  acetylcholine  acetyl- 
hydrolase)  while  the  latter,  cholinesterase,  is  active 
against  choline  esters  and  a  few  other  compounds  and  is 
given  the  systematic  name  acyleholine  acyl-hydrolase. 
(E.  C.  3.1.1.8). 
Since  there  are  innumerable  naturally  occurring  esters 
there  must  be  enzymes  capable  of  hydrolysing  all.  of  them. 
An  elementary  knowledge  of  protein  structure  denies  the 
possibility  of  one  enzyme  being  capable  of  hydrolysing  all, and  equally  it  can  be  inferred  that  there  is  not  an  enzyme 
for  each  ester  'since  a  protein  capable  of  binding  and 
activating  one  will  also  be  effective  against  other  esters 
with  closely  related  electronic  configurations.  Thus  most 
of  the  simple  choline  esters  are  also  hydrolysed  by  the 
so-called  ali-esterases  which  act  on  aliphatic  esters  and 
glycerides.  Similarly  compounds  such  as  benzoylcholine  or 
phenylacetate  which  are  substrates  for  cholinesterase  are 
also  hydrolysed  by  the  arylesterases  which  are  present  in 
human  blood  plasma.  However  both  acetyleholinesterase  and 
cholinesterase  are  extremely  sensitive  to  eserine  (physo- 
stigmine)  being  completely  inhibited  at  a  concentration  of 
10- 
5M 
and  it  is  upon  this  rather  tenuous  point  that  the 
specific  existence  of  these  enzymes  is  recognised. 
Acetyleholinesterase  and  cholinesterase  are  readily 
differentiated  from  each  other  by  specific  substrates  such 
as  acetyl-0-methyl  choline  for  acetylcholinesterase  and 
benzoyleholine  for  cholinesterase.  Differentiation  can  be 
achieved  even  by  substrate  concentration;  acetyleholinester- 
ase  is  inhibited  at  concentrations  of  acetylcholine  greater 
I  than  10-  3  11  at  which  levels  cholinesterase  exhibits  maximal 
activity.  Selective  inhibitors  have  also  been  employed, 
tri-o-cresyl  phosphate  for  cholinesterase  (Ifendel  and  Myers, 
1952)  and  Ral-dichlorodiethyl-N-methylamine  for  acetyl- 
cholinesterase  (Adams  and  Thompson,  1948).  In  any  case 
since  the  present  study  was  mainly  concerned  with  investi- 
gation  of  human  blood  the  two  enzymes  are  already  separated, 
acetylcho,  linesterase  in  the  erythrocytes  and  cholinesterase 
in  the  plasma  or  serum. Molecular  Properties 
Wilkinson  (1970)  gives  the  molecular  weight  of 
cholinesterases  as  2-12xIO  6 
without  however  quoting  the 
source  of  this  information.  Certainly  the  molecular  weight 
of  human  serum  cholinesterase  is  greater  than  200,000  since 
it  appears  immediately  after  the  void  volume  in  gel  filtra- 
tion  on  Sephadex  G-200.  After  purifying  human  serum 
cholinesterase  3400-fold  Surgenor  and  Ellis  (1954)  found 
the  preparation  to  contain  four  protein  fractions  with  the 
major  part  of  the  activity  in  the  10  S  fraction  with  a 
molecular  weight  calculated  as  300,000.  With  material 
purified  10  4  times  from  human  serum  Haupt,  Heide,  Zwisler 
and  Schwick  (1966)  found  a  molecular  weight  of  348,000  and 
measured  immunologically  the  serum  concentration  of  cholin- 
esterase  was  about  9  mg/litre.  With  an  even  more  highly 
purified  preparation  Das  and  Liddell  (1970)  calculated  a 
molecular  weight  of  366,000  from  ultracentrifuge  data. 
Jansz  and  Cohen  (1962)  by  titration  with  diisopropylfluoro- 
phosphate  (DFP)  calculated  a  molecular  weight  of  84,000  per 
active  site.  From  these  data  it  would.  appear  that  the 
cholinesterase  molecule  possesses  four  active  sites. 
From  ethanol-water  solubility  studies  Surgenor,  StroTig, 
Taylor,  Gordon  and  Gibson  (1949)  estimated  the  isoelectric 
point  of  human  serum  cholinesterase  to  be  pli  4.6-4.9. 
Svensmark  (1961)  showed  the  enzyme  to  be  an  acid  glycoprotein 
containing  several  sialic  acid  residues  and  in  a  classical. 
paper  electrophoresis  study,  Svensmark  and  Kristenren  (1.963) 
showed  the  isoelectric  point  of  native  human  cholinesterase 
to  be  pII  2.9-3.0,  that  of  neuraminidase  treated  enzyme pH  6.7-7.0.  These  experiments  showed  that  at  p1l  8.6  native 
human  cholinesterase  behaves  as  an  a2  globulin  migrating 
slightly  more  slowly  than  the  main  fraction.  At  pH  11.0 
the  enzyme  behaves  as  a  ý-globulin  at  p1l  6.0  as  an  aI 
globulin  and  at  pH  5.0  as  an  albumin.  At  a  p1l  lower  than 
4  .  7,  the  isoelectric  point  of  albumin,  cholinesterase  can 
therefore  be  expected  to  migrate  as  a  pre-albumin  fraction. 
Das  and  Liddell  (1970)  found  an  isoelectric  point  of 
pH  3.99  on  a  high  purified  enzyme  sample  by  isoelectro- 
focusing  technique. 
Electrophoresis  of  human  serum  on  starch  gel  has 
resulted  in  contradictory  reports.  Thompson  and  Cook 
(1961)  and  Ecobichon  and  Kalow  (1962)  found  one  fraction 
while  one  or  more  weaker  bands  have  been  recorded  by  Dubbs, 
Vivonia  and  Hilburn  (1960)  Bersohn,  Barron  and  11css,  (1901), 
Harris,  Hopkinson,  Robson  and  Whittaker  (196).  Harris  ;  u)d 
co-workers  employed  two-dimensional  electrophoresis  at 
p1l  8.6  on  filter  paper  for  the  first  run  followed  by  starch 
gel  in  the  second.  In  fresh  normal  serum  four  zone.,.,,  of  " 
activity  termed  C1  to  C4  were  separated  migrating  on  paper 
between  the  a2  and  a  globulins,  C2  slightly  fastest.  The 
C4  fraction  which  was  slowest  moving  in  both  directions 
contained  about  90%  of  the  total  activity.  All  four 
fractions  were  sialo-proteins  and  mobilities  were  reduced 
by  neuraminidase  treatment  (Harris,  Hopkinson  and  Robson, 
1962).  Fresh  foetal  or  cord  blood  had  an  additional  zone 
overlapping  the  C4  fraction  and  after  storage  two  more 
minor,  faint  and  fast-moving  spots  appeared. 
La  Motta,  McComb  and  17etst(3ne  (1965)  also  separated five  cholinesterase  fractions  from  human  serum  concentrates 
by  starch-gel  electrophoresis.  The  forms  were  found  to  be 
interconvertible  and  multiplicity  was  attributed  to  poly-; 
merisation.  Two  further  fractions  were  later  reported  by 
La  Motta,  McComb,  Noll,  Wetstone  and  Reinfrank  (1968) 
which  like  the  others  could  be  converted  into  a  single 
fraction  by  concentration.  Harris  and  Robson  (1963) 
reported  that  the  C1  to  C4  fractions  isolated  by  starch- 
gel  electrophoresis  could  also  be  separated  in  reverse 
order  by  gel-filtration  through  a  Sephadex  column  thereby 
confirming  that  the  molecular  sizes  increased  from  C1  to 
C  4' 
Despite  these  findings  a  simple  polymerisation  is 
doubtful  as  a  single  explanation  of  the  heterogeneity 
since  it  does  not  account  for  the  increased  mobility  of 
the  C2  fraction  on  paper  electrophoresis.  This  fraction 
and  the  foetal  cholinesterase  may  differ  in  sialic  acid 
content. 
Enzyme  Characteristics 
The  sialic  acid  moieties  are  in  no  way  concerned  with 
the  catalytic  properties  of  serum  cholinesterase.  Removal 
of  the  sialic  acid  does  not  alter  the  enzyme  activity  and 
it  has  been  shown  (Svensmark,  1961;  Augustinsson  and 
Eskedahl,  1962)  that  carbohydrate-free  serum  cholinester- 
ase  is  identical  to  the  native  enzyme  with  regard  to 
neostigmine  inhibition  and  to  hydrolysis  of  acetylcholine, 
propionylcholine  and  butyryleholine  as  determined  by 
Michaelis  constants.  Dibucaine  and  fluoride  inhibitions 
of  native  and  neuraminidase-treated  cholinesterase  is 
identical  (Echibicon  and  Kalow,  1963). No  prosthetic  groups  have  been  proposed  or  found  for 
serum  cholinesterase  and  there  is  no  evidence  that  the 
enzyme  is  a  metalloprotein.  Ammon  (1943)  however  suggested 
that  magnesium  or  calcium  ions  were  required  for  maximum 
activation  and  some  reduction  in  activity  was  found  on 
removal  of  these  ions  and  by  addition  of  fluoride,  oxalate 
or  citrate. 
The  three-stage  mechanism  of  hydrolysis  by  cholin- 
esterase  elaborated  by  Davies  and  Green  (1958)  in  which 
the  last  two  stages  are  not  reversible  is  now  generally 
accepted. 
k+j  k+2  k+3 
EII+XO'(I  EH+XY 
k-I 
(EH-XY)  EX+IIY 
1120 
Where  EH  is  the  enzyme,  XY  the  ester,  EH-XY  the  Michaolis- 
Menten  complex  and  EX  the  acylated  enzyme. 
To  explain  the  affinity  of  choline  ester  hydrol-aseri 
for  cationic  substrates  and  inhibitors  (Piguro  1),  Zollor 
and  Bissegger  (1943)  postulated  the  presence  of  an 
"anionic"  and  an  Ilesteratic"  site  at  the  active  centre  of 
acetylcholinesterase.  Since  cholinesteraso  was  not 
inhibited  by  high  substrate  concentrations  it  was  assumed 
to  have  only  an  esteratic,  site.  Wilson  (1954)  suggested 
the  presence  of  both  sites  in  the  active  centre  of  cholin- 
esterase  and  Bergmann  (1958)  explained  the  substrate 
inhibition  by  attributing  two  anionic  sites  -to  acetylcholin-- 
esterase.  The  problem  is  still  controversial. 
The  amino-acid  sequence  of  a  peptide  assumed  to  come 
from  the  active  contre  by  its  binding  to  labelled  diiso- 
propy1fluorophosphate  has  been  analysed  (CoheD,  Oosterbaan, 71 
Jansz  and  Berends,  1959)  and  found  to  be  similar  to  that 
of  a  large  group  of  hydrolases  containing  a  serine  resi- 
due  with  one  of  the  dicarboxylic  aspartic  or  glutamic 
acids  on  one  side  and  glycine  or  alanine  on  the  other 
(Sanger,  1963). 
Assay  Procedures 
For  the  assay  of  cholinesterase  activity,  procedures 
of  every  type  exist,  fixed-time,  fixed  end  point  and  initial 
reaction  rate  methods.  In  general  these  assays  may  be 
divided  into  three  categories.  First  there  are  those 
measuring  the  liberation  of  acid,  by  estimating  the  carbon 
dioxide  released  from  a  bicarbonate-containing  medium  in 
the  Warburg  manometric  apparatus  (Ammon,  1933;  McArdle, 
1940),  by  the  time  taken  to  achieve  a  fixed  pH  electromet- 
rically  (Michel,  1949;  Courville  and  Ledington,  1951), 
or  colorimetrically  by  means  of  such  indicators  as  phenol 
red  (Reinhold,  Tourigny  and  Yonan,  1953;  Molander,  Friedman 
and  LaDue,  1954;  Caraway,  1956),  bromthymol  blue  (Biggs, 
Carey  and  Morrison,  1958)  or  m-nitrophenol  (Rappaport, 
Fishl  and  Pinto,  1959),  or  by  rate  of  manual  (Stedman, 
Stedman  and  Easson,  1932;  Glick,  1938;  Alles  and  Hawes, 
1940)  or  automatic  (Jorgensen,  1959;  Nabb  and  Whitefield, 
1967)  continuous  titration  to  maintain  a  constant  pH. 
In  the  second  group  use  is  made  of  chromogenic 
substrates  such  as  0-carbonaphthoxycholine,  coupling  the 
liberated  $-naphthol  with  tetrazotised  diorthoanisidine 
(Ravin,  Tsou  and  Seligman,  1951)  or  non-choline  esters 
such  as  phenylbenzoate  with  which  the  phenol  liberated 
by  enzymic  hydrolysis  is  estimated  with  the  Folin- t 
Ciocalteau  reagent  (Smith,  Lowenthal,  Lehmann  and  Ryan, 
1959).  Reaction  rate  procedures  with  substrates  of 
doubtful  specificity  for  cholinesterase  such  as  indo- 
phenylacetate  at  625nm  (Kramer  and  Ganeson,  1958)  or 
o-nitrophenylbutyrate  at  414nm  (Main,  Miles  and  Braid, 
1961;  McComb,  La  Motta  and  I'letstone,  1965;  Szasz,  1968; 
Whittaker  and  Hardesty,  1969)  have  also  been  published. 
Perhaps  the  most  generally  successful  approach  has  been 
I 
that  using  thiocholine  esters  and  the  estimation  of  the 
sulphydryl  released  by  enzyme  hydrolysis.  This  has  been 
followed  by  means  of  the  nitroprusside  colour  reaction 
(McOsker  and  David,  1959)  or  by  iodometric  titration 
(Augustinsson,  1955)  in  two-point  assays  or  in  reaction 
rate  procedures  by  coupling  to  the  reduction  of,  2:  6 
dichlorophenolindophenol  reading  at  600nm  (Gal  and  Roth, 
1957);  by  complexing  with  2121  or  4141  dithiodipyridine  and 
reading  at  324  or  343nm  respectively  (Uete  et  al.,  1972) 
or  with  5,5'-dithiobis  (2-nitrobenzoicacid)  following  the 
reaction  at  410nm  (Ellman,  Courtney,  Andres  and  Featherstone, 
1961;  Garry  and  Routh,  1965;  Szasz,  1968a,  b;  Garry,  1971). 
The  last  is  a  most  simple  and  sensitive  procedure. 
In  the  final  group  the  unreacted  ester  is  estimated. 
This  has  been  done  in  fixed-time  assays  employing  an 
acetylcholine  substrate  by  means  of  the  ferric-hydroxa- 
mate  reaction  (De  La  Huerga,  Yesinick  and  Popper,  1952) 
or  in  reaction  rate  procedures  with  thiocholine  substrates 
using  absorption  of  the  ester  at  226nm  or  with  benzoyl- 
choline  by  following  the  change  in  absorption  at  240nm 
(Kalow  and  Lindsay,  1955).  The  last  method  is  of  particular .4 
interest  because  of  the  recognised  specificity  of  the 
substrate,  the  fact  that  it  is  an  initial  reaction  rate 
assay  and  was  found  to  have  an  excellent  precision. 
Further  reasons  for  interest  in  this  assay  are  expanded 
upon  in  the  next  section. 
Methods  for  the  determination  of  cholinesterase 
activity  have  recently  been  reviewed  by  Augustinsson 
(1971). 
Physiological  Function 
Plasma  cholinesterase  is  synthesised  in  the  liver 
but.  cholinesterases  are  widespread  in  human  tissues,  in 
intestine,  muscle,  lung,  uterus,  pancreas  and  other  glands 
and  in  certain  ganglia.  Cholinesterase  is  present  in 
lymph  and  effusion  fluids.  Activity  is  detectable  in 
cerebrospinal  fluid  but  not  normally  in  urine,  bile, 
gastric  juice  or  saliva. 
The  physiological  role  of  cholinesterase  and  its 
natural  substrates  are  matters  for  speculation.  At  its 
simplest  Funnell  and  Oliver  (1965)  have  suggested  that 
cholinesterase  plays  a  part  in  the  homeostatic  mechanism 
controlling  the  levels  of  free  choline.  Again  since 
butyryleholine,  which  has  a  possibly  undesirable  nicotinic 
effect,  may  be  synthesised  by  the  choline  acetylase 
system  from  butyryl-  coenzyme  A  during  fatty  acid 
metabolism,  Clitherow,  Mitchard  and  Harper  (1963)  have 
speculated  that  the  function  of  the  enzyme  may  be  to 
prevent  accumulation  of  this  substance.  Similarly 
y-aminobutyryl  choline  which  is  present  in  brain  tissue 
may  be  a  substrate  for  cholinesterase  (Holmstedt  and 101 
Sjoquist,  1960). 
Perhaps  the  discovery  that  acety1cholinesterase  and 
cholinesterase  were  different  enzymes,  the  former  in  high 
concentration  at  neural  junctions  was  misleading  since  it 
lead  to  the  assumption  that  cholinesterase  was  not 
concerned  with  nervous  transmission  (Ilendel  and  Rudney, 
1943p  1944).  Certainly  the  lack  of  pharmacological 
reaction  to  selective  cholinesterase  inhibition  (Hawkins 
and  Gunter,  1946;  Mazur  and  Bodansky,  1946)  appeared  to 
confirm  this  but  more  recent  work  has  shown  that  such 
inhibition  affects.  intestinal  motility  (Jamieson,  1963) 
and  the  enzyme  may  play  a  part  in  transmittory  processes 
in  other  tissues  also  (Koelle,  1963). 
However  speculation  concerning  the  role  of  cholin- 
esterase  must  take  into  account  that  normal  healthy 
individuals  have  been  found  devoid  of  serum  cholinesterase 
activity  from  which  it  would  appear  that  the  function  of 
the  enzyme  is  not  critical  or  else  can  be  taken  over  by 
alternative  mechanisms. 
Following  enzyme  blocking  with  diisopropylfluoro- 
phosphate  Neitlich  (1966)  has  calculated  from  the 
generation  curve  that  the  biological  half-life  of 
cholinesterase  is  ten  days.  This  value  has  been  corrobor- 
ated  independently  by  Jenkins,  Balinsky  and  Patient  (1967) 
from  the  rate  of  disappearance  of  transfused  normal  plasma 
activity  into  a  patient  lacking  plasma  cholinesterase. 
Clinical  Significance 
The  activity  of  most  enzymes  in  human  blood  plasma 
is  low  and  their  presence  there  in  health  is  a  result  of I  '1' 
normal  tissue  wear  and  tear.  They  are  cellular  detritus 
and  form  part  of  the  circulating  protein  pool.  In 
clihical  enzymology  it  is  an  increase  in  the  activity  of 
these  enzymes  which  is  sought,  an  increase  which  would 
indicate  an  abnormal  efflux  into  the  circulation  as  a 
result  of  some  pathological  situation.  Apart  from  the 
enzymes  of  the  coagulation  mechanism,  cholinesterase  is 
the  only  enzyme  of  interest  in  clinical  enzymology  which 
may  be  termed  plasma  or  serum  specific.  As  such  cholin- 
esterase  is  normally  present  in  human  blood  serum  in 
relatively  high  concentration  and  it  is  a  decrease  in 
activity  which  is  clinically  meaningful.  Further,  since 
cholinesterase  is  synthesised  in  the  liver,  it  should  be 
a  useful.  index  of  the  protein  synthesising  function  of  the 
liver.  In  this  respect  it  is  very  similar  to  serum  albumin 
and  indeed  there  would  appear  to  be  a  concomitance  in  the 
synthesis  of  these  two  proteins. 
Hence  in  hepatitis,  liver  metastases  (Molander, 
Friedman  and  La  Due,  1954;  Burnet  ,  1960)  and  cirrhosis 
(Kunkel  and  Ward,  1947;  La  Motta,  Williams  and  Wetstone, 
1957;  Hunt  and  Lehmann,  1960)  where  there  is  a  lesion  of 
the  synthesising  mechanism,  low  levels  of  both  cholinesterase 
and  albumin  are  found  in  serum.  In  obstructive  jaundice 
both  are  essentially  normal  (Antopol,  Schifrin  and  Tuchman, 
1938;  McArdle,  1940;  Burnett,  1960)  except  where  the 
causative  factor  is  malignant  (Mann,  Mandel,  Eichman, 
Knowlton  and  Sborov,  1952;  Williams,  La  Motta  and  Wetstone, 
1957).  The  last  instance  is  probably  a  reflection  of  the 
effect  of  the  tumour  on  protein  metabolism  and,  like I 
malnutrition  (Vorhaus  and  Kark,  1953),  the  low  serum  levels 
are  a  result  of  d.  epletion  of  material  for  synthesis.  The 
only  lack-of  coincidence  occurs  in  nephrosis,  in  which 
albumin.,  the  much  smaller  molecule,  but  not  cholinesterase 
is  lost  through  the  damaged  kidney.  The  compensatory 
increase  in  protein  synthesis  results  in  high  serum  cholin- 
esterase  activity  in  the  presence  of  low  serum  albumin 
levels  (Kunkel  and  Ward,  1947;  Vorhaus  and  Kark,  1953; 
Vincent,  1958).  The  finding  of  normal  albumin  levels  in 
individuals  having  a  total  lack  of  serum  cholinesterase 
activity  or  of  normal  cholinesterase  activity  in  analbumin- 
aemia  (Dietz,  Rubinstein  and  Lubrano,  1966)  in  no  way  negates 
the  speculation  that  there  is  an  intimate  connection  between 
the  hepatic'synthesis  of  albumin  and  serum  cholinesterase. 
In  myocardial  infarction  there  is  a  characteristic 
fall  in  serum  cholinesterase  activity  (Oka,  1954)  which 
reaches  a  minimum  about  the  fifth  day  and  then  increases 
to  normal  levels;  a  failure  to  rise  carries  a  grave  prognosis 
(Moore,  Birchall,  Horack  and  Batson,  1957).  Not  only  in 
myocardial  infarction,  but  also  in  pulmonary  embolism, 
acute  infectious,  surgery,  indeed  any  precipitation  of  the 
"acute  phase  reaction"  (Hauss  and  Leppelmann,  1958)  gives 
rise  to  lowered  serum  cholinesterase  activity. 
Increased  serum  activity  is  found  in  cases  of  thyro- 
toxicosis  and  reduced  levels  in  myxoedema  (Thompson,  1959; 
Thompson  and  Whittaker,  1965)  but  the  high  values  reported 
in  diabetes  mellitus  are  a  reflection  of  obesity,  not  of 
the  disease  (Thompson  and  Trounce,  1956).  In  myastheilia 
gravis,  a  disease  characterised  by  muscle  weakness  which -P  -"  A  IW 
responds  to  eserine  and  prostigmine  treatment,  Stedman  and 
Russell  (1937)  found  low  serum  cholinesterase  activities 
but  later  studies  did  not  confirm  this  (Vorhaus  and  Kark, 
1953).  Stedman  and  Russell  also  noted  low  serum  activities 
in  progressive  muscular  dystrophy  and  myotonia  congenita 
and  Moore,  Birchall,  Horack  and  Batson  (1957)  reported 
similar  results  in  dermatomyositis  but  normal  levels  in 
other  collagen  diseases. 
Some  observers  have  reported,  lowered  serum  cholinester- 
ase  activity  in  schizophrenia  and  increased  levels  in 
anxiety  states.  Plum  (1960)  however  noted  increased 
cholinesterase  activity  in  manic  depressive  psychosis  and 
schizophrenia  as  well  as  in  anxiety  and  depressive  neurosis 
but  while  Antebi  and  King  (1962)  observed  increased  levels 
in  207o  of  chronic  schizophrenics,  they  found  no  correlation 
between  the  enzyme  abnormality  and  the  disease  type  or 
clinical  state 
ýf  the  patients. 
Although  assay  of  serum  cholinesteraso  activity  would 
appear  capable  of  yielding  information  of  clinical  value 
in  the  correct  setting,  only  in  Germany  has  it  gained  such 
recognition.  This  is  probably  a  result  of  the  fact  that 
normal  serum  cholinesterase  activity  is  so  high  and  the 
range  of  activities  so  wide  that  unless  the  patient's  usual 
activity  is  at  the  lower  end  of  the  range  such  variations 
are  not  readily  obvious.. 
As  it  is,  it  is  not  in  the  diagnosis  or  monitoring 
of  any  pathology  that  assay  of  serum  cholinesterase  is 
most  often  sought  but  rather  in  the  field  of  pharmaco- 
genetics,  that  is,  the  study  of  genetic  variants  in  man 4 
which  are  responsible  for  alterations  in  the  response  to 
drugs. 
Polymorphism 
Some  of  the  pharmacological  properties  of  succinyl- 
dicholine  (suxamethonium,  Scoline  (R)-)  were  first  described 
by  Hunt  and  Taveaux  (1906)  but  forty-three  years  were  to 
elapse  before  its  potential  as  a  short-acting  muscle 
relaxant  was  discovered  (Bovet,  Bovet-Nitti,  GuarinoLongo 
and  Marotta.,  1949).  Succiny1dicholine  produces  a  depolaris- 
ing  type  of  neuromuscular  block  since  it  acts  as  a  compet- 
itive  inhibitor  of  acetylcholinesterase.  The  short  period 
of  action,  three  to  five  minutes,  results  from  the  hydrolysis 
of  the  drug  by  the  cholinesterase  of  the  circulation.  It 
was  therefore  to  be  expected  that  in  any  pathology  in 
which  serum  cholinesterase  was  low  that  the  duration  of 
paralysis  would  be  extended  and  indeed  not  long  after  its 
introduction  cases  were  reported  of  prolonged  apnocit 
following  administration  of  usual  doses  of  suxamethonium. 
JIowever  these  episodes,  up  to  two  hours  duration,  occurred 
in  individuals  not  suffering  from  liver  disease,  malnutrition 
or  other  disease  which  might  account  for  their  low  serum 
cbolinesterase  activity  (Evans,  Gray,  Lehmann  and  Silk, 
1952;  1953;  Bourne,  Collier  and  Somers,  1952;  Forbat, 
Lehmann  and  Silk,  1953). 
A  great  advance  in  understanding  of  this  phenomenon 
came  from  the  family  studies  of  sensitive  individuals 
(Lehmann  and  Ryan,  1956;  Lehmann,  Patston  and  Ryan,  1958) 
which  resulted  in  the  hypothesis  of  an  inherited  enzyme 
defect,  the  enzyme  level  determined  by  two  allelic  genes I 
ýýJý 
neither  of  which  showed  dominance.  However  although  Calvert, 
Lehmann,  Silk  and  Slack  (1954)  demonstrated  a  close 
correlation  between  suxamethonium  dose  and  duration  of 
paralysis,  and  that  when  the  serum  cholinesterase  activity 
was  doubled  by  injection  of  purified  enzyme  the  apnoeic 
response  was  halved,  patients  who  suffered  what  came  to  be 
known  as  I'Scoline  apnoeall  often  had  serum  cholinesterase 
levels  higher  than  other  patients  who  showed  no  unusual 
response  to  the  drug.  Lehmann  and  Simmons  (1958)  while 
confirming  the  hereditary  nature  of  the  phenomenon  stated 
the  anomaly  as  "it  is  often  difficult  to  understand  why 
patients  with  an  identically  low  pseudocholinesterase  level 
show  a  varying  duration  of  apnoea  following  the  same  dose 
of  suxamethonium;  the  duration  may  vary  from  no  excessive 
prolongation  to  a  very  prolonged  apnoeall. 
The  explanation  of  this  was  unfolded  by  the  work  of 
Kalow  and  colleagues  in  Toronto  who  showed  that  the  affinity 
of  the  enzyme  in  the  sera  of  sensitive  individuals  for  a 
wide  range  of  substrates  was  lower  than  that  of  the  serum 
enzyme  of  normal  individuals  (Kalow,  1959a;  Davies,  Marton 
and  Kalow,  1960).  Indeed  the  enzyme  in  the  serum  of 
sensitive  patients  had  no  detectable  activity  against 
succiny1dicholine  at  therapeutic  concentrations.  The 
behaviour  of  the  two  enzymes  to  various  inhibitors  also 
varied  considerably,  the  normal  enzyme  in  most  cases  being 
more  strongly  affected  (Kalow  and  Davies,  1958).  The 
compound  which  produced  the  greatest  differential  inhibition 
was  dibucaine  (cinchocaine,  Nupercaine)  at  a  concentration 
of  10-  5  It  and  this  gave  a  means  of  detecting  the  "atypical" +,.  -CH  3 
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Figure  1.  Structural  formulae  of  some  substrates  and  inbibitors 
of  cholinesterase. 
Further  examples  are  illuotrated  in  Figure  20. Iq 
enzyme  as  it  was  called  (Kalow  and  Staron,  1957).  With  a 
50  VM  benzoyleholine  substrate  (Kalow  and  Lindsay,  1955) 
the  usual  enzyme  was  inhibited  about  80%,  the  atypical 
enzyme  about  207o  and  heterozygous  sera  about  60%.  The 
percentage  inhibition  was  termed  the  dibucaine  number  (DN) 
and  this  procedure  clearly  segregated  the  three  genotypes 
irrespective  of  the  level  of  cholinesterase  activity. 
In  view  of  the  apparent  particular  affinity  of  cholin- 
esterase  for  compounds  containing  a  positively  charged 
nitrogen  atom  particularly  when  linked  to  methyl  groups 
(Figure  I)  it  is  not  surprising  that  most  of  the  inhibitors 
examined  by  Kalow  and  co-workers  contained  such  a  positively- 
charged  nitrogen.  That  this  constitution  was  not  essential 
in  a  differential  inhibitor  was  shown  by  Harris  and 
Whittaker  (1961)  who  found  that  sodium  fluoride  provided 
a  similar  inhibition  segregation  to  that  of  dibucaine. 
However  when'these  workers  compared  the  dibucaineý  and 
fluoride  numbers  of  individuals  from  families  of  suxamethonium- 
sensitive  patients  besides  the  three  groups  already  segregated, 
two  further  groups  were  recognisable  with  slightly  lower 
dibucaine  numbers  and  much  lower  fluoride  numbers.  Further 
work  (Harris  and  Whittaker,  1962,1963)  showed  that  this 
increased  resistance  to  fluoride  inhibition  is  inherited 
through  a  gene  allelic  to  the  usual  and  atypical  genes. 
The  heterozygote  for  the  atypical  and  fluoride-resis-il.  -ant 
genes  is  sensitive  to  suxamethonium  (Lehmann,  Liddell, 
Blackwell,  O'Connor  and  Daws,  1963)  as  is  the  homozygote 
for  the  fluoride-resistant  cholinesterase  (Liddell,  Lehmann 
and  Davies.,  1963;  Griffiths,  Davies  and  Lebmann,  1966). Ia14 
Sodium  chloride  at  high  concentration  (0.5M)  also  differ- 
entially  inhibits  the  cholinesterase  variants  (Whittaker, 
1968b).  The  chloride  number  differs  from  both  dibucaine 
and  fluoride  numbers  in  that  suxamethonium-sensitive 
individuals  have  the  higher  values  and  normals  the  lower 
f  igures. 
Cases  have  also  been  described  (Liddell,  Lehmann  and 
Silk,  1962;  Hart  and  Mitchell,  1962;  Gutsche,  Scott  and 
Wright,  1967)  with  little  or  no  cholinesterase  activity, 
attributable  to  a  homozygous  state  for  a  "silent"  gone, 
which  is  allelic  with  the  other  cholinesterase  variants 
(Simpson  and  Kalow,  1964).  The  locus  of  these  genes  is 
closely  linked  to  the  transferrin  locus  (Robson,  Sutherland 
and  Harris,  1966). 
A  further  serum  cholinesterase  variant  was  discovered 
by  two-dimensional  clectrophoresis,  the  first  run  on  paper 
being  followed  by  starch-gel  at  pH  8.6  (Harris,  Hopkinson 
and  Robson,  1962).  In  normal  serum  four  zones,  of  activity 
termed  CI  to  C4  are  separated.  The  C4  fraction  is  the 
slowest  moving  and  contains  about  907o  of  the  total  activity. 
In  about  107o  of  the  British  population  an  even  slower  fifth 
zone,  C  51  is  found,  which  is  genetically  determined  and 
possessors  have  on  the  average  257a  more  serum  cholinesterase 
activity  than  those  without  it  (Harris,  Hopkinson  and 
Robson,  1962;  Harris,  Hopkinson,  Robson  and  Whittaker,  1963; 
Robson  and  Harris,  1966).  This  variant  is  determined  by  a 
gene  acting  at  a  locus  distinct  and  separate  from  that 
determining  the  inhibitor-sensitive  variants  (Harris,  Robson, 
Glen-Blott  and  Thornton,  1963;  Simpson,  1968).  The  mode  of 00 
action  of  the  C5  gene  and  the  relationship  of  the  two  loci 
are  not  understood. 
Two  conventions  have  been  proposed  for  classifying  the 
generally-recognised  genes.  In  the  first  nomenclature 
(Motulsky,  1964)  the  two  loci  are  designated  E1  and  E2 
while  that  of  Goedde  and  Baitsch  (1964)  uses  Ch,  and  Ch 
2* 
The  four  variants  at  the  first  locus  are  symbolised  Eu  or  1 
Ch  U  for  the  usual  enzyme,  Ea  or  Ch 
D 
for  the  atypical 
(dibucaine-resistant)  gene,  Ef  or  Ch 
F 
for  the  fluoride-  11 
resistant  allele  and  Es  or  Ch  S  for  the  silent  gene.  At  the 
11 
second  locus  the  two  variants  are  designated  as  E2  or  Ch2 
for  normals  or  as  E+  or  Ch+  for  the  C  variants.  In  that  225 
which  follows,  the  convention  of  Motulsky  (1964)  is  used 
exclusively. 1.  (b)  Multiple  Forms  of  Enzymes. Ifl 
(b)  Multiple  Forms  of  Enzymes 
The  knowledge  that  certain  basic  metabolic  pathways 
such  as  the  glycolytic  system  and  the  citric  acid  cycle 
occur,  with,  at  most,  only  minor  modification,  in  almost 
all  living  cells  of  animals,  plants  and  micro-organisms  would 
suggest  that  the  enzymes  constituting  these  systems  are 
similar.  This  concept  was  supported  by  the  knowledge  that 
all  the  important  prosthetic  groups  and  coenzymes,  such  as 
pyridoxal.  phosphate,  coenzyme  A,  nicotinamide-adenine  di- 
nucleotide  had  the  same  chemical  structures  regardless  of 
their  derivation. 
The  basic  conviction  was  definitively  stated  by  Dixon 
and  Webb  (1958). 
"It  is  a  remarkable  fact  that  in  general  the  catalytic  properties,  specificity, 
activity,  affinities,  etc.  of  a  given 
enzyme  vary  little  with  the  source.  Although 
there  may  be  slight  physical  differences  in 
a  given  enzyme  when  it  is  produced  by 
different  cell  s,  they  are  usually  unimportant, 
and  the  enzyme  remains  essentially  the  -same  enzyme.  This  is  in  fact  a  commonplace  of 
enzymology;  for  all  practical  purposes  the 
source  of  an  enzyme  is  usually  regarded  as  a 
somewhat  secondary  matter.  " 
This  creed  may  still  be  valid  for  enzymologists  but  to  the 
clinical  biochemist  the  source  of  an  enzyme  is  of  paramount 
importance  and  any  facet  of  enzyme  existence  which  will 
disclose  this  origin  is  earnestly  examined.  Again,  to  the 
geneticist,  any  ontogenic  or  phylogenic  variation  in  a 
specific  enzyme  is  meaningful. 
As  Fischer  (1895)  observed  "the  various  maltases  that 
undoubtedly  exist  should  be  termed  corn,  yeast,  etc. 
maltases  depending  on  their  origin",  it  is  the  exception 
rather  than  the  rule  to  find  molecular  or  enzymic  identity 2[j 
between  functionally  similar  enzymes  from  different  species 
(Paul  and  Fottrell,  1961).  Even  within  the  same  species 
differences  in  functionally  similar  enzymes  had  been  noted 
as  early  as  1937  when  Bodansky  by  means  of  bile  acid  inhibi- 
tion  showed  that  the  alkaline  phosphatases  of  human  intestine 
and  bone  were  not  identical.  Abul-Fadl  and  King  (1949) 
showed  that  in  the  same  tissue,  the  human  erythrocyte,  there 
were  two  acid  phosphatases  which  differed  in  pH  optima  and 
stability  and  in  the  ultimate  case,  that  of  a  crystalline 
enzyme,  ox-heart  lactate  dehydrogenase,  Meister  (1950)  noted 
that  it  was  composed  of  two  protein  fractions  both  of  which 
possessed  lactate  dehydrogenase  activity  (Neilands,  1952). 
While  because  of  these  and  other  similar  observations,  the 
existence  of  functionally  similar  but  distinguishable  enzymes 
had  been  superficially  accepted  it  was  not  until  the  demon- 
stration  by  Wieland  and  Pfleiderer  (1957)  of  the  presence 
in  a  single  tissue  of  several  physically-separable  lactate 
dehydrogenases  that  the  phenomenon  was  generally  accepted. 
This  appreciation  of  the  existence  of  multiple  molecular 
forms  of  enzymes  has  provided  a  source  for  research  which 
has  spilled  over  into  the  fields  of  protein  chemistry, 
physiology,  pharmacology,  genetics,  evolutionary  and 
developmental  biology. 
Obviously  the  many  multiple  forms  of  enzymes  which  have 
been  described,  even  the  few  mentioned  above,  are  of  different 
types.  The  alkaline  phosphatases  would  appear  to  be 
distinctly  different  proteins  which  are  tissue  specific  within 
a  species.  Acid  phosphatases  are  probably  similar  but  there 
is  also  heterogeneity  within  tissues  as  Abul-Fadl  and  King 211 
(1949)  showed.  Hopkinson,  Spencer  and  Harris  (1963,1964) 
later  demonstrated  that  the  patterns  of  human  red  cell  acid 
phosphatases  separated  electrophoretically  are  genetically 
determined  and  have  recognised  six  phenotypes  in  European 
populations.  Following  the  work  of  Vessell  and  Bearn  (1957, 
1958)*,  IVieme  (1959)  and  Wroblewski  and  Gregory  (1960)  who 
demonstrated  the  existence  of  five  forms  of  human  lactate 
dehydrogenase,  Patterns  of  which  were  tissue  specific.,  the 
studies  of  Appella  and  Markert  (1961)  Cahn,  Kaplan,  Levine 
and  Zwilling  (1962),  and  Markert  (1963,1968)  showed  that 
these  enzymes  were  tetramers  composed  of  two  different 
polypeptide  subunits. 
Nomenclattre 
Markert  and  Moller  (1959)  proposed  the  name  isozyme, 
or  isoenzyme  (Wroblewski  and  Gregory,  1960),  for  the 
"different  molecular  forms  in  which  proteins  may  exist  with 
the  same  enzymatic  specificity".  This  was  meant  to  define 
the  forms  of  lactate  dehydrogenase  since,  Markert  and  Moller 
found  that  "all  of  the  lactate  dehydrogenase  isozymes  were 
alike  in  the  relative  catalytic  efficiency  displayed  towards 
different  substrates".  However  this  judgement  was  only 
based  on  qualitative  evidence  using  hydroxyacid  substrates 
to  visualise  the  positions  of  the  lactate  dehydrogenase 
following  electrophoresis.  It  had  already  been  shown  by 
Hess  (1958)  that  the  different  forms  showed  differences  in 
affinity  for  pyruvate,  in  optimum  pH  and  in  sulphite  inhibi- 
tion,  while  Hill  (1958)  had  reported  differences  in  heat 
stability.  This  definition  did  not  therefore  categorise  the 
types  of  multiple  enzyme  forms  which  were  to  be  called 2,21 
isoenzymes,  except  possibly  to  exclude  that  one  for  which 
it  was  specifically  introduced. 
I 
Webb  (1960)  pointed  out  that  there  was  probably  'a 
continuous  range  of  cases  and  that  any  division  of  this 
range  must  be  completely  arbitrary.  He  further  suggested 
that  the  fundamental  distinction  between  those  proteins 
which  are  recognised  as  different  enzymes  and  those  as 
isoenzymes  might  be  that  the  former  were  synthesised  under 
the  control  of  different  genes  and  the  latter  were  modifica- 
tions  of  a  single  gene  product.  However  neither  this 
definition  nor  that  of  Augustinsson  (1961)  who  suggested 
that  the  term  isoenzyme  be  "restricted  to  enzymes  the 
molecular  structures  of  which  differ,  only  in  those  parts  of 
the  molecule  that  are  not  directly  involved  in  the  enzymatic 
reaction"  appear  capable  of  practical  implementation  in  our 
present  state  of  knowledge. 
More  practicable  was  the  suggestion  of  Wieland  and 
Pfleiderer  (1962)  that  the  name  heteroenzyme  be  given  to 
proteins  of  different  origin  which  had  the  same  biological 
action  but  differed  in  physical,  chemical  and  biochemical 
properties  and  that  the  term  isoenzyme  or  multiple  form  be 
given  to  enzymes  from  the  same  source  with  very  similar  but 
distinguishable  proteins.  This  system  would  categorise  the 
alkaline  phosphatases  as  heteroenzymes  and  the  red  cell  acid 
phosphatases  and  lactate  dehydrogenases  as  isoenzymes. 
The  Standing  Committee  on  Enzymes  of  the  International 
Union  of  Biochemistry  (Webb,  1964)  then  put  forward  the 
recommendation  that  "multiple  enzyme  forms  in  a  single  species 
should  be  known  as  isoenzymes,  although  since  either  form is  readily  intelligible,  this  recommendation  is  not  to  be 
interpreted  as  excluding  the  use  of  lisozymel  if  any  ' 
individual  author  prefers  it".  This  retrograde  recommendation 
classified  all  multiple  forms  as  isoenzymes  and  the  situation 
concerning  definition  and  nomenclature  became  so  confused 
that  King  (1965)  noted  that  unless  the  International  Union 
of  Biochemistry  clarified  and  defined  the  new  concepts  of 
different  molecular  forms  of  enzymes,  many  of  the  terms  would 
soon  cease  to  have  any  meaning. 
Recently  further  recommendations  have  been  published 
(International  Union  of  Biochemistry,  1972)  dealing  specific- 
ally  with  isoenzymes  and  genetic  variants.  Basically  two 
recommendations  were  made;  that  "the-term  'multiple  forms 
of  an  enzyme'  should  be  used  as  a  broad  term  covering  all 
proteins  possessing  the  same  enzymatic  activity  and  occurring 
naturally  in  a  single  species"  and  that  "the  term  lisoenzymel 
or  lisozymel  should  apply  only  to  those  multiple  forms  of 
enzymes  arising  from  genetically  determined  differences  in 
primary  structures  and  not  to  those  derived  by  modification 
of  the  same  primary  sequence".  Of  the  seven  groups  of  multiple 
forms-listed,  only  three,  those  due  to  genetically  independent 
proteins  as  alkaline  phosphatases,  heteropolymers  of  two  or 
more  polypeptide  chains,  non-covalently  bound  such  as  lactate 
dehydrogenase  and  allelic  variants  such  as  red  cell  acid 
phosphatases  are  isoenzymes.  Multiple  forms  derived  from 
proteins  conjugated  with  other  groups,  proteins  derived  from 
one  polypeptide  chain,  protein  polymers  of  a  single  subunit 
and  proteins  differing  in  conformation,  that  is  allosterically 
modified,  are  not  to  be  classed  as  isoenzymes. 211 
It  may  be  a  moot  point  as  to  whether  acetyl-cholinesterase 
and  cholinesterase  possess  "the  same  enzymatic  activity"  to 
a  lesser  degree  than  placental  and  liver  alkaline  phosphatases 
but  for  the  present  undertaking  they  will  be  treated  as 
distinctly  separate  entities.  The  cholinesterases  synthesised 
at  the  first  and  second  loci  are  certainly  of  the  first 
category  that  of  genetically  independent  isoenzymes  while 
the  variants  at  the  first  locus  are  obviously  allelic. 
isoenzymes.  Of  the  fractions  separated  by  electrophoresis 
the  foetal  cholinesterase  probably  differs  only  in  its 
conjugation  with  sialic.  acid  while  the  others  most  likely 
represent  polymers  of  a  single  subunit  and  therefore  these 
multiple  forms  are  not.  classed  as  isoenzymes. 
Methods  of  Characterisation 
The  means  available  for  the  recognition  and  differentia- 
tion  of  isoenzymes  fall  into  four  categories,  physical, 
chemicalp  immunological  and  biochemical. 
Physical*Methods 
Most  of  these  techniques  require  extensive  preparation 
and  handling;  preferably  the  enzyme  should  be  in  a  high  state 
of  purity,  ideally  in  crystalline  form.  Then  determination 
of  molecular  weight  by  ultracentrifuge,  potentiometric 
titration  of  acidic  and  basic  groups,  determination  of 
solubility  and  isoelectric  point,  ultraviolet  absorption, 
rotational  dispersion  and  X-ray  crystallography  may  be 
attempted.  Column  chromatography  on  ion-exchange  resins  or 
uncharged  adsorbers  and  gel  filtration  are  also  available 
without  obligatory  preliminary  purification.  Human  serum 2,  E] 
cholinesterase  has  been  purified  13,000  fold  (Das  and  Liddell, 
1970)  but  crystalline  preparations  of  the  enzyme  have  not 
yet  been  obtained.  The  data  obtained  from  such  means  have 
been  summarised  earlier  (page  3). 
Electrophoresis  has  undoubtedly  played  the  single  most 
important  role  in  the  recognition  and  separation  of  multiple 
forms  of  enzymes.  It  has  certain  inherent  advantages  in 
that  it  has  wide  applicability,  is  rapid,  achieves  a  high 
degree  of-resolution  and  is  less  likely  to  produce  artifacts 
than  some  other  methods.  This  technique  has  been  success- 
fully  applied  to  the  separation  of  the  polymeric  multiple 
forms  of  serum  cholinesterase  and  the  first  and  second  loci 
isoenzymes  (page  4  an  d17).  However,  physical  methods  have 
not  been  so  efficacious  with  regard  to  the  allelic  isoenzymes 
and  conflicting  reports  have  appeared  concerning  their 
electrophoretic  and  chromatographic  separation.  Kalow  (1959) 
obtained  no  differentiation  by  fractional  precipitation  with 
ammonium  sulphate  nor  by  chromatography  on  DEAE  cellulose. 
Attempts-to  separate  the  usual  and  atypical  variants  by 
means  of  electrophoresis  were  also  unsuccessful  (Kalow,  1959; 
Ecobichon-and  Kalowp  1963;  Svensmark,  1963).  However, 
Liddell,  Lehmann,  Davies  and  Sharih  (1962)  claimed  to  obtain 
complete  separation  of  the  usual  and  atypical  variants  by 
paper  electrophoresis  at  pH  9.7  and  partial  separation  of 
the  fluoride-resistant  isoenzyme  (Liddell,  Lehmann  and  Davies, 
1963).  Separation  on  DEAE-cellulose  was  also  reported  by 
Liddell  and  colleagues  (1962).  Again  Hodgkin,  Giblett, 
Levine,  Baur,  and  Motulsky  (1965)  found  no  difference  between 
sera  of  usual  and  atypical  homozygotes  by  starch-gel 2CI 
electrophoresis  nor  by  immunoelectrophoresis. 
Chemi'c'al*  lietho*ds 
Procedures  in  this  category  include  determination  of 
terminal  and  functional  groups,  of  component  groups  either 
by  two-dimensional  paper  chromatography  or  electrophoresis 
following  proteolysis  and  indeed  sequential  analysis  of  the 
primary  structure.  In  this  field  even  moreso  than  in  the 
last,  enzyme  purity  is  mandatory  and  accounts  for  the 
depressed  statement  of  the  International  Union  of  Biochemistry 
(1972)  that  "with  regard  to  structural  criteria,  it  has  long 
been  the  hope  of  many  workers  in  the  field  that  the  inter- 
relationships  of  multiple  forms  might  soon  be  delineated  in 
chemical  terms.  However,  such  information  is  available  only 
for  a  very  few  enzyme  systems  .......  11 
Immunological  Methods 
Again  these  techniques  require  the  enzyme  proteins  in 
individual  states  of  high  purity  for  the  preparation  of  the 
antibody  and  it  must  be  confessed  that  such  methods  are  not 
as  quantitative  and  reproducible  as  required  where  minor 
differences  in  protein  structure  are  being  investigated. 
This  is  indicated  by  the  work  of  Hodgkin,  Giblett,  Levine, 
Baur  and  Motulsky  (1965)  who  found  that  neutralisation  of 
anti-human  usual  cholinesterase  was  obtained  by  similar 
amounts  of  serum  from  both  usual  and  atypical  homozygotes. 
The  technique  however  has  proved  useful  in  establishing 
heterogeneity  within  the  silent  gene  homozygote,  phenotype. 
Thus  Hodgkin  et  al.  (1965),  Szeinberg,  Pipano,  Ostfeld  and 
Eviator  (1966)  and  Kattamis,  Davies  and  Lehmann  (1967) found  a  lack  of  cross-reacting  material  in  the  sera  of  such 
individuals  but  Goedde,  Gehring  and  Hoffmann  (1965)  described 
two  similar  serum  specimens  which  neutralised  the  antibody 
to  almost  the  same  extent  as  normal  serum.  Presumably  the 
latter  cases  represented  structural  alterations  which  resulted 
in  loss  of  enzyme  activity  without  loss  of  ability  to  react 
with  normal  enzyme  antibodies. 
Biochemical  Methods 
In  contrast  to  the  foregoing  categories  most  of  the 
biochemical  criteria  can  be  obtained  without  extensive 
preparatory  work.  Determinations  of  optimum  pH,  of  substrate 
and  cofactor  affinities,  of  the  effects  of  activators  or 
inhibitors  and  of  temperature  coefficients  are  not  unduly 
influenced  by  use  of  the  enzyme  in  its  natural  milJou  or  in 
crude  preparations.  Vindication  of  this  statement  as  far 
as  human  serum  cholinesterase  is  concerned  is  given  by  the 
studies  of  Das  and  Liddell  (1970)  who  purified  the  enzyme 
13,000  fold.  These  workers  found  that  the  Michaelis  con- 
stants  with  benzoylcholine,  acetylthiocholine  and  butyryl- 
thiocholine  did  not  differ  significantly  for  the  untreated 
plasma  and  the  purified  enzyme.  Similarly  the  inhibitory 
effects  of  various  concentrations  of  dibucaine  hydrochloride, 
sodium  fluoride  and  the  neostigmine  analogue  R02-0683 
(11offman  La  Roche)  were  recorded  with  50  VII  benzoylcholine, 
5mll  acetylthiocholine  and  7.5  mM  butyrylthiocholine  and 
identical  results  obtained  with  the  purified  enzyme  and 
untreated  plasma. 
Further  the  findings  of  Kalow  (1962)  and  Liddell, 
Newman  and  Brown  (1963)  indicate  that  in  this  particular instance,  studies  on  serum  provide  a  valid  picture  of  the 
cholinesterase  present  in  other  tissues.  These  workers 
obtained  post-mortem  specimens,  in  the  studies  of  Liddell 
and  colleagues,  of  liver,  kidney,  brain,  ileum  and  skin 
from  subjects  homozygous  and  heterozygous  for  the  usual  and 
atypical  serum  variants  and  found  the  inhibition  character- 
istics  of  the  cholinesterase  of  the  tissue  extracts  to  be 
the  same  as  serum.  Doenicke,  Gurtner,  Kreutzberg,  Remes, 
Spiess  and  Steinbereithner  (1963)  found,  in  a  silent  gene 
homozygote,  that  a  liver  biopsy  specimen,  like  the  serum, 
was  devoid  of  cholinesterase  activity.  Evidently  the 
mutant  gene  products  are  found  throughout  the  body  and  their 
synthesis  is  controlled  by  the  same  genes  in  all  tissues. 
Of  the  biochemical  criteria  used  in  isoenzyme  differ- 
entiation,  that  of  the  effect  of  pIl,  buffer  and  substrates 
has  been  extensively  investigated  for  serum  cholinesterase 
as  indicated  earlier  (p.  7  et  seq.  ).  The  use  of  differential 
inhibitors  was  the  means  by  which  the  allelic  isoenzymes 
were  first  distinguished  and  there  is  now  a  considerable 
literature  on  this  aspect  (p.  16  et  seq.  ).  However  little 
or  no  attention  has  been  given  to  the  effect  of  heat  on 
cholinesterase  kinetics  although  Kalow  and  Lindsay  (1955) 
observed  that  "the  effects  of  temperature  on  the  rate  of 
hydrolysis  of  benzoylcholine  and  procaine  are  almost  identical, 
while  the  hydrolysis  of  acetylcholine  is  differently  affected". 
Apparently  no  attempt  has  been  made  to  investigate  the  possible 
differential  effect  of  temperature  on  the  enzymic  kinetics 
of  the  allelic  cholinesterases  and  Harris  (1970)  could 
conclude  "it  should  be  noted  that  in  a  number  of  properties, a"I 
for  example  thermostability  and  electrophoretic  mobility 
the  two  forms  of  the  enzyme  do  not  apparently  differ". 
Accordingly  this  appeared  to  be  an  area  in  which  investi- 
gation  was  required  and  one  which  might  provide  insight 
into  structural  differences  in  the  allelic  cholinesterase 
isoenzymes. 1.  (c)  Effect  of  Heat  on  Isoenzymes. 301 
(c)  Effect  of  Heat  on  Isoenzymes. 
Herbert  (194  4)  was,  if  not  the  first,  among  the  earliest 
workers  to  employ  differences  in  thermolability  as  a  means 
of  differentiating  enzyme  species.  She  found  that  the  acid 
phosphatase  of  prostate  extract  was  irreversibly  inactivated 
by  incubation  for  one  hour  at  37  0C  at  p1l  7.4.  At  pH  4.8 
the  enzyme  was  more  stable.  The  same  result  was  obtained 
with  prostatic  extract  added  to  human  serum  but  the  acid 
phosphatase  of  normal  serum  was  not  affected  by  this  treat- 
ment.  The  pH  of.  the  sera  during  incubation  was  not  recorded 
but  was  probably  in  excess  of  8.0  since  the  pH  of  serum 
separated  from  cells  rises  from  PH  7.4  to  8.0  in  fifteen 
minutes  at  room  temperature  due  to  loss  of  carbon  dioxide 
(King,  1965).  In  a  later  report  (Herbert,  1946),  the 
destruction  of  the  acid  phosphatase  of  prostatic  extract 
in  one  hour  at  37  0  C.  in  a  variety  of  buffers  at  p1l  7.4  was 
confirmed  but  only  a  slight  reduction  in  activity  occurred 
at  pIl  4.8  under  the  same  conditions. 
This  phenomenon  was  re-examined  by  Woodard  (1951)  who 
confirmed  that  the  thermostability  of  prostatic  acid 
phosphatase  was  pll-dependent.  However  she  found  that  heating 
for  one  hour  at  370C  at  pII  8.0  or  above,  nearly,  or  quite 
completely,  inactivated  not  only  the  acid  phosphatase  of 
the  serum  of  patients  with  metastasising  carcinoma  of  the 
prostate  but  also  the  acid  phosphatase  of  normal  female 
sera. 
The  difference  in  observations  may  have  been  the  result 
of  the  different  substrates  employed;  phenylphosphate  by 
Herbert  and  B-glycerophosphate  by  Woodard.  The  latter 31: 
author  indicated  that  she  was  aware  that  the  behaviour  of 
phosphatases  varied  considerably  with  different  substrates 
but  neither  she  nor  Herbert  appear  to  have  examined  the 
thermostability  of  the  enzymes  bver  a  range  of  temperature. 
Herbert  (1946)  did  note  that  during  the  five  hour  incubation 
proposed  by  Gutman  and  Gutman  (1938)  that  although  hydrolysis 
was  constant  at  first  there  came  a  sharp  fall-off  in 
activity,  sometimes  before  two  hours,  but  always  evident 
by  three  hours  and  progressing  until  hydrolysis  almost  ceased. 
Accordingly  she  reduced  the  reaction  time  to  one  hour. 
Again  however  she  did  not  study  the  thermostability  of  the 
enzyme  over  a  range  of  temperatures  in  the  presence  of 
substrate.  In  any  case  this  possible_means  of  different- 
iating  the  tissue-specific  acid  phosphatases  does  not  appear 
to  have  been  generally  accepted  and  employed. 
Indeed  no  further  use  of  the  phenomenon  was  apparently 
made  in  clinical  enzymology  until  Wroblewski  and  Gregory 
(1961)  utilised  the  differences  in  heat  stability  of  the 
human  lactate  dehydrogenases  earlier  noted  by  Hill  (1958). 
Wri5blewski  and  Gregory  showed  that  the  electrophorctically- 
fastest  fractions  which  predominate  in  heart  muscle  vvere 
unaffected  by  beating  for  30  minutes  at  57  0C  in  the  presence 
of  reduced  nicotinamide-adenine  dinucleotide  (NADII)  which 
increased  heat  stability.  A  scheme  for  determining  the 
relative  amounts  of  isoenzymos  present  in  serum  was  proposed. 
This  consisted  of  adding  0.2  ml  NADII  solution  (2.5  mg/ml) 
to  2  ml  of  serum,  dividing  into  three  aliquots  which  were 
then  incubated  for  30  minutes  at  bench  temperature  (A), 
57  0C  (B)  and  650C  (C)  prior  to  assay  of  lactate  dehydrogenase activities.  Total  serum  lactate  dehydrogenase  activity 
was  given  by  specimen  (A)  the  heat-labile  fraction  (LD115) 
by  (A)  -  (B),  the  heat-stable  LDH1  by  specimen  (C)  and 
intermediate  fractions  (LDH2,,  LDH3  and  LDI14)  by  (B)  -  (C). 
A  good  correlation  with  electrophoretic  separation  was 
found  in  a 
ýide 
variety  of  disease  states  by  means  of  this 
heat  stability  test  which  however  tended  to  give  relatively 
high  values  for  LDH5.  This  difference  was  attributed  to 
inactivation  of  LDH5  by  the  heat  generated  during  electro- 
phoresis. 
Independently,  Strandjord  and  Clayson  (1961)  found  that 
heating  liver  homogenates  for  30  minutes  at  65  0C 
resulted 
in  a  loss  of  99.57o  of  lactate  dehydrogenase  activity  but 
only  477o  of  heart  homogenate  activity  was  destroyed  under 
these  conditions.  They  suggested  measurement  of  the 
heat-stable  lactate  dehydrogenase  in  serum  as  a  diagnostic 
index  of  myocardial  infarction.  In  patients  with  congestive 
heart  failure,  hepatitis  and  after  surgical  operation  the 
'heat-stable  lactate  dehydrogenase  activity  was  -the  same  as 
in  normal  sera  and  this  was  confirmed  and  expanded  in  a 
later  report  (Strandjord,  Clayson  and  Freier,  1963). 
In  the  interval  Van  Der  Helm,  Zondag,  Hartog  and  Van 
Der  Kooi  (1962)  demonstrated  that  following  heating  for 
thirty  minutes  at  560C,  LD113,  LDH4  and  LD115  were  no  longer 
demonstrable  by  electrophoresis  and  the  scheme  of  Wro"blewski 
and  Gregory  (1961)  was  simplified  by  Bell  (1963)  and  Latner 
and  Skillen  (1963)  to  heating  at  60  0C  for  one  hour.  The 
latter  workers  found  that  the  "heat  stability  index",  that 
is,  the  ratio  of  activities  of  the  heated  and  unheated  samples, 3,  "-,  l 
was  greater  than  0.5  in  myocardial  infarction,  consistently 
less  than  this  in  other  diseases  and  in  health  was  less 
than  0.3.  This  last  figure  is  difficult  to  reconcile  with 
the  known  isoenzyme  composition  of  normal  sera  and  was  not 
confirmed  personally  (King,  1966). 
Even  the  simplified  procedures  have  not  enjoyed  a  wide- 
spread  use  in  routine  clinical  practice  mainly  because  of 
the  lengthy  periods  of  denaturation.  Employment  of  a 
sub-optimal  concentration  of  2-oxobutyrate  in  the  assay  of 
"alpha-hydroxybutyrate  dehycrogenase"  (Rosalki  and 
Wilkinson,  1960)  has  proved  more  acceptable,  albeit 
possibly  with  less  vindication  of  its  diagnostic  value 
(Ellis  and  Goldberg,  ý971;  King,  1972). 
The  relative  stabilities  to  heat  displayed  by  tho 
isoenzymes  of  lactate  dehydrogenase  are  almost  mirrored 
by  their  cold  stability.  Zondag  (1963)  demonstrated  that 
tile  LD114  and  LDI15  of  liver  extract  in  barbital  buffer  of 
p1l  7.9  were  destroyed  overnight  at  -20 
0  C.  Thin  occurred 
in  the  buffered  extract  only,  was  not  evident  in  the  tissue 
alone  at  -20 
0C  and  could  be  prevented  In  the  buffered 
homogenate  by  addition  of  NAD.  This  addition  also  appeared 
to  increase  the  speed  of  anodal  migration  of  LDIII  and  LD112. 
The  lability  at  low  temperatures  of  the  slower-moving 
fractions  was  confirmed  by  Kreutzer  and  Ferris  (1964)  who 
reported  however  that  LD114  was  less  stable  than  LD115  under 
these  conditions. 
Differences  in  the  heat-sensitivity  of  alkaline 
phosphatases  were  first  reported  by  Moss  and  King  (1962), 
who  recorded,  without  further  discussion,  that  at  55  0C  and 34 
pH  7.0,  the  times  required  to  reduce  the  activities  of 
bone,  kidney,  intestine  and  liver  isoenzymes  to  half  the 
initial  level  were  8,12j  15  and  18  minutes  respectively. 
The  remarkable  stability  to  heat  of  placental  alkaline 
phosphatase  was  later  demonstrated  by  Neale,  Clubb,  Hotchkis 
and  Posen  (1965).  The  activity  of  this  isoenzyme,  which 
predominates  in  serum  in  the  third  trimester  of  pregnancy 
(McMaster,  Tennant,  Clubb,  Neale  and  Posen,  1964)  is  not 
altered  by  heating  for  30  minutes  at  70  0C  in  the  presence 
of  10-  211 
magnesium  ions.  The  presence  of  the  metal  ion 
activator  was  not  necessary  with  fresh  placental  homogenate 
or  with  serum  enriched  with  placental  enzyme. 
The  studies  of  Posen,  Neale  and,  Clubb  (1965)  to 
determine  the  source  of  origin  by  the  heat  lability  of  the 
alkaline  phosphatase  indicated  that  the  heat  sensitivity 
of  each  isoenzyme  remained  characteristic  and  independent 
of  the  influence  of  others  in  the  mixture.  They  were  able, 
by  means  of  heating  for  30  minutes  at  560C,  to  distinguish 
between  "osteoblastic"  and  "hepatic"  sera  and  to  conclude 
that  normal  serum  behaved  like  a  mixture  containing  50  to 
759o'  of  the  skeletal  isoenzyme.  Further,  on  the  observed 
differences  between  bile  and  liver  isoenzymes  they  concluded 
that  the  serum  alkaline  phosphatase  from  patients  with 
hepatic  disorders  behaves  like  a  mixture,  predominantly  of 
the  bile  enzyme.  Fishman  and  Ghosh  (1967)  confirmed  most 
of  this  work  but  found  that  since  the  heat  inactivation  of 
the  intestinal  enzyme  (50  -  657o)  was  similar  to  that  of  the 
liver  (50  -  75'io)*it  was  not  possible  to  determine  the 
tissue  source  of  the  serum  alkaline  phosphatase  by  heat r 
sensitivity  alone.  An  indication  of  the  aimount  of  intestinal 
enzyme  present  by  means  of  L-phenylalanine  inhibition  was 
also  deemed  necessary. 
In  all  of  these  studies  it  was  the  permanent  irrevers- 
ible  effect  of  heat  on  the  enzyme  protein  which  had  been 
examined,  and  while  this  was  followed  over  a  wide  range  of 
temperatures  in  some,  it  was  only  the  total  loss  of  activity 
by  one  species  following  prolonged  incubation  that  was 
sought.  Indeed  the  progressive  effect  of  heat  upon  enzyme 
activity  in  the  presence  of  substrate,  apart  from  establishing 
temperature  correction  factors  had  apparently  not  been 
studied  in  clinical  enzymology.  Certainly  it  had  not  been 
examined  with  a  view  to  possible  usefulness  in  differentiating 
enzyme  species. 
Interest  in  this  field  was  first  awakened  by  the  need 
to  determine  temperature  correction  factors  for  a  numbor 
of  serum  enzymes  (King,  1965).  This  work  revealed  that  the 
temperature-activity  curves  showed  no  abrupt  point  of 
denaturation  and  while  one  temperature  might  denature  one 
enzyme  and  not  another,  this  was  only  a  particular  facet 
of  an  individual,  characteristic  temperature-activity 
relationship.  It  was  obvious  that  where  there  were  differences 
in  the  so-called  "optimum  temperature",  that  beyond  which 
inactivation  played  a  major  role,  then  there  were  equally 
discernible  differences  at  lower  temperatures.  Thus  it 
was  found  that  the  ratios  of  activities  at  37  0C 
and  25  0C 
were  2.78  for  caeruloplasmin,  2.13  for  aspartate  transaminase 
and  1.88  for  cholinesterase.  It  could  be  argued  that  these 
represent  different  categories  of  enzymes  but  this  is  not Ilk 
%J 
a  valid  point.  As  it  is  even  in  the  same  class,  say  the 
oxido-reductases,  differences  as  wide  were  found  with  values 
of  2.78  for  isocitrate  dehydrogenase;  2.5  for  malate 
dehydrogenase;  and  1.89  for  6-phosphogluconate  dehydrogenase. 
Early  studies  on  heat  denaturation  at  60  0C  with 
lactate  dehydrogenase  and  malate  dehydrogenase  in  the  sera 
of  patients  suffering  from  a  wide  range  of  diseases  had 
indicated  that  clinically  useful  information  could  be 
derived  from  the  differing  isoenzyme  responses  to  heat 
(King,  1966).  On  the  practical  side  however  the  delays 
during  the  pre-assay  denaturation  process  militated  against  its 
employment  in  routine  clinical  laboratories.  A  study  of 
the  temperature-activity  relationship-of  lactate  dehydrogenase 
in  human  serum  was  then  undertaken  and  while  distinct 
differences  were  noted  depending  upon  the  isoenzyme.  compo- 
sition  there  was  invariably  present  in  varying  proportions 
at  least  four  of  the  five  isoenzymes  as  revealed  by  agar-gel 
electrophoresis  (Wieme,  1959).  The  same  applied  to  tissue 
extracts  and  facilities  for  isolating  the  isoenzymos  of 
human  lactate  dehydrogenase  were  not  available  at  that  time. 
The  same  impediments  applied  to  the  "tissue-specific" 
isoonzymes  of  alkaline  phosphatase.  The  obvious  solution 
to  this  was  the  study  of  an  enzyme,  the  molecular  species 
of  which  were  already  completely  separated  in  human  sera, 
and  in  this  respect  the  genetically-determined  isoenzymes 
of  cholinesterase  appeared  to  be  a  perfect  example.  In 
homozygous  individuals  only  one  enzyme  variant  is  present. 
Further  cholinesterase  is  clinically  labelled  as  -a  "serum- 
specific"  enzyme  and  as  such  evinces  a  relatively  high 'S 
activity  precluding  the  need  for  preliminary  purification. 1.  (d)  Aims  of  the  study. t>  'ýýi 
(d)  Aims  of  the  study 
The  scheme  of  work  envisaged  was  an  investigation  into 
methods  of  differentiating  the  human  serum  cholinesterase 
variants  and  an  examination  of  these  as  a  means  of  assessing 
molecular  differences.  An  emphasis  was  to  be  placed  on  the 
effect  of  heat  on  the  enzyme  kinetics. 
It  was  considered  that  studies  with  various  inhibitors 
and  substrates  might  reveal  further  phenotypes  and  possibly 
give  some  indication  of  the  structural  differences.  On  a 
more  practical  plane  it  was  hoped  to  elaborate  simple 
screening  procedures  for  suxamethonium-sensitive  individuals 
and  to  gain  enlightenment  on  the  anomalies  between  biochem- 
ical  parameters  and  physiological  observations. 2.  Benzoylcholine  Hydrolysis. 
(a)  TemperatUre  studies. sq, 
Benzoylcholine  has  certain  recommendations  as  a  substrate 
for  studies  on  cholinesterase.  First,  it  has  the  advantage 
of  specificity  (Mendel  and  Rudney,  1943)  and  therefore 
although  it  was  proposed  only  to  examine  human  serum,  even 
a  degree  of  haemolysis  would  not  invalidate  results. 
Secondly,  benzoylcholine  has  an  absorption  maximum  at 
232  nm  much  greater  than  its  hydrolysis  products  which 
absorb.  maximally  at  224  nm.  The  rate  of  hydrolysis  can 
therefore  be  readily  monitored  in  an  ultraviolet  spectro- 
photometer.  The  validity  of  an  initial  reaction  rate  assay 
compared  to  other  types  of  enzyme  activity  determination 
is  well  established.  Finally,  benzoylcholine  has  proved 
to  be  a  particularly  useful  substrate  in  studying  the 
allelic  variants  of  human  cholinesterase  (Kalow  and  Staron, 
1957;  Harris  and  11.1hittaker,  1962).  Indeed  it  was  with  this 
substrate  in  the  assay  procedure  of  Kalow  and  Lindsay 
(1955)  that  the  means  of  identifying  these  variants  was 
discovered  by  dibucaine  inhibition  (Kalow  and  Genest,  1957). 
Almost  as  a  matter'of  custom  since  then,  the  same  assay 
procedure  has  been  employed  in  investigations  with  other 
inhibitors  in  differentiating  the  human  cholinesterase 
allelic  isoenzymes. 
Kalow  and  Lindsay  (1955)  did  not  follow  the  substrate 
hydrolysis  at  232  nm  but  at  240  nm.  The  difference  in 
absoxýptions  between  benzoylcholine  and  its  hydrolysis 
products,  mainly  benzoate,  is  greatest  at  235  nm  but  this 
is  reduced  by  less  than  10%  at  240  nm.  At  the  lower 
wavelength  the  dilute  serum  itself  has  an  absorption  of 
1.2  but  at  240  nm  this  is  reduced  to  0.5.  This  latter 1  40 
wavelength  was  obviously  chosen  as  giving  an  acceptable 
initial  absorption  while  retaining  adequate  sensitivity 
in  following  the  hydrolysis  of  benzoyleholine.  A  50  vM 
concentration  of  benzoylcholine  in  the  final  reaction 
M 
mixture  was  employed  at  PH  7.4  given  by  a  -f-5  Sbrensen 
phosphate  buffer.  These  workers'were  obviously  aware  that 
these  conditions  did  not  give  maximal  activities  but,  as 
with  the  choice  of  wavelength,  were  optimal  compromises. 
This  knowledge  was  explicit  in  later  reports  which  gave 
a  ratio  of  5.5  between  the  Ifichaelis-Menten  constants  for 
the  atypical  and  usual  enzymes  and  of  0.5  for  the  Vmax 
ratio  (Davies,  Marton  and  Kalow,  1960)  thereby  indicating 
that  the  substrate  concentration  for  maximal  activity 
varied  with  the  cholinesterase  phenotype. 
Preliminary  experiments  with  the  limited  phenotype 
sera  available  at  the  beginning  of  this  project  indicatod 
that  a  50  lilt  benzoylcholine  concentration  was  indeed 
optimal  for  the  usual  enzyme  at  25  0  C.  The  atypical  enzyme 
required  a  substrate  concentration  of  about  125  Of  for 
saturation.  However  since  inhibition  by  excess  substrate 
was  found  with  all  variants  tested  and  most  acutely  with 
the  usual  enzyme,  it  was  obvious  that  unless  the  substrate 
concentration  were  to  be  varied  for  each  phenotype  then 
that  optimal  for  the  usual  enzyme  was  the  best  compromise. 
Tentative  investigations  into  the  effect  of  pll  on 
benzoylcholine  hydrolysis  were  generally  in  agreement  with 
the  findings  of  Kalow  (1964).  The  oPtimum  p1l  varies  with 
the  type  and  ionic  strength  of  the  buffer,  with  the  substrate 
concentration  and  also  with  the  enzyme  variant.  With  a If 
M 
50  VM  benzoylcholine  concentration  and  1-5  Sbrenson  phosphate  15 
buffer  the  usual  enzyme  has  an  optimu  m  pH  about  9.0,  the 
atypical  about  8.5.  At  a  100  pM  substrate  concentration 
the  atypical  pH  optimum  was  slightly  increased  towards  that 
of  the  usual  enzyme  at  its  optimal  substrate  concentration. 
At  these  hydrogen  ion  concentrations  however  the  spontaneous 
hydrolysis'of  the  substrate  was  no  longer  neglibible  and 
certainly  not  at  higher  temperatures.  This  factor 
presumably  had  made  for  the  original  choice  of  pH  7.4. 
As  it  was,  the  proposed  scheme  of  study  did  not 
envisage  elaborating  new  assay  conditions  if  those  already 
available  and  well-tested  were  adequate.  Obviously  the 
kinetics  of  cholinesterase  are  very  complex  and  any  now 
sot  of  assay  conditions  would  be  difficult  to  justify  as 
superior  to  those  originally  set  out  by  Kalow  and  Lindsay 
(1955).  Even  if  this  could  have  been  done  the  knowledge 
with  regard  to  phenotyping  accumulated  over  the  intervening 
years  would  be  void,  and  it  would  be  an  empty  exercise  to 
repeat  this  with  the  new-assay  conditions.  Accordingly 
the  assay  procedure  of  Kalow  and  Lindsay  (1955)  which  had 
been  found  to  give  remarkably  reproducible  results  was 
adopted  without  modification  for  temperature  studies. 
The  negligible  variation  with  temperature  in  the  difference 
in  molar  absorptivities  of  benzoylcholine  and  benzoate  at 
pH  7.4  was  a  bonus  since  this  meant  that  the  rate  of  change 
in  absorption  (AA)  was  directly  and  constantly  related  to 
enzyme  activity  at  all  temperatures  studied. ilt  2- 
Instrumentation,  Methods  and  Materials 
Initially,  estimations  were  carried  out  on  a  Unicam 
SP  800  recording  spectrophotometer  with  scale  expansion  to 
a  Servoscribe  recorder.  Temperature  control  was  obtained 
by  circulating  water  from  a  Shandon  water-bath  through  the 
jacketed  cuvette-holder.  Cooling  was  obtained  by  adding 
ice  chips  to  the  water-bath.  Later,  a  Unicam  SP  8000 
recording  spectrophotometer  with  Unicam  AR  25  linear 
recorder  and  with  temperature  control  given  by  a  Tecam 
water-bath  and  Grant  Instruments  dip-cooler  was  employed. 
In  the  final  stages,  studies  were  performed  on  a  Unicam 
SP  1800  recording  spectrophotometer  with  Unicam  AR  25 
linear  recorder,  constant  temperature-being  assured  by  a 
circulating  Heto  water-bath  and  Grant  Instruments  dip- 
cooler.  This  last  group  of  instrumentation  was  provided 
by  the  Medical  Research  Council  under  grant  G971/343/C 
and  acknowledgment  of  this  generous  support  is  gratefully 
recorded. 
With  all  these  instruments  the  temperatures  of  the 
water-bath  and  of  the  cuvette  contents  were  correlated 
over  the  temperature  range  15  0C  to  600C  by  means  of  a 
standardised  mercury  thermometer  and  Wayne  Kerr  contact 
thermometer  respectively.  The  difference  between  the  bath 
and  cuvette  temperatures  increased  with  temperature 
deviation  from  the  ambient  as  did  the  time  required  for 
equilibration.  Temperature  control  was  improved  by  the 
use  of  Techne  polypropylene  spheres  floating  in  the 
water-bath. 
Oxford  pipettes  were  used  for  sampling  or  dispensing 0ý0 
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Figure  2.  Phenotype  ranges  of  inhibitor  numbers. 
These  inhibitor  numbers  or  percentage  inhibitions  refer 
to  the  assay  procedure  of  Kalow  and  Lindsay  (1955)  with 
a  50  IAI  benzoylcholinc  substrate  in  phosphate  buffer  at 
p1l  7.4. 
The  ranges  refer  to  25  0C  from  earlier  personal  experience 
and  to  26.50C  from  Whittaker  (1968b)  and  Lehmann  and 
Liddell  (1969). 40" 
all  volumes  less  than  2  millilitres. 
Serum  cholinesterase  activity  was  estimated  by  the 
procedure  of  Kalow  and  Lindsay  (1955),  modified  by  King 
(1965)  and  results  were  expressed  in  nanomoles  of  benzoyl- 
choline  hydrolysed  per  minute  by  one  millitre  of  serum,  . 
that  is.,  mU/ml  (International  Union  of  Biochemistry,  1961; 
1965).  Normal  values  obtained  by  this  method  range  from 
620  to  1370  mU/ml  at  259C  (King,  1965).  For  cholinesterase 
phenotyping,  activity  was  simultaneously  and  separately  assayed 
in  the  presence  of  10  pM  dibucaine  (Kalow  and  Genest, 
1957),  50  vM  sodium  fluoride  (Harris  and  Whittaker,  1961) 
and  500  mM  sodium  chloride  (Whittaker,  1968b).  All  pheno- 
typing  assays  were  performed  at  250C. 
- 
Figure  2  indicates  ' 
the  ranges  of  inhibition  by  dibucaine,  fluoride  and  chloride, 
culled  from  the  literature  and  personal  experience  and 
which  were  used  to  phenotype  serum  specimens. 
Reagents 
Benzoylcholine,  sodium  fluoride,  sodium  chloride  and 
orthophosphate  salts  were  obtained  from  BDII  Chemicals  Ltd. 
and  the  cinchocaine  hydrochloride  (dibucaine  hydrochloride) 
from  Ciba. 
67  m1l.  Sbrensen  phosphate  buffer,  pH  7.4.  Dissolve 
19.19  g  disodium  hydrogen  phosphate  dihydrate 
(Na  2  11  PO  4'  211  2  0)  and  3.48  g  potassium  dihydrogen 
phosphate  (KII  2  PO  4)  in  Nvater  and  make  to  2  litres. 
200  jill  substrate  solution.  Dissolve  48.8  mg 
benzoylcholine  chloride  in  I  litre  of  water. 
40  pM  dibucaine  solution.  Dissolve  15.2  mg 
cinchocaine  hydrochloride  in  1  litre  of  water. (iv)  200  p1l  sodium  fluoride  solution.  Dissolve  8.4  mg 
sodium  fluoride  (AR)  in  I  litre  of  water. 
(v)  2M  sodium  chloride  solution.  Dissolve  117  g 
sodium  chloride  (AR)  in  water  and  make  to  I  litre. 
Procedure 
A1  in  200  dilution  of  serum  in  buffer  was  prepared 
and  placed  in  the  blank  euvettes.  A  further  100  V1  of 
serum  was  diluted  to  10  ml  with  phosphate  buffer  and  2  ml 
of  this  dilution  added  to  each  of  the  four  test  euvottes. 
To  the  first  euvette,  that  giving  the  cholinesterase 
activity,  was  added  1  ml  of  water  and  to  the  other  three 
euvettes  I  ml  of  the  respective  inhibitor  solution.  Time 
was  allowed  for  temperature  equilibration,  then  I  ml  of 
substrate  solution  was  added  to  each  cuvotte,  the  contents 
thoroughly  mixed  with  a  plastic  paddle  and  the  reaction 
rates  recorded  at  240  nm  for  a  minimum  of  five  minutes. 
From  this  the  decrease  in  absorption  per  minuto  (AA)  was 
obtained. 
Using  the  micromolar  extinction  coefficient  for 
benzoylcholine  of  6.6  at  240  nm  (Kalow  and  Lindsay,  1955) 
then  in  a4  ml  reaction  volume  with  a  light  path  of  10  Dim 
activity  is  given  by:  - 
4 
AA  V  moles  benzoylcholine  hydrolysed  per  min 
6.6  per  20  V1  serum 
4  1000  1000  AA  =n  moles/min/ml 
6.6  20 
or  30300  AA  =  mU/ml 
It  is  not  necessary  to  calculate  the  activities  in 
the  presence  of  the  inhibitors  and  the  inhibitor  numbers 
4,4e, 11  g 
, 21%01 
(percentage  inhibition)  were  calculated  as:  - 
100  change  in  absorbance  of  inhibited  assay 
change  in  absorbance  of  uninhibited  assay) 
In  all  of  these  studies  the  substrate  solution  and 
pipette  tips  were  always  maintained  at  the  bath  temperature 
which,  below  ambient  was  lower,  and  above  ambient  higher 
than  the  euvette  contents.  Opening  the  cuvette*compartment 
causes  a  slight  change  in  the  cell-housing  temperature  in 
an  opposite  direction  so  that  the  two  effects  have  a 
tendency  to  cancel  each  other.  Certainly  after  30-60 
seconds  no  consistent,  significant  variation  in  the  reaction 
rates  with  time  was  evident  within  the  limits  imposed  by 
substrate  saturation. 
It  was  also  established  that  the  activity  and  the 
response  to  inhibitors  of  serum  diluted  in  phosphate  buffer 
did  not  alter  significantly  during  eight  hours  at  bench 
temperatures.  All  temperature  variation  experiments, 
usually  from  15  0C  to  60  0C  in  steps  of  0C  wore  undertaken 
in  one  run  which  usually  took  from  six  to  eight  hours.  For 
these  temperature  studies  therefore  1  ml  of  serum  was 
diluted  to  100  ml  with  phosphate  buffer.  This  was  then 
employed  throughout  the  experiment  and  reduced  errors  due 
to  preparing  fresh  dilutions  for  each  temperature. 
The  enzyme  source  for  these  studies  was  sera  from 
normal,  healthy  volunteers,  from  hospital  patients  with  a 
wide  variety  of  pathologies,  from  patients  who  had  exhibited 
prolonged  apnoeic  responses  to  suxamethonium  and  from  their 
relatives.  A  service  was  instituted  at  the  Department  of 
Biochemistry,  Royal  Infirmary,  Glasgow  which  offered  to 
phenotype  any  serum  spec.  imen  referred  and  also  offered il 
cholinesterase  phenotyping  to  close  relatives  of  those 
confirmed  as  sensitive  by  inhibition  studies.  Sensitivity 
cards  (Telfer,  McDonald  and  Dinwoodic,  1964)  are  issued  to 
all  individuals  of  the  four  phenotypes  invariably  at  risk, 
that  is,  Ea  1  Ea  1  Ea  1  Ef  1  EfEf  and  11  EsEs  11 
As  a,  result  of  the  widespread  use  whicli  has  been  made 
of  this  service,  an  adequate  suPPly  of  material  has  becn 
available  and  individuals  of  all  the  ten  generally-recognised 
genotypes  have  been  discovered,  some  the  first  recorded  in 
Scotland.  Table  I  indicates  the  generally-accepted  geno- 
types  at  the  first  locus,  the  nomenclature  employed 
(Motulsky,  1964)  and  the  frequency  of  occurrence  in  the 
population  (Lehmann  and  Liddell,  1969). 
PHENOTYPE 
I 
Usual  liomozygote 
Usual/  Fluoride-resistant  ficterozygote 
Usual/Atypical  Heterozygote 
F1  uorido-  resistant  Homozygote 
I 
Atypica  I/Fluoride-  resistant  Heterozygote 
GENOTYPE  FREQUENCY 
-U  E.  u  E.  95  in  100 
e,  E,  '  11.190 
Eý  E!  I  in  280 
I  in  26 
f  E!  EI  1  In  300.000 
ý  Eý  lin20Q000 
a  Ef  I  in  29.000 
0.1  in  2,800 
Atypicol  Homozygote 
E5,  I  in  20,000 
Silent  Homozygote  E,  I  in  140,000 
Table  1.  Frequency  of  occurrence  of  the  cholinesterase  phenotypes. 47 
Experimental  Results 
As  indicated  earlier  (page  35)  differentiation  of 
isoenzymes  by  heat  had  only  been  attempted  where  there 
were  differences  in  the  irreversible  denaturation  of  the 
molecular  species.  To  determine  whether  such  differences 
exist  between  the  cholinesterase  variants,  serum  specimens 
of  the  three  usual/atypical  genotypes  were  incubated  for 
various  periods  at  temperatures  from  25  0C  to  60  0  C.  The 
samples  were  then  assayed  at  25  0C  for  cholinesterase 
activity.  Below  50  0C  there  was  no  evidence  of  denaturation 
in  any  sample  for  incubation  periods  up  to  one  hour. 
Table  2  shows  some  typical  results  obtained  from  this  series 
of  experiments  which  indicated  that  there  was  no  substantial 
difference  in  the  irreversible  thermal  denaturation  of  the 
cholinesterase  variants  studied.  That  the  change  was 
irreversible  was  confirmed  by  re-assay  of  the  specimens 
four  to  six  hours  after  original  removal  of  the  heated 
aliquot  and  dilution  in  buffer  (Table  2). 
These  denaturation  experiments  were  carried  out  at  the 
50  VII  benzoylcholine  concentration  of  Kalow  an6  Lindsay 
(1955)  which  preliminary  studies  bad  indicated  was  substrate- 
saturating  at  250C  for  usual  homozygote  sera.  The  prelim- 
inary  studies  had  also  confirmed  the  findings  of  Davies, 
Marton  and  Kalow  (1960)  that  heterozygotes  had  higher  optimal 
substrate  concentrations.  Obviously  these.  optimal  concen- 
trations  would  increase  with  temperature  but  no  cognisance 
of  this  or  of  change  in  the  optimal  p1l  with  temperature  was 
taken  in  the  next  series  of  experiments.  In  this  study 
sera  from  patients  who  had  undergone  prolonged  paralysis 9P  r'll 
ýtq 
following  suxamethonium  administration  and  from  members 
of  their  families  were  assayed  at  increasing  temperatures 
as  indicated  under  Methods.  Preliminary  studies  (King,  1967) 
had  shown  striking  differences  in  the  effect  of  heat  on 
the  enzyme  reaction  rate  and  these  are  confirmed  and 
extended  in  the  following  family  studies  (King  and  Dixon, 
1969;  King,  McQueen  and  Morgan,  1971). Table  2. 
Heat  Denaturation  of  Serum  Cholinesterase 
uuu  'a  aa  Temperature  (minutes)  El  El  (J.  B.  )  El  El  (M.  G.  )  El  El  (j.  L.  ) 
0  610  mU/ml  5so  MU/Ml  184  mU/ml 
5  98.57o 
500 
98.57o  m 
C 
30  93%  96.5%  91ck 
60  75.57o  79.57o  73% 
0  585  mU/ml  560  mU/ml  176  m.  U/ml 
0C 
5  657o  Mo  76'/o 
30  12.57o  I%  297o 
60  1.57o  1.57o  3.576 
0  606  mU/n-a  565  mU/ml  179  mU/ml 
600C 
5  37o  3.57o  im 
30  1.570  1.970  6.5"'10 
60  1.57o  1.57o  3.9jo 
Repeat  assays  after  4  to  6  liours 
0  615  niU/n-a  575  mU/ml  173  mU/nil 
5CPC 
5  957o  957o  96.5%, 
30  847o  9070  88% 
60  707o  76'lo  '12k 
0  615  mU/na  585  mU/ml  186  rnU/ml 
0C 
5  687o  727o  77.57o 
30  177o  19%  297o 
60  3.57o  -  1070 4,11 
Case  1 
The  patient  (A)  exhibited  Prolonged  apnoea  after 
suxamethonium  was  given  during  an  obstetric  procedure  prior 
to  delivery.  Assay  of  her  serum  yielded  values  of 
395  mU/ml  for  cholinesterase  activity,  21  for  dibucaine 
number  (DN)  and  17  for  fluoride  number  (FN).  She  was 
aa  accordingly  classified  as  phenotype  E,  El,  homozygous  for 
the  atypical  enzyme.  Later  figures  for  the  son  (B)  were; 
serum  cholinesterase  700  mU/ml,  DN  =  58,  FN  =  46  indicating 
a  genotype  EuEa  while  the  father  (C)  was  a  usual  homozygote, 
EuEu  with  cholinesterase  activity  of  920  mU/ml,  DN  =  78  11 
and  FN  =  66.  Cord  blood  serum  from  a  second  child,  a 
daughter  (D)  permitted  classification-as  an  atypical 
heterozygote  with  cholinesterase  activity  470  mU/ml,  DN  =  61 
and  FN  =  50. 
The  cholinesterase  temperature/activity  relationship 
of  this  family  are  shown  in  Figure  3. 
Cas  e 
The  brother  (E)  of  a  suxamethonium-sensitive  patient 
was  found  to  have  a  serum  cholinesterase  activity  of 
475  mU/ml,  dibucaine  number  51,  fluoride  number  46  and  was 
u  it  therefore  classed  as  an  atypical  heterozygote,  EI  r"  1.  Of 
his  two  sons,  one  (F)  was  apparently  a  usual  homozygote 
with  DN  =  77  and  FN  =  62  but  with  a  low  serum  cholinesterase 
activity  of  370  mU/ml  while  the  other  (G)  exhibited  an  even 
lower  activity  of  220  mU/ml  with  DN  =  29  and  FN  =  27. 
These  latter  figures  suggested  an  atypical  homozygote  but 
investigation  of  the  mother's  serum  gave  values  of  555  mU/ml 
for  cholinesterase  activity  and  80  and  57  for  percentage ,E 
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Figure  3.  Cholinesterase  teniperature/nctivity  curves  of  desiCnated 
family  members  of  Case  1 
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Figure  4.  Cholinesterase  temperature/activity  curves  of  desIgnated 
family  members  of  Case  2  (pages  49,50). nk 
dibucaine  and  fluoride  inhibition  respectively.  The 
presence  of  a  silent  gene  in  the  mother  (11)  was  therefore 
evident,  assumed  in  the  son  (F)  and  both  Nvere  classified 
as  genotype,  EU  Es.  The  second'son  was  obviously  an  11 
atypical/silent  heterozygote,  EaES  1V 
The  variation  of  serum  cholinesterase  activity  with 
temperature  in  this  family  is  illustrated  in  Figure  4. 
Case  3 
Following  suxamethonium  injection  during  dental 
anaesthesia  patient  (J)  was  apnoeic  for  35  minutes.  Serum 
assays  indicated  that  he  was  heterozygous  for  both 
dibucaine  -  and  fluoride-resistant  genes,  EaEf  with  11 
cholinesterase  activity  of  305  mU/ml,  DN  =  42  and  FN  =  34. 
Both  his  daughter  (K)  and  a  grand-daughter  (L)  were 
classified  as  atypical  heterozygotes,  Eu  E  CIL 
1  1,  with  cholin- 
esterase  activities  of  640  mU/ml  and  685  MU/ml,  dibucaine 
numbers  of  65  and  67  and  fluoride  numbers  of  55  and  52 
respectively.  Figure  5  illustrates  the  temperature/activity 
curves  for  serum  cholinesterase  in  the  three  generations 
of  this  family. 
Case  4 
The  patient  (M)  suffered  prolonged  paralysis  following 
suxamethoniuri  administration  prior  to  external  cdphalic 
version  of  her  second  child.  Assay  of  her  serum  at  this 
time  yielded  anomalous  figures  (page  124)  but  later  results 
indicated  a  phenotype  of  EfEf  with  cholinesterase  activity  11 
of  480  mU/ml  and  dibucaine,  fluoride  and  chloride  numbers 
of  64,36  and  28  respectively.  The  baby  girl  was  found  to (E3E?  ) 
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Figure  5.  Cholinesterase  temperature/activity  curves  of  OesiCnated 
family  members  of  Case  3  (page  50). 
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be  genotype  E  U.  Ef  as  was  the  elder  boy  (0)  whose  serum 
cholinesterase  activity  was  1010  MU/ml  with  DN  =  70, 
FN  =  47  and  C1  N=  19.  Assay  of  the  husband's  serum  (N) 
gave  results  for  cholinesterase  activity  of  695  mU/ml 
and  DN  =  79,  FN  =  59  and  C1  N=  10,  a  usual  phenotype 
although  the  rather  low  activity  in  a  healthy  young  adult 
might  suggest  the  presence  of  a  silent  gene.  Equally, 
of  course,  it  was  realised  that  the  patient's  phenotypic 
behaviour  might  mask  a  silent  gene. 
The  patient's  mother  was  deceased  but  her  father  (P) 
with  dibucaine)  fluoride  and  chloride  numbers  of  74,52 
and  IS  respectively  was  classified  as  a  usual/fluoride- 
resistant  hoterozygote,  Eu  Ef  as  was-.  paternal  aunt.  11 
On  examining  the  sera  of  the  maternal.  uncle  and  aunt  it 
was  found  that  they  were  homozygous  for  the  usual  and 
fluoride-resistant  genes  respectively.  The  aunt  (Q)  had 
a  sertim  cholinesterase  activity  of  78  mU/ml,  DN  =  67, 
FN  =  39  and  C1  N=  26,  a  second  fluoride-resistant  homozygote 
in  the  same  family  but  in  an  earlier  generation.  This 
evidence  for  the  presence  of  a  fluoride-resistant  gene  in 
the  maternal  family  made  it  unnecessary  to  postulate  the 
presence  of  a  silent  gene  and  the  cholinesterase  activity 
of  1400  mU/ml  in  the  maternal  uncle  made  it  unlikely.  The 
temperature-activity  relationships  of  the  members  of  this 
family  given  letters  in  the  text  are  shown  in  Figure  6. 
Details  of  the  serum  assays  on  all  members  studied  are 
given  in  Table  3  and  the  cholinesterase  phenotyping  is 
illustrated  in  Figure  7. X- 
C) 
Ö 
Reaction  Temperature  ('C) 
Figure  6.  Cholinesterase  temperature/activity  curves  of  designated 
family  members  of  Case  4  (pages  50,51). Table  3 
Assay  values  for  thefamily  of  Case  4 
Scr=  cholinesterase 
(mTJ/Pil  at  250C) 
Dibucaine 
N'Limber 
Fluoride 
Number 
. 
Cliloride 
.. 
NuiTbcr  Phenotype, 
Patient  (11)  480  64  36  28  EfEf 
Son  (0)  1010  70  47  19  EUEf 
11 
Daughter  580  72  55  18  E  u.  Ef 
Husband  (N)  695  79  59  10  it  u  EIE 
rather  (P)  645  74  52  18  E"ýý  Fý 
f 
1 
Paternal  Uncle  1.070  82  64  13  EUEu 
11 
Paternal  Aunt  880  77  48  20  F,  -ý.  E,  f 
11 
Maternal  Uncle  1400  81'--  59  IG  EU  11,  U 
Maternal  Aunt  780  67  39  26  f  r" 
Figure  7.  Phenotype  relationship  of  Case  4  family  (pages  50,51). 52 
Case  5 
The  patient  (R)  was  a  month-old  baby  boy.  Serum  assay 
gave  a  cholinesterase  activity  of  530  mU/ml,  dibucaine 
number  52,  fluoride  number  29  and  chloride  number  39 
af  consistent  with  a  genotype  E1E1  Cholinesterase  pheno- 
typing  of  the  parents  indicated  that  the  father  (S)  was  an 
atypical  heterozygote  with  cholinesterase  activity  of 
585  mU/ml,  DN  =  60,  FN  =  48  and  Cl  N=  23  while  the  mother 
(T)  had  a  serum  cholinesterase  of  210  mU/ml  with  dibucaine, 
fluoride  and  chloride  numbers  of  62,33  and  28  respectively. 
The  inhibitor  numbers  suggested  that  she  was  a  fluoride- 
resistant  homozygote,  EfEf  but  assay  of  her  parents' 
sera  revealed  that  she  was  in  fact  a  fluoride-resistant/ 
silent  heterozygote  since  her  father  (U)  was  genotype 
Eu  Ef  and  her  mother  (V)  apparently  a  usual  homozygote  but 
11 
obviously  heterozygous  for  the  silent  gone.  The  paternal 
grandmother  was  deceased  and  both  the  paternal  grandfather 
(W)  and  paternal  uncle  were  found  to  be  usual  homozygotes. 
The  cholinesterase  temperature  activity  curves  of  the 
indicated  members  of  this  family  are  shown  in  Figure  8, 
the  assay  figures  in  Table  4  and  the  cholinesterase  phono- 
type  relationship  in  Figure  9. 
Case  6 
The  patient  (X)  underwent  orthopaedic  surgery  in 
Bridge  of  Earn  Hospital,  Perthshire.  The  parents  were 
somewhat  disquieted  by  reports  of  untoward  reactions  which 
they  felt  might  have  been  a  cardiac  arrest.  Professor 
II.  G.  Morgan  thought  that  the  episode  could  have  been  a 
scoline  apnoea  and  took  blood  samples  from  the  girl  (X), E 
IN 
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Figure  S.  Cholinesterase  temperature/activity  curves  of  designated 
family  members  of  Case  5  (page  52). Table  4. 
Assay  Figures  for  th6  Family  of  Case  5 
Serm 
Cholinesteý&!  e  Dibucaine  Fluoride  ailoride 
(mU/ml  at  25  Q  Number  Number  Nunbor  Phenotyr 
Patient  (R)  530  52  29  39  EaEf  11 
F  ather  (S)  585  60  48.  23  ,u  ra  El  jjI 
Mother  (T)  210  62  33  28  Ef  11  I 
Yaternal  Grandfather  (U)  -1080  74  53  23  E,  Ef 
Maternal  Grandmther  (V)  390  79  62  15  jj  1  J. 
Paternal  Grandfather  (W)  740  80  65  13  EuEu 
Paternal  Wele  920  so  58  15  11  u  1!  "  1,  ý 
. 
1. 
FiCure  9.  Phenotype  relationship  of  Case  5  family  (page  52). r" 
her  father  (Y),  mother  (Z)  and  younger  sister.  Analysis 
of  the  sera  indicated  that.  the  patient  had  cholinesterase 
activity  less  than  30  mU/ml  and  that  the  father,  mother 
and  sister  were  of  the  usual  phenotype  with  serum  activities 
of  385.,  280  and  465  mU/ml  at  25  0C  respectively.  The  patient 
was  accordingly  classified  as  homozygous  for  the  silent 
gene,  phenotype  EsEs  and  the  parents  as  hcterozygotes 
11 
Eu  Es.  The  sister  is  probably  also  a  usual/silent  heterozy- 
11 
gote. 
The  temperature  activity  curves  for  this  famil.  y.  are 
shown  in  Figure  10. 
Another  family  of  which  at  least  two  were  silent  gene 
homozygotes  was  referred  by  Professor--Richterich  of  Berne. 
However  due  to  the  untimely  death  of  this  renowned  clinical 
biochemist  most  of  the  serum  specimens  and  all  the  details 
of  relationship  and  clinical  data  were  not  received. 
From  the  curves  of  the  foregoing  cases  which  include 
all  ten  generally-acknowledged  genotypes  and  from  studies 
on  other  sera  totalling  21  samples  of  EuE  11 
,6  of  EuE,  f 
Uaffaf11  111  Ift 
I  JP 
11  of  E1  Elp  3  of  E1EI,  5  of  E1E1  and  9  of  E. 
1  E,  mean 
values  were  calculated  relative  to  unit  activity  at  "  C,  050 
30  0C  and  370C.  These  temperature-activity  relationships 
are  illustrated  in  Figures  11,12  and  13.  Table  5  contains 
the  Q10  values  for  all  six  phenotypes  throughout  the  range 
of  temperatures  studied.  Also  derived  from  these  studies, 
the  temperature  correction  factors  for  the  three  homozygous 
phenotypes,  EUEupEfEf  and  EaEa  are  given  in  Tables  6, 
111111 
7  and  8  respectively. 
The  cholinesterase  activities  at  25  0C 
and  37  0C 
of  a Figure  10.  Cholinesteraso  temperature/activity  curves  of  do.  -Aguated 
family  members  of  Case  6  (pages  52,53). 
The  rate  of  benzoyleholine  hydrolysis  by  the  propositus 
X  was  minimal  and  of  the  same  order  as  the  spontaneous 
hydrolysis.  Despite  this  and  the  knowledge  that  at  such  0 
levels  of  activity  laree  proportional  errors  can  result 
there  was  in  several  experiments  a  tendency  for  increase 
in  the  rate  of  hydrolysis  with  temperature  exhibiting  a 
maximum  about  450C. 
20  30  ,  40  50 
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Figure  11.  Temperature/activity  relationships  of  serum  cholinesterase 
phenotypes  referred  to  unity  at  250C.  Assay  procedure 
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phenotypes  referred  to  unity  at  370C. 
of  Kalow  and  Lindsay  (1955). 
serum  cholinesterase 
Assay  procedure Table  5. 
Temperature  Coefficients  of  Serum  Cholinesterase  Variants 
uufuaffafaa  QIO  E1E11  El  Eý  ]Ej  El  El  El  El  El  El 
150  -  25  0C  1.89  1.96  1.76  1.70  1.70  1.72 
20  0-  300C  1.94  1.77  1.71  1.50  1.45  1.37 
250  -  350C  1.76  1.67  1.60  1.30  1.23  1.14 
30  0-  40()C  1.60  1.58  1.45  1.14  1.01  0.93 
350  -  45  0C  1.47  1.42  1.29  0.93  0.80  0.75 
400  -  50()C  1.26  1.19  1.11  0.65  0.58  0.59 
450  -  55  0C  0.97  0.8.0  0.85  0.35-  0.30  0.39 Table  6. 
Teffperature  correction  factors  for  sermn  cholinesteras"henotype  Oý  F'ý  1--Lll 
Reaction  Standard  Tcrnperature 
Temperature 
(0c)  2EPC  309C  37  0C 
15  1.89  2.58  3.62 
16  1.80  2.45  3.44 
17  1.70  2.32  3.25 
18  1.61  2.19  3.08 
19  1.52  2.08  2.92 
20  1.42  1.94  2.72 
21  1.33  1.81  2.54 
22  1.24  1.69  2.37 
23  1.15  1.57  2.21 
24  1.07  1.47  2.06 
25  1.00  1.37  1.92 
26  0.94  1.28  1.80 
27  0.88  1.20  1.68 
28  0.62  1.13  1.58 
29  0.78  1.06  1.49 
30  0.73  1.00  1.41 
31  0.69  0.95  1.33 
32  0.66  0.90  1.26 
33  0.63  0.86  1.20 
34  0.60  0.82  1.14 
35  0.57  0.78  1.09 
36  0.54  0.74  1.04 
37  0.52  0.71  1.00 
38  0.50  0.68  0.96 
39  0.48-  0,65  0.92 
40  0.46  0.63  0.88 Table  7. 
Tapperature  correction  factors  for  serwn  cholinesterase  phenotype  EfRf ='-l-"  1 
Reaction  Standard  Temperature 
Temperature 
OC  30'C  37  0C 
15  1.70  2.00  2.26 
16  1.60  1.89  2.13 
17  1.50  1.77  2.00 
18  1.42  1.67  1.89 
19  1.35  1.59  1.80 
20  1.28  -1.51  1.71 
21  1.22  1.43  1.62 
22  1.16  1.36  1.54 
23  1.10  1.30  1.46 
24  1.05  1.24  1.39 
25  1.00  1.18  1.33 
26  0.96  1.14  1.28 
27  0.93  1.10  1.24 
28  0.90  1.06  1.20 
29  0.87  1.03  1.16 
30  0.85  1.00  1.13 
31  0.83  0.97  1.10 
32  0.81  0.95  1.08 
33  0.79  0.93  1.06 
34  0.78  0.92  1.04 
35  0.77  0.91  1.02 
36  0.76  0.90  1.01 
37  0.75  0.89  1.00 
38  0.75  0.89  1.00 
39  0.75  0.88  1.00 
40  0.75  0.88  1.00 Table  S. 
Temperature  correction  factors  for  serum  cholinesterase  pjicnotype  aa 
Reaction  Standard  Temperature 
Tenperature 
2ýOC  30'C  370C 
15  1.75  1.96  1.95 
16  1.61  1.80  1.80 
17  1.50  1.67  1.67 
18  1.39  1.56  1.65 
19  1.30  1.46  1.45 
20  1.23  1.38  1.37 
21  1.17  1.31  1.30 
22  1.12  1.25  1.24 
23  1.07  1.20  1.19 
24  1.03  1.16  1.15 
25  1.00  1.12  1.11 
'26  0.97  1.09  1.08 
27  0.95  1.06  1.05 
28  0.93  1.03  1.03 
29  0.91  1.01  1.01 
30  0.89  1.00  1.00 
31  0.88  0.99  0.98 
32  0.87  0.98  0.97 
33  0.87  0.97  0.97 
34  0.87  0.98  0.97 
35  0.88  0.98  0.98 
36  0.89  0.99  0.99 
37  0.90  1.00  1.00 
38  0.91  1.02  1.02 
39  0.93  1.05  1.04 
40  0.96  1.08  1.07 wider  selection  of  sera  comprising  178  usual  homozygotes,, 
24  usual/fluoride-resistant.  heterozygotes,  60  usual/atypical 
heterozygotes,  3  fluoride-resistant  homozygotes,  11  atypical/ 
fluoride-resistant  heterozygotes  and  20  atypical  homozygotes 
are  shown  in  Figures  14  and  15. m'  (Ilý  j  Z> 
Discussion 
Not  all  prolonged  responses  to  suxamethonium  can  be 
attributed  to  enzymic  anomalies  and  indeed  may  not  be 
attributable  to  suxamethonium  alone  but  may  be  caused  by 
a  complex  situation'dependent  upon  anaesthctic  premedication 
or  simple  reduction  in  cholinesterase  activity  in  conjunction 
with  electrolyte  imbalance  (Kalow,  1959a).  That  there  exist 
routes  of  inactivation  or  removal  of  suxamethonium  apart 
from  hydrolysis  by  serum  cholinesterase  is  shown  by  the 
recovery  from  suxamethonium  apnoea,  albeit  slow,  of 
individuals  homozygous  for  the  silent  gene  and  therefore 
devoid  of  the  enzyme  (Hart  and  Mitchell,  1962;  Liddell, 
Lehmann  and  Silk,  1962).  It  may  well  be  a  failure  of  these 
supporting  or  alternative  mechanisms  which  results  in 
prolonged  paralysis  in  individuals  for  whom  no  genetic 
anomaly  can  be  demonstrated  (Telfer,  McDonald  and  Dinwoodie, 
1964). 
However,  a  low  serum  cholinesterase  leval  alone  is 
rarely  a  cause  for  concern  in  the  use  of  suxamethonium 
while  the  mass  of  evidence  accumulated  over  the  last  decade 
or  so  concerning  the  inherited  variants  of  serum  cholinest- 
erase  has  indicated  that  individuals  homozygous  for  one 
ssaaff 
of  the  variant  species  (E  1  Ell  El  Ell  El  E,  )  or  heterozygous 
sasfaf  for  two  (El  Ell  El  Ell  El  El)  show  undue  sensitivity  to 
suxamethonium.  Individuals  homozygous  or  heterozygous  for 
the  usual  enzyme  (E  uEu  or  E  11  EspEUEf)EuEa)  do  not 
usually  exhibit  prolonged  response  (Kalow,  1959;  Lehmann, 
Liddell,  Blackwell,  O'Connor  and  Daws,  1963).  The  rate  of 
occurrence  of  suxamethonium  apnoea  among  the  different 5  CA 
phenotypes  has  been  summarised  by  Lehmann  and  Liddell 
(1969). 
Kalow  (1959)  demonstrated  that  compared  to  the  usual 
enzyme,  the  atypical  or  dibucaine-resistant  enzyme  had  a 
reduced  affinity  for  succiny1dicholine  and  calculated  that 
at  in  vivo  concentrations  the  drug  would  not  combine  with 
the  atypical  esterase.  This  last  postulate  took  no 
account  of  the  relatively  increased  concentration,  at 
least  one-hundred  fold.,  of  enzyme  in  vivo  compared  to  the 
in  vitro  experiments  but  certainly  a  reduced  efficiency  in 
hydrolysing  suxamethonium  was  demonstrated  for  the  atypical 
enzyme.  Where  apnoea  is  connected  with  an  inherited 
cholinesterase  variant  it  has  therefore  been  assumed  that 
the  sole  cause  is  the  reduced  affinity  for  suxamethonium 
and  this  was  summed  up  by  Wylie  and  Churchill-Davidson  (1966) 
as  follows:  "The  only  difference  between  these  two  enzymes 
is  one  of  degree.  Both  are  capable  of  hydrolysing 
suxamethonium  in  vitro  but  only  the  normal  enzyme  can  do 
it  in  clinical  conditions  where  the  concentration  of 
suxamethonium  is  low.  Thus  if  a  patient  with  the  atypical 
enzyme  receives  a  dose  of  suxamethonium,  the  dilution 
caused  by  the  blood  volume  rapidly  causes  a  drop  in  its 
concentration  below  the  effective  level  for  the  atypical 
esterase.  In  these  circumstances  the  patient  remains 
paralysed  for  a  long  period  of  time". 
The  results  of  the  present  study  indicate  however 
that  the  reduced  enzyme-suxamethonium.  affinity  is  not  the 
sole  factor  causing  the  increased  time  of  paralysis  through 
decreased  hydrolysis  of  the  drug.  There  is  also  the 57 
inactivation  at  body  temperature  of  the  enzyme  variants 
present  in  the  serum  of  scoline-sensitive  subjects  which 
reduces  the  rate  of  hydrolysis.  At  least  this  has  been 
conclusively  shown  in  the  foregoing  studies  with  benzoyl- 
choline  and  was  so  reported  (King  and  Dixon,  1969).  It 
was  realised  that  this  might  not  be  the  case  with  other 
substrates,  in  particular  with  succ  inyldicholine  and 
therefore  this  was  examined  and  is  discussed  later, 
I 
(page  103  et  seq.  ) 
These  studies  also  show  that  the  presence  of  a  silent 
gene  does  not  affect  the  temperature-activity  characteristics 
of  the  allele  present  in  heterozygotes.  In  this  respect 
tile  characteristics  of  the  usual/silent  heterozygote  Ell  ES 
shown  in  loci  F  and  11  (Figure  4)  and  V  (Figure  8)  are 
identical  with  the  usual  homozygote  curves,  C  (Piguro 
N  (Figure  6)  and  W  (Figure  8).  Similarly  the  curvo  of  tho 
It 
,  ttypical/silent  lieterozygote  EIs  IE1  of  G  (Figuro  4)  is 
identical  with  curve  A  (Figure  3)  given  by  an  atypic,,  1.1 
homozygote.  Curve  T  (Figure  8)  that  of  genotype  Ef  ES  has  11 
the  same  temperature-activity  characteristics  as  those  of 
M  and  Q  (Figure  6)  given  by  the  fluoride-resistant  homozygotes. 
I 
This  was  to  be  expected,  has  already  been  noted  in  inhibition 
studies  and  was  confirmed  by  the  investigation  of  the  only 
silent  homozygote  to  be  discovered  in  this  study;  curve  X 
(Figure  10).  This  does  not  deny  that  there  may  in  some 
cases  be  minor  but  probably  undetectable  variations  due  to 
the  silent  variant  since  this  has  been  shown  conclusively 
to  be  a  heterogeneous  group  (Goedde  and  Altland,  1968; 
Rubinstein,  Dietz,  Hodges,  Lubrano  and  Czebotor,  1970). 1;  c. 
Harris,  Lehman  and  Silk  (1960)  reported  that  there 
was  "a  significant  correlation  between  the  dibucaine  numbers 
and  cholinesterase  levels  within  the  'intermediate'  phenotype". 
This  has  been  generally  confirmed  in  the  present  study 
with  the  outstanding  exception  of  individual  D  of  Case  1. 
However,  the  cholinesterase  activity  of  cord  blood  serum 
is  generally  lower  than  adult  normal  (Lehmann,  Cook  and 
Ryan,  1957;  King,  1965)  and  this  probably  accounts  for  the 
low  activity  found  in  that  case  (Figure  3).  Dibucaine  and 
fluoride  numbers  were  readily  determined  on  this  specimen 
which  also  yielded  a  curve  similar  to  those  found  in  the 
adult  phenotype.  It  is  perhaps  noteworthy  that  at  250C  at 
which  activity  was  measured  this  neonate's  serum  cholin" 
esterase  activity  was  only  a  little  higher  than  that  of  the 
mother  A  (Figure  2)  while  at  370C,  the  functional  tempera- 
turo  of  the  enzymo,  the  cord  serum  activity  was  nearly  twice 
as  high  and  this  alone  indicates  some  reduction  of  risk  in 
the  use  of  suxamethonium. 
This  single  examplc  of  the.  general  findings  reported 
above  also  helps  to  resolve  some  anomalies  noted  in  the 
literature.  Bush  (1961)  for  instance  found  "a 
scatter  of  cholinesterase  levels  imthe  heterozygote  and 
abnormal  homozygote  groups"  than  that  observed  by  Lehmann, 
Patston  and  Ryan  (1958)  and  later  by  Harris,  Lehmann  and 
Silk  (1960).  All  these  workers  used  acetylcholine  as 
substrate,  but  Bush  (1961)  employed  the  procedure  of  Biggs, 
Carey  and  Morrison  (1958)  in  which  the  pH  change  is  measured 
during  30  minutes  at  25  0  C,  while  Lehmann  and  colleagues 
recorded  the  volume  of  carbon  dioxide  liberated  in  a Distribution  of  Cholinesterose  AdiAtias  by  Phenofypo  (250C) 
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Figure  14.  Serum  cholinesterase  activities  by  phenotype  assayed 
at  250C  by  the  procedure  of  Kalow  and  Lindsay  (1959). 
The  vertical  broken  line  indicates  the  lower  limit  of 
normal  activity  (King,  1965). 
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Figure  15.  Serum  cholinesterase  activities  by  phenotype  assayed 
at  370C  by  the  procedure  of  Kalow  and  Lindsay  (1955). 
The  vertical  broken  line  indicates  the  lower  limit  of 
normal  activity  (King,  1965). U-. 
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Warburg  micromanometer  at  37  0  C.  From  the  results  of  these 
present  studies  it  is  obvious  why  the  latter  workers 
obtained  at  37  0Ca  better  separation  of  the  phenotypes  by 
assay  alone  and  indeed  emphasises  the  fact  that  a  true 
index  of  serum  cholinesterase  activity  can  only  be  obtaiDed 
if  the  estimation  is  conducted  at  the  functioning  tempera- 
ture  of  the  enzyme,  that  is,  37  0  C.  This  is  reinforced  by 
the  values  shown  in  Figures  14  and  15  of  activities  on 
the  same  specimens  by  assay  at  250C  and  37  0C  respectively. 
The  usual  homozygote  group  illustrated  in  these  figures 
is  by  no  means  representative  of  a  normal  population  and 
contains  at  least  six,  presumptive  but  almost  certain, 
usual/silent  heterozygotes  and  a  number  of  hospital  pntients, 
some  suffering  from  diseases  in  which  low  cholJnestera;  --;  o 
levels  are  to  be  expected.  Despite  this  it  it.,  readily  soon 
that  there  is  a  wide  overlap  of  activities  from  all  pliono- 
types  at  250C  (Figure  14)  and  that  a  number  of  suxamothonium.  - 
sensitive  individuals  have  serum  cholinesterase  activities 
which  can  only  be  classed  as  normal.  While  with  activities 
at  370C  (Figure  15)  the  distribution  of  the  usual  homozy.  - 
gotes  does  not  alter  significantly,  a  larger  proportion  of 
the  usual/atypical  heterozygote  group  have  activities 
which  fall  below  the  lower  limit  of  normal.  Most  conclus- 
ively  however  is  the  change  in  distribution  of  the  three 
scoline-sensitive  phenotypes  where  all  activities  are  seen 
to  be  abnormally  low.  This  is  one  of  the  facts  used  by 
King  (1972)  in  recommending  the  adoption  of  370C  as  the 
standard  temperature  for  enzyme  assays. 
Certainly  if  cholinesterase  estimations  are  carried out  at  any  other  temperature  then  for  valid  results  tliese 
must  be  corrected  to  37  0  C.  This  would  involve  determining 
the  phenotype  and  then  employing  the  appropriate  set  of 
temperature  correction  factors.  King  and  Morgan  (1970) 
suggested  that  for  routine  purposes  this  could  be  simplified 
without  incurring  a  gross  error  by  considering  two  groups 
only.  In  support  of  this  it  was  noted  that  the  phenotypes 
EUEUtEuEf  and  EuEa  have  respectively  Q  (250  -  35  0  C) 
II1111  10 
of  1.76,1.67  and  1.61  and  correction  factors  from  25  0C  to 
37  0C  of  1.92,1.82  and  1.72.  This  represents  a  maximum 
divergence  of  about  117o  in  the  range  25  0-  370C.  Again 
the  variants  EaEa  and  EaEf  have  Q  (250  -  350C)  -f  1.14  1111  10 
and  1.23  and  25  0C  to  37  0C  conversion  factors  of  1.11  and 
1.22  respectively,  a  divergence  of  less  than  10%.  Later 
(King  and  Morgan,  1971)  it  was  noted  that  for  the  Ef  I 
phenotype  the  Q  10  (250  -  350C)  was  1.30  and  the  correction 
factor  from  25  0C  to  37  0C  was  1.33,  a  divergence  of  nearly 
20%  from  the  atypical  homozygote  values  and  more  t,..  I,  i  . 3070 
from  the  normal  homozygote  figures.  This  suggested  a  third 
set  of  temperature  correction  factors  were  required.  Such 
figures  to  convert  activities  to  25  0  C,  30  0C  and  37(  the 
temperatures  recommended  (International  Union  of  Biochemistry, 
1961;  1965)  or  commonly  used  as  standard  temperatLres,  for 
the  usual  enzyme,  the  fluoride-resistant  variant  and  the 
atypical  cholinesterase  are  given  in  Tables  6,7  and  8 
respectively. 
It  is  realised  thatIthese  figures  only  apply  to  a 
benzoylcholine  substrate  and  in  fact  only  to  a  50  VM 
benzoylcholine  concentration  under  the  assay  conditions 61 
used  in  these  studies.  These  are  relevant  facts  which 
dispute  the  validity  of  using  temperature  correction 
factors  and  reinforce  the  arguments  for  international 
adoption  of  a  standard  assay  temperature  in  clinical 
enzymology  (King,  1972). 
From  these  studies  the  ratio  of  activities  at  37  0C 
and  26  0C  is  1.78  and  the  temperature  coefficient  (Q  10 
)  in 
the  range  15  0C-  25  0C  is  1.90  for  the  usual  enzyme.  These 
figures  are  in  excellent  agreement  with  the  values  given 
by  Kalow  and  Lindsay  (1955).  The  literature  does  not 
contain  comparable  thermal  characteristics  for  the  other 
serum  cholinesterase  variants. 
Reports  that  the.  magnitude-and  duration  of  suxameth- 
onium  paralysis  are  increased  by  hypothermia  (Zaimis, 
Cannard  and  Price,  1958;  Cannard  and  Zaimis,  1959)  are  in 
keeping  with  the  facts  presented  here  (Figure  12)  although 
it  is  doubtful  if  this  phenomenon  can  be  attributed  solely 
to  the  decrease  in  serum  cholinesterase  activity  with 
reduction  in  body  temperature.  In  fact  this  effect  should 
be  less  in  suxamethonium-sensitive  individuals  and  indeed 
it  is  interesting  to  speculate  that  whatever  the  function 
of  serum  cholinesterase  (Clitherow,  Mitchard  and  Harper, 
1963)  those  individuals  of  phenotypes  EaEaIEaEf  and  1111 
EfEf  will  be  less  affected  by  a  reduction  in  body  tempera-  11 
ture  than  will  normal  individuals. 
-ions  employed  in  these  studies,  Under  the  assay  condit 
the  temperatures  at  which  maximal  activities  are  obtained 
is  50  -  510C  for  the  usual  enzyme,  about  48  0C  for  the  usual 
heterozygotes  EuEf  and  EuEa$  40  0C  for  the  fluoride-  1111 62 
resistant  homozygote,  about  36  0C  for  genotype  EaEf  and  11 
32  -  33  0C  for  the  atypical  homozygote.  The  results  of  the. 
denaturation  experiments  (Table  2)  would  therefore  indicate 
that  only  in  the  case  of  the  usual  enzyme  is  the  optimal 
temperature  dictated  by  an  irreversible  process  and  that 
the  temperature  of  maximal  activity  for  the  other  variants 
is  set  by  a  progressive,  reversible  inactivation.  This 
constitutes  a  previously  undescribed  phenomenon  of  isoenzyme 
differentiation  and  indeed  would  appear  to  contradict 
Harris  (1970),  who,  referring  to  the  usual  and  atypical 
enzymes,  stated  "However  it  should  be  noted  that  in  a  number 
of  properties,  for  example  thermostability  and  clectro- 
phoretic  mobility  the  two  forms  of  the  enzyme  do  not 
apparently  differ".  This  contradiction  results  from  the 
earlier  approaches  to  thermal  differentiation  which  had 
relied,  as  in  Table  2  experiments,  upon  the  irreversible 
effect  of  heat  on  the  protein  itself  rather  than  on  its 
catalytic  activity. 
It  is  possible,  if  not  to  differentiate  each  pheno- 
type,  at  least  to  segregate,  suxamethonium-sensitive 
individuals  from  those  at  no  predictable  risk,  by  means 
of  assays  at  two  temperatures.  The  two  most  feasible 
temperatures  in  the  light  of  present  discussions  on  standard 
temperature  would  appear  to  be  25  0C  and  370C  or  30  0C  and 
37  0  C.  This  would  provide  a  method  of  differentiating  the 
usual  homozygote  and  heterozygotes  from  the  EaEa  and  EaEf  1111 
variants,  that  is,  those  most  at  risk  to  succiny1dicholine. 
The  latter  group  havO  370/25  0 
and  37  0  /300  ratios  of  less 
than  1.3  and  less  than  1.1.  respectively  while  for  the a 
U. 
former  group  these  temperature  ratios  are  1.7  to  2.0  and 
1.3  to  1.5.  It  is  not  possible  to  differentiate  further 
within  these'two  groups  with  certainty  and  King  and  Morgan 
(1970)  further  predicted  that  the  phenotype  EfEf  would  be  11 
found  to  occupy  a  position  intermediate  to  the  two  groups. 
In  fact  the  fluoride-resistant  homozygote  was  found  to  be 
closer  to  the  other  suxamethonium-sensitive  phenotypes 
than  expected  with  37  0  /25  0 
and  37  0  /300  activity  ratios  of 
about  1.35  and  1.15  (King  and  Morgan,  1971).  This  makes 
segregation  less  certain  using  30  0C  and  370C  as  the  assay 
temperatures  but  the  difference  between  the  sensitive  and 
non-predictable  groups  is  adequate  when  25  0C  and  37  0C  are 
the  temperatures  employed.  Differentiation  would  obviously 
be  improved  with  greater  divergence  in  the  two  temperatures. 
One  hesitates  to  employ  500C  which  is  close  to  the  tempera- 
ture  of  denaturation  but  assays  at  250C  and  45  0C  would  give 
ratios  of  activities 
EaEa  and  a  Ef  respi  1111 
resistant  homozygote 
phenotypes  EuEa,  Eu  I11 
f  orm  the  basis  f  or  a 
about  0.85  and  1.0  for  the  phenotypes 
actively,  about  1.2  for  the  fliioride- 
and  from  2.0  through  2.35  to  2.65  for 
fuu  E1  and  E1E1  This  could  readily 
simple  screening  test  of  surgical 
patients  for  suxamethonium-sensitivity. 
However  at  this  time  there  was  no  means  of  recording 
reaction  rates  at  240  nm  with  such  temperature  differentials 
which  could  be  mechanised  to  give  through-put  rates 
compatible  with  screening  procedures.  The  Unicam  AC  60/1800 
system  was  the  only  available  instrumentation  which  seemed 
I  to  have  the  capability.  In  co-operation  with  Mrs.  Christine 
Witchell  of  the  Applications  Dcpartment  of  Pye-Unicam, 
L 64 
Cambridge  a  study  involving  the  use  of  inhibitors  (Witchell, 
1971)  and  of  different  assay  temperatures  was  carried  out. 
The  temperature  change  proved  cumbersome  and  time-consuming 
and  even  reducing  the  scan-time  to  two  minutes  only  permitted 
processing  ten  to  fifteen  specimens  perhour.  In  addition, 
the  instrumentation  embodied  no  automatic  range  selection 
and  permanent  attendance  at  the  spectrophotometer  was 
essential.  In  later  models  of  this  spectrophotometer, 
Unicam  have  improved  the  sensitivity  and  introduced 
automatic  adjustment  of  the  absorption  range  so  that 
screening  for  suxamethonium-sensitivity  may  now  be  a 
feasible  proposition  with  this  instrument. 
Continuous-flow  mechanisation,.  as  in  the  Auto-Analyser 
systems  is  not  capable  of  yielding  valid  enzyme  reaction 
rate  assays  nor  apparently  even  valid  two-point  determina- 
tions.  In  enzyme  estimations  the  time  of  the  reaction  must 
be  precisely  known  and  the  reaction  temperature  must  be 
constant  throughout  the  reaction.  While  it  would  seem 
possible  to  arrange  these  conditions,  the  writer  is  not 
aware  of  any  fixed-time  enzyme  assay  by  continuous  flow 
technology  which  does.  Again  the  simple  filter  colori- 
meters  employed  in  Auto-Analyser  systems  do  not  permit  of 
recording  absorptions  at  240  nm.  However,  if  a  ratio  of 
activities,  as  opposed  to  an  absolute  activity  is  all  that 
is  required  then  assays  by  continuous-flow  mechanisation 
are  permissible.  The  hydrolysis  of  thiocholine  esters  may 
be  followed  at  405  nm  using  Ellman's  reagent  and  this  removes 
the  problem  of  recording  absorptions  in  the  ultra-violet 
range  with  a  benzoylcholine  substrate.  This  seemed  an 65 
eminently  practical  procedure  and  Dr.  E.  D.  Lash  of 
,  Technicon  Instruments  Corporation,  Tarrytown,  New  York 
expressed  interest  and  was  given  the  temperature-activity 
data  and  different  phenotype  samples.  By  an  ingenious 
arrangement  of  splitting  the  sample-reactant  stream  into 
water  baths  at  37  0C  and  55  0C  and  by  arranging  for  the 
signals  from  both  colorimeters  to  be  simultaneously  drawn 
on  the  same  recorder  with  peak  heights  made  equal  with 
usualýhomozygote  sera,  the  presence  of  a  suxamethonium- 
sensitive  phenotype  could  be  detected  by  a  simple  scrutiny 
of  the  chart  (Lash,  Ponzio,  Rush  and  Garry,  1972). 
Further  experiments  and  stu  . dies  in  the  field  of  mass 
screening  are  more  fully  and  appropriately  described 
later  (page  103  et  seq.  ). 
As  recorded  earlier  (page  10  et  seq.  )  variations  in 
cholinesterase  activity  occur  in  certain  disease  states 
and  in  pregnancy  (page  123)  and  some  such  specimens  are 
included  in  Figures  14  and  15.  Apart  from  this  even  in 
a  normal  healthy  population  the  scatter  of  serum  cholin- 
esterase  activities  is  regarded  as  wide  and  contradictory 
reports  and  speculations  abound  to  account  for  this. 
There  would  certainly  appear  to  be  a  positive  cor- 
relation  between  body  weight  and  cholinesterase  activity 
(Thompson  and  Trouce,  1956;  Kalow  and  Gunn,  1959)  and  this 
factor  may  in  turn  be  the  major  influence  in  the  higher 
activities  reported  in  males  (Reinhold,  Tourigny  and 
Yonan,  1953;  Breuer  and  Schbnfelder,  1961)  or  with  age 
(Kalow  and  Gunn,  1959).  In  infancy,  after  the  first 
week  of  life  (Lehmann,  Cook  and  Ryan,  1957)  and  in  children 661 
(King,  1965)  significantly  higher  activities  are  reported-. 
These  influences  have  either  not  been  observed  by  other 
workers  or  positively  refuted  (lVetstone,  Honeyman  and 
McComb,  1965). 
These  last  workers  from  a  study  of  twins,  parents  and 
sibs  concluded  on  statistical  evidence  that  there  was  a 
major  genetic  control  of  quantitative  levels  of  cholin- 
esterase  activity.  On  the  other  hand,  Simpson  and  Kalow 
(1963)  from  a  similar  examination  of  monozygotic  twins, 
like-  and  unlike-sexed  dizygotic  twins,  sibs  and  parents 
concluded  that  the  observed  variation  in  cholinesterase 
activities  was  largely  environmentally  determined  and  found 
no  evidence  for  any  important  homogenic  or  multigenic' 
control. 
With  regard  to  the  wide  range  of  cholinesterase 
activity  and  its  quantitative  control  it  has  not  been 
i 
clearly  stated  that  this.  may  be  due  to  two  possible  causes. 
The  first  is  an  alteration  in  the  rate  of  synthesis  and 
could  be  caused  either  by  a  mutation  in,  or  other  influence 
on,  a  regulator  gene,  or  by  a  similar  effect  in  an  unrelated 
gene  resulting  in  a  change  of  some  inducer  or  repressor 
substance.  This  would  involve  a  change  in  the  actual 
number  of  enzyme  molecules  produced.  The  second  cause  could 
be  the  synthesis  of  an  altered  enzyme  protein  with  consequent 
changes  in  either  catalytic  efficiency  or  structural 
stability.  This  does  not  envisage  a  change  in  the  number 
of  enzyme  molecules  produced,  but  a  quantitative  change  in 
activity  or  in  vivo  stability  secondary  to  a  qualitative 
change  in  the  enzyme. 67 
The  reduced  catalytic  activity  of  the  unusual  variants 
is  readily  appreciated  (Figure  15)  but  of  these  only  the 
genotypes  EUEf  and  Eu  Ea  occur  in  a  significant  proportion  1111 
of  the  population,  0.4%  and  47o  respectively  (Lehmann  and 
Liddell,  1969).  These  therefore  contribute  to  the  observed 
scatter  of  serum  cholinesterase  activities.  However  this 
was  appreciated  by  the  protagonists  of  the  genetic  control 
of  quantitative  enzyme  activity  who  accordingly  selected 
their  cases  from  the  "usual"  phenotype.  Although  they  did 
not  specify  the  mode  of  control  it  is  therefore  evident 
that  they  meant  factors  influencing  the  rate  of  synthesis 
as  outlined  above.  About  951,  o  of  the  population  are  pheno- 
type  EUEu  and  about  0,57o  are  probably  genotype  EUEs  The 
latter  certainly  have  reduced  cholinesterase  activity.  The 
C5  variant  E+  which  confers  additional  cholinesterase  21 
activity  occurs  in  about  10%  of  the  population  (Harris, 
Hopkinson  and  Robson,  1962).  Already  therefore  in  a 
selected  phenotype,  that  regarded  as  normal,  there  are 
two  inherited  factors  contributing  to  an  extension  at  both 
ends  of  the  "normal"  range  of  activities.  If  these 
influences  are  eliminated  from  the  population  to  be 
investigated  it  can  be  reasoned  that  the  range  of  serum 
cholinesterase  activities  will  be  much  reduced.  Only  then 
would  the  population  also  be  free  from  the  second  cause  of 
genetic  quantitative  control  previously  outlined. 
As  it  is  the  range  of  serum  cholinesterase  activities 
is  not  wide  compared  to  other  enzymes;  the  upper  limit  of 
normal  is  only  twice  the  lower  limit.  For  the  normal 
ranges  of  aspartate  transaminase  and  alanine  transaminase 63 
activities  in  serum  the  upper  limits  are  four  to  five  times 
the  lower  limits  (King,  1973).  The  normal  serum  range  for 
creatine  kinase  activities  is  0  to  100  mU/ml,  and  this  is 
doubtless  environmentally  and  to  a  lesser  extent  hormonally 
controlled.  The  higher  numerical  values  attached  to  serum 
cholinesterase  activities  are  merely  a  reflection  of  its 
"serum  specificity"  (page  11). 2.  (b)  Arrhenius  Relationships. Rl 
Preliminary  studies  had  indicated  that  the  50  jill 
benzoyl-choline  employed  in  these  studies  although  optimal 
for  the  usual  enzyme  at  25  0C  was  grossly  suboptimal  for 
the  other  allelic  isoenzymes.  At  25  0C  the  atypical  enzyme 
exhibited  maximal  velocity  with  100  pM  benzoyleholine  and 
this  was  the  concentration  required  for  substrate  saturation 
of  the  usual  enýyme  at  37  0  C.  It  was  realised  that  the 
activities  recorded  in  the  previous  experiments  did  not, 
for  the  most  part,  represent  maximum  velocities  and  that 
the  differences  in  thermal  inactivation  might  be  due  to 
differences  in  substrate  concentration  requirements  rather 
than  true  reversible  alterations  in  protein  structure. 
Specimens  of  the  threp  homozygous  sera  were  therefore 
assayed  through  the  temperature  range  at  both  50  IiM  and 
100  IN  benzoylcholine  concentrations.  The  results  shown 
in  Figure  16  would  appear  to  indicate  that  the  temperaturo 
of  maximum  activity,  or  more  precisely,  the  temperature  of 
zero  activation  energy  is  a  reflection  of  the  protein 
structure  and  relatively  independent  of  the  substrate 
concentration,  altbough  some  substrate  protection  may  be 
afforded  at  the  temperature  of  irreversible  denaturation. 
Arrhenius  plots  (Figure  17)  taken  from  the  data  of 
Figure  11  reveal  that  the  customary  linear  relationship 
can  only  be  said  to  exist  for  the  usual  homozygote  and 
heterozygotes  and  that  over  a  very  limited  temperature 
range  below  300C.  While  Figure  18  would  appear  to  indicate 
that  linearity  of  the  relationship  is  extended  by  the  use 
of  100  VII  benzoylcholine  this  is  probably  fallacious  since 
at  this  concentration  substrate  inhibition  is  encountered I 
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r-igure  16.  Temperature/activity  relationships  of  the  three 
cholinesterase  homozygotes  with  50-10.1  and  100  IiM 
benzoylcholine  substrate  in  phosphate  buffer,  p1l  7.4. 
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Figure  18.  Arrhenius  relationships  of  the  usual  cholincsteraso 
enzyme  at  benzoylcholine  concentrations  of  50  IN 
and  100  VM. 70 
at  temperatures  below  30  0C  (Figure  16)  and  this  doubtless 
contributes  to  the  extended  linearity  of  the  locus.  This 
extended  linearity  with  100  pM  benzoylcholine  is  therefore 
spurious  and  emphasises  that  a  valid  temperature-activity 
relationship  can  only  be  established  by  use  of  reaction 
conditions  which  are  optimal  at  each  temperature. 
As  it  is  these  studies  were  not  only  conducted  at  a 
fixed  substrate  concentration  but  also  at  a  fixed  hydrogen 
ion  concentration.  While  the  pII  of  a  phosphate  buffer 
does  not  change  dramatically  with  temperature  it  must  at 
the  same  time  be  conceded  that  the  p1l  7.4  buffer  employed 
by  Kalow  and  Lindsay  (1955)  does  not  permit  measurement 
of  maximum  activity.  Except  at  the  lower  temperatures 
therefore  and  then  only  for  the  usual  homozygote  and 
possibly  the  usual/fluoride-resistant  heterozygote  were 
the  conditions  employed  optimal,  yielding  maximal  velocities. 
There  was  therefore  evidence  that  the  substrate  concentration 
necessary  for  enzyme  saturation,  and  lience  the  Michaelis- 
Ifenten  constant,  the  Km,  varied  with  temperature.  Use 
could  therefore  be  made  of  the  Van't  Hoff  equation  which 
relates  the  variation  with  temperature  of  the  reaction 
0 
equilibrium  with  the  standard  enthalpy  (A  Hf)  for  the 
reaction. 
A  Ho  RT 
2d  loge  Keq 
f  dT 
This  however  would  only  be  valid  if  the  Michaelis-Menten 
constant  represented  a  true  equilibrium  constant.  Since 
it  is  generally  accepted  that  the  reaction  catalysed  by 
cholinesterase  occurs  in  three  stages,  the  last  two 
probably  irreversible. 71 
k+k 
+2 
k 
+3  EH  +  Al.  Ac.  (Ell-Al.  Ac.  Alcohol  +  E.  Ac.  H0)  EII  +  acid  T: 
1  2 
This  complicates  calculations  based  on  a  simple  reversible 
chemical  reaction. 
However  the  effect  of  temperature  on  the  rate  constant 
of  a  reaction  is  given  by  the  Arrhenius  equation 
E  RT  2d  loge  k  2.303  X  1.98  T2  _d 
logr 
a  dT  dT 
where  E.  is  the  Arrhenius  activation  energy. 
The  similarity  of  the  precise  thermodynamic  Van't  Hoff 
equation  to  the  empirical  Arrhenius  equation  can  be  recon- 
ciled  by  appeal  to  the  theory  of  absolute  reaction  rates 
which  postulates  that  the  rate  of  a  reaction  is  proportional 
to  the  concentration  of  an  activated  complex  which  is  in 
equilibrium  with  the  reactants  and  thus  governed  by  the 
usual  laws  of  thermodynamics.  It  can  be  shown  that 
E,  AT-I*  +  RT 
Where  AII4-  is  the  enthalpy  difference  between  the  actJ.  vated 
complex  and  the  reactants,  that  is,  the  enthalpy  of 
activation  which  is  related  to  the  other  thermodynamic 
functions,  the  standard  free  energy  (AF*)  and  the  standard 
entropy  (AS*)  of  activation  by  the  equation 
AFt  =  All*  -  TAS* 
The  energy  of  activation  is  readily  calculated  from 
the  differentiated  Arrhenius  equation 
4.56  T,  T2  E  --  2  10  9  T, 
ý 
T2  -  Tj 
k2 
Where 
k 
is  the  ratio  of  recorded  activities,  proportional 
to  the  rate-limiting  constant,  at  the  temperatures  T2  and  T,., 72 
that  is,  the  Q  10  values  if  T2  and  T,  are  100  C  apart.  Table  9 
shows  the  activation  energi.  es  so  calculated  from  Q10  and  Q5 
values  for  all  six  genotypes  over  the  temperature  range 
studied. 
The  Arrhenius  equation. 
d  loge  k  Ea 
dT  -ýfý2  becomes  on  integration 
E 
loge  k  loge  A-a  RT 
Ea 
Or  -T  -4.56  log  k+4.56  log  A 
Where  A  can  be  considered  a  constant  provided  the  temperature 
range  is  narrow.  Certainly  over  the  range  20-30  0C  linearity 
of  the  slopes  can  be  accepted  and  A  therefore  considered 
to  be  a  constant.  Figure  19  shows  the  loci  of  variation 
of  activation  energy  with  temperature  for  all  six  genotypes 
over  the  temperature  range  examined.  The  slopos  of  the 
loci  are  then  -4.56  log  k,  that  is  proportional  to  the 
logarithm  of  the  rate-limiting  rate  constant. 
From  this  diagram  it  can  be  seen  that  the  reaction 
catalysed  by  the  three  enzyme  variants,  the  usual,  fluoride- 
resistant  and  atypical  cholinesterases  have  zero  activation 
energies  at  49.5  0  Cj  39.5  0C 
and  33  0C 
respectively.  Above 
these  temperatures  the  reactions  become  exothermic.  In 
addition  to  these  points,  previously  recorded  in  earlier 
sections  as  temperatures  of  maximum  activity,  Figure  19 
would  indicate  that  transitions  in  the  rate-limiting  steps 
occur  for  the  usual  enzyme  at  46  0  C,  the  fluoride-resistant 
variant.  at  40.5  0C  and  the  atypical  isoenzyme  at  41  0  C. 
The  latter  two  transitions  occur  in  the  exothermic  phase Table  9  Activation  Energies  of  Cholinesterase  Phenotypes. 
(Cal/mole/degree) 
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E 
a 
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E 
a 
af 
a 
a  , -L 
E 
15-20  9310  12000  9560  9310  10800  11500 
20-25  12400  10900  9310  8550  7730  6890 
25-30  11000  9550  9390  5930  5320  4600 
30-35  9440  9440  7650  3630  2155  730 
35-40  7830  7600  6320  1150  -1890  -3645 
40-45  6200  5870  3770  -4120  -10680  -7860 
45-50  2765  808  197  -13300  -14900  -13750 
50-55  -4380  -10800  -6950  -30600  -.  35900  -25800 
15-25  11650  11500  9620  9050  9050  9240 
20-30  11650  10050  9,150  7150  6550  5400 
25-35  10600  9550  8600  4790  3780  2390 
30140  8870  8630  7100  2470  187  -1450 
35-45  7480  6810  4940  -1495  -4490  -5680 
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Figure  19.  Variation  of  activation  energies  with  temperature 
of  the  cholinesterase  phenotypes. "1" 
I 
.i 
of  the  reaction.  Other  transitional  stages  would  appear 
to  be  indicated  by  change  in  slope  of  the  loci  at  lower 
temperatures  but  there  is  no  consistent  pattern  to  these 
and  it  must  also  be  conceded  that  at  these  temperatures 
the  activities  measured  are  comparatively  low  and  hence 
least  precise  and  reliable. 
It  has  been  assumed  earlier  that  at  the  temperature 
of  zero  activation  energy,  reversible  alterations  in  the 
protein  structure  occur  and  it  is  tempting  to  speculate 
that  further  configuration  changes  occur  in  the  enzyme 
molecule  at  the  transitional  points  but  there  is  no  basis 
for  this  in  the  data  from  which  these  facts  were  obtained. 
It  is  however  valid  to  suggest  that  at  different  tempera- 
tures  short  of  protein  denaturation,  changes  do  occur  in 
the  rate-limiting  steps  which  are-characteristic  of  the 
human  serum  cholinesterase  variants. 
Because  of  the  limitations  outlined  earlier  it  is 
not  possible  to  derive,  nor  were  the  experiments  designed 
to  give,  any  absolute  thermodynamic  data  regarding  the 
enzymic  activation.  Indeed  as  far  as  these  are  concerned 
Dixon  and  Webb  (1958)  stated 
"In  fact  it  must  be  admitted  that 
remarkably  little  is  known  about 
any  of  these  quantities  and  that 
such  values  as  are  given  in  the 
literature  have  meanings  which 
are  doubtful 
Certainly  in  biological  work  the  symbol  p  is  used  instead 
of  Ea  to  signify  that  the  quantity  measured  may  not  be  as 
rigorously  defined  as  the  energy  of  activation.  That  aside 
however  the  data  recorded  in  this  study  would  indicate 
that  under  the  specific  experimental  conditions  employed 74 
there  are  temperature-dependent  changes  in  the  efficiencies 
with  which  the  enzymes  catalyse  the  hydrolysis  of  benzoyl- 
choline.  In  addition,  at  any  specific  temperature  these 
efficiencies,  as  exemplified  by  the  rate-limiting  constant, 
of  which  the  recorded  activity  is  an  index,  also  differ. 
Further,  solely  and  specifically  under  the  assay  conditions 
employed  the  energies  of  activation  at  any  on  e  temperature 
are  an  index  of  the  relative  catalytic  efficiencies  of  the 
variants.  While  these  values  have  no  absolute  significance 
they  do  have  a  valid  relative  meaning  and  this  validity  is 
most  acceptable  at  temperatures  where  activities  are  most 
accurately  measured  and  the  response  to  change  in  tempera- 
ture  most  linear. 
These  last  stipulations  inexorably  suggest  the  range 
25-30  0C  and  between  these  values  the  energies  of  activation 
were  calculated  as  11.0  Kcals  for  the  usual  homozygote, 
9.55  Kcals  for  the  usual/fluoride-resistant  heterozygote, 
9.39  Kcals  for  the  usual/atypical  heterozygote,  5.93  Kcals 
I  for  the  fluoride-resistant  homozygote,  5.32  Kcals  for  the 
atypical/fluoridc-resistant  heterozygote  and  4.6  Kcals  for 
the  atypical  homozygote.  These  represent  mean  values  for 
the  sera  studied  as  illustrated  in  Figures  12  and  17. 
A  study  of  these  activation  energies  indicates  that 
af  with  the  possible  exception  of  the  E,  E,  phenotype  the 
activation  energies  of  the  heterozygous  sera  are  obviously 
not  derived  from  a  50:  50  proportional  activity  of  the 
two  variants.  If  then  X  is  taken  as  the  fractional 
activity  of  the  usual  enzyme  and  Y  that  of  the  fluoride- 
resistant  variant  in  the  heterozygote,  EUEf 
11 75 
11.0  X+5.93  Y=9.5  where  X+Y=1 
or  5.93  X+5.93  Y=5.93 
Subtracting  5.07  X=3.57 
or  X=  .  704 
and  X=  .  296 
Similarly  for  the  usual/atypical  heterozygote 
11.0  X+4.6  Y=9.39  and  4.6  X+4.6  Y=4.6 
Subtracting  6.4  X=4.78 
or  X=  .  748 
and  Y=  .  252 
For  the  atypical/fluoride-resistant  heterozygote 
5.93  X+4.6  Y=5.32  and  4.6  X+4.6  Y=4.6 
Subtracting  1.33  X=0.72 
or  X=  .  54 
and  Y=  .  46 
The  proportions  of  activity  due  to  the  atypical  and  fluoride- 
af 
resistant  enzymes  in  the  E,  E,  phenotype  are  in  excellent 
agreement  with  their  relaýive  proportions  in  the  respective 
usual  heterozygotes. 
As  an  independent  check  on  the  validity  of  these 
calculated  proportions  of  activity  in  heterozygous  sera 
the  inhibition  of  the  cholinesterase  variants  may  be 
considered.  The  usuall  fluoride-resistant  and  atypical 
enzymes  have  mean  inhibitions  of  80%,  65%  and  207o  respect- 
ively  (Figures  2  and  29)  in  the  presence  of  10-  5  11  dibucaine 
under  the  assay  conditions  employed. 
Uf  Considering  then  the  E1E,  phenotype  every  100  units 76 
of  activity  comprises 
70  units  Eu  inhibited  807o  =  14  units  1 
and  30  units  Ef  inhibited  657o  =  10.5  units. 
therefore  inhibited  activity  24.5 
=  75.5%  inhibition. 
uninhibited  lactivity  100 
Similarly  for  the  EY  Eal  phenotype  every  100  units  of 
activity  comprises 
75  units  EU  inhibited  807a  =  15  units  1 
and  25  units  Ea  inhibited  207o  =  20  units.  1 
therefore  inhibited  activity  35  657o  inhibition. 
uninhibited  activity  100 
af  For  the  El  E,  phenotype  every  100  units,  of  activity 
comprises 
It  46  units  Et  inhibited  20%  =  37  units  I 
and  54  units  Ef  inhibited  65%  =  19  units  I 
therefore  inhibited  activity  44%  inhibition 
uninhibited  activity  100 
These  calculated  inhibitions  or  dibucaine  numbers  are  in 
excellent  agreement  with  the  mean  values  found  for  the 
heterozygous  phenotypes  (Figures  2  and  29). 
By  the  same  procedure  using  mean  fluoride  inhibitions 
of  607o,  377o  and  247o  for  phenotypes  EuEu,  EfEf  and  Ea  Ea  111111 
respectively  the  calculated  mean  inhibitions  for  the  hetero- 
zygotes  EuEfpEuEa  and  EaEf  are  537o,  51%  and  317o,  figures  I11111 
which  are  in  good  agreement  with  the  values  determined 
experimentally.  The  same  agreement  is  found  between  the 
calculated  and  experimentally  determined  figures  for 
chloride  and  succinyl-dicholine  inhibition  (Table  10). Cd 
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It  is  a  matter  of  common  observation  that  the  inhibitor 
numbers  of  heterozygous  sera  do  not  occupy  a  medial 
position  between  the  homozygous  phenotypes.  For  instance 
the  mean  dibucaine  numbers  for  the  usual  and  atypical 
enzymes  are  80  and  20  respectively  while  that  of  the 
heterozygote  is  about  62.  As  discussed  in  greater  detail 
later  (page  86  et  seq.  )  in  the  heterozygote  this  could  be 
due  to  an  unequal  rate  of  synthesis  of  the  two  variant 
enzymes,  to  unequal  enzymic  efficiences  or  a  combination 
of  both.  However  the  foregoing  data  is  independent  of  the 
absolute  activity,  that  is,  the  quantity  of  enzyme,  but 
solely  reflects  the  catalytic  efficiency  of  the  enzyme  in 
the  same  way  that  the  turnover  number-does.  The  foregoing 
calculations  in  equating  enzymic  efficiencies  (V  values) 
does  not  rule  out  the  possibility  of  unequal  rates  of 
synthesis  of  the  variants,  but  only  show  that  in  the 
heterozygote  the  activities  due  to  to  the  enzymic  species 
are  not  equal. 
However  if  one  assumes  equal  molecular  proportions 
of  the  usual  and  fluoride-resistant  enzymes  in  the  betero- 
zygote  the  percentage  activity  due  to  the  usual  variant 
would  be 
100  x  11.0  1100  657o 
11.0  +  5.93  16.93 
By  similar  arithmetic  it  can  be  shown  that  on  an  equimolecular 
basis,  the  proportions  of  activity  in  the  Eua  and  Ea  Ef 
II11 
heterozygotes  are  71:  29  and  44:  56  respectively.  The  inhibi- 
tions  calculated  from  these  proportions  are  shown  in  Table  10 
and  if  anything  are  closer  to  the  exp6rimentally  determined 
means  than  those  calculated  from  equating  the  p  values. 781) 
The  difference  between  the  two  sets  of  calculated 
proportional  activities  in  the  heterozygotes  are  obviously 
not  significant  and  can  readily'be  appreciated  when  it  is 
considered  that  all  the  values  involved  are  mean  figures 
and  there  are  cogent  reasons  to  believe  that  the  currently 
accepted  variants  are  not  homogeneous  (p.  go  et  seq.  ). 
Certainly  the  foregoing  indicates  that  there  is  no  need  to 
postulate  a  quantitative  difference  in  the  rates  of 
synthesis  of  the  enzyme  variants  in  the  hetcrozygous  state; 
all  the  observed  experimental  facts  are  entirely  resolved 
on  qualitative  differences. 
Confirmation  of  some  of  the  experimental  and  derived 
data  obtained  in  this  study  is  to  be  found  in  the  literature. 
Thus  Kalow  and  Lindsay  reported  an  activation  energy  of  tho 
usual  homozygote  to  be  11.2  Kcals/degrec/mole  wiliell  is  ill 
good  agreement  with  that  recorded  herein.  Tile  literature 
does  not  appear  to  contain  values  for  the  activation 
energies  of  the  other  cholinesterase  variants.  In  the 
classical  studies  of  Liddell,  Lehman,  Davies  and  Sharih 
(1962)  the  usual  and  atypical  enzymes  in  heterozygous  sera 
were  separated  by  chromatography  on  diethyl  amino-ethyl 
cel 
. 
lulose  columns  and  by  paper  electrophoresis  at  P11  9.7. 
Determination  of  the  cholinesterase  activity  in  the  chromato- 
graphy  eluate  fractions  gave  a  usual  to  atypical  ratio  of 
69:  31  and  from  paper  strip  elution  of  71:  29.  These  values 
are  in  excellent  agreement  with  those  obtained  on  an 
equimolecular  basis  in  this  study.  No  other  such  ratios 
appear  to  have  been  determined  and  Lehmann  and  co-workers 
did  not  seek  confirmation  of  their  activity  ratios  by 79) 
calculating  the  inhibitions  of  the  hetcrozygote  from  those 
of  the  homozygotes. 2.  (c)  Inhibition  of  Benzoyleholine  Hydrolysis. so 
Inhibition'  of  Denzoylcholine  Hydrolysis 
In  routine  analysis  of  specimens  referred  from 
"suxamethonium  apnoeas"  and  in  preliminary  studies,  the 
inhibitions  by  10  VII  dibucaine  (Kalow  and  Genest,  1957) 
and  50  Q  sodium  fluoride  (Harris  and  Whittaker,  19G1) 
of  the  hydrolysis  of  a  50  pM  benzoylcholine  substrate  in 
phosphate  buffer,  pH  7.4  and  at  25  0C  (Kalow  and  Lindsay, 
1955)  have  been  found  necessary  and  sufficient  for  precise 
phenotype  identification.  At  an  early  stage  in  these 
investigations  the  inhibition  by  500  nill  sodium  chloride 
(Whittaker,  1968b)  was  also  included  in  the  hope  that 
correlations  of  the  three  inhibitors  might  yield  further 
evidence  to  substantiate  the  claim  (Whittaker  1968c)  that 
its  use  revealed  now  phenotypes. 
It  seemed  reasonable  that,  in  the  specific  clinical 
setting  under  investigation,  that  of  suxamethonium  apnoca, 
use  of  the  causative  agent,  succiny1dicholine,  as  a  differ- 
entiating  substrate  or  inhibitor  woul(I  have  potential 
advantages.  The  investigation  of  succiny1dicholine  and  its 
sulphur  analogue  as  substrates  is  detailed  later  (p.  103et  seq.  ). 
In  the  light  of  modern  theories  of  neuro-muscular-trans- 
mission,  the  classification  of  muscle-relaxant  drugs  becomes 
increasingly  complex.  In  the  classic  picture  which  satisfied 
elementary  stereochemical,  pharmacological  and  physiological 
precepts,  such  drugs  were  separated  into  two  categories, 
depolarising  and  non-depolarising.  The  former  were  long, 
thin  molecules  which  achieved  their  effect  by  depolarising 
the  motor  end  plate  in  the  same  way  as  acetylcholine.  Indeed 
high  doses  of  acetylcholine  itself  produce  blockade  and .0 
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Figure  20.  Structural  formulae  of  some  substrates  and  inhibitors 
of  cholinesterase.  Other  exnmples  are'il2ustrated  in 
Figure  1  indicating  the  affinity  of  cholinesterase 
for  compounds  containing  a  positively  charged  nitrogen 
atom  particularly  when  linked  to  methyl  or  ethyl  groups. ol 
through  this  so  do  the  anti-acetyleholinesterases.  These 
are  therefore  classed  as  depolarising  agents.  The  non- 
depolarising  relaxants  were  bulky  molecules  which  acted 
post-synaptically  by  occupying  the  receptor  sites  for  acetyl- 
choline.  Succiny1dicholine  and  tubocurarine  are  the  typical 
examples  of  depolarising  and  non-depolarising  muscle 
relaxants  respectively  and  their  structural  formulae  are 
shown  in  Figure  20. 
Pancuronium,  bromide  (Pavulon)  is  a  recently-introduced 
non-depolarising  muscle  relaxant.  The  structural  formula 
(Figure  20)  shows  it  to  be  steroidal  with  two  methyl  pyridine 
and  two  acetyl  residues  attached.  It  is  interesting  to 
note  that  in  both  instances  the  ester  oxygens  are  separated 
by  two  carbon  atoms  from  the  quaternary  nitrogens.  Pharma- 
cologically  the  neuromuscular  block  produced  by  p-ancuronium 
is  of  curariformtype  and  stereochemically  the  molecule  is 
typically  non-depola-rising.  However  the  presence  of  the 
methylated  quaternary  nitrogens  and  acetyl  groups  suggested 
possible  anticholinesterase  potential  and  this  latter  aspect 
was  accordingly  investigated. 
Instrtimentation,  'Metliods  and  Materials 
Instrumentatlon  and  methods  were  as  described  in  the 
previous  section  (page  42).  All  assays  were  carried  out 
at  25  0C 
unless  otherwise  stated. 
In  addition  to  the  reagents  previously  employed 
(page  43)  succiny1dicholine  chloride  dihydrate  was  obtained 
from  BDH  Chemicals,  Pancuronium  bromide  (Pavulon)  from 
Organon  Laboratories,  tubocurarine  chloride  (Tubarine) 
from  Burroughs  Wellcome  and  gallamine  triethiodide  (Plaxedil) 82 
from  May  and  Baker  Ltd.  Aqueous  solutions  of  these  inhibitors 
were  made  up  to  different  concentrations  and  1  ml  aliquots. 
employed  as  inhibitors  in  the  assay  scheme  detailed  earlier 
(page  44  ). 
Sera  from  six  phenotypes,  100  usual  homozygotes  EUEu  1  11 
25  usual/fluoride-resistant  heterozygotes  EuEf,  61  usual/  11 
atypical  heterozygotes  EuEa,  3  fluoride-resistant  homozy- 
11 
gotes  EfEf  12  atypical/fluoride-resistant  heterozygotes 
1  11 
EaEf  and  20  atypical  homozygotes  EaEa  were  used  in  defining 
1111 
the  phenotype  ranges  and  in  comparing  inhibitor  numbers. 
Experimental  Results 
At  a  benzoylcholine  concentration  of  50  pM  the 
succiny1dicholine  concentration  in  the  reaction  mixture  was 
varied  from  5  11H  to  100  mM.  The  inhibition  curves  obtained 
for  the  six  commonly-recognised  phenotypes  are  shown  in 
Figure  21.  These  follow  the  typical  sigmoid  pattern.  It 
was  evident  that  maximum  differentiation  between  the  pheno- 
types  was  obtained  at  a1  mll  concentration  of  succinyldi- 
choline  in  the  reaction  mixture.  Preincubation  of  the 
reaction  mixture  without  benzoylcholine,  that  is,  buffered 
dilute  serum  in  the  presence  of  1  mAl  succiny1dicholine  for 
periods  up  to  one  hour  did  not  alter  the  percentage  inhibition 
significantly. 
By  employing  a4  WvI  aqueous  solution  of  succinyl- 
dicholine  (397  mg  succiny1dicholine  chloride  dihydrate  per 
litre)  in  the  assay  scheme  outlined  earlier  the  percentage 
inhibition  (Scoline  Number)  was  determined  simultaneously 
with  dibucaine,  fluoride  and  chloride  numbers  on  the  sera 
of  221  individuals  as  detailed  above.  The  values  obtained Elu  Blu 
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Figure  21.  Inhibition  of  seruin  cholinesterase  activities  by 
succiny1dicholine  in  the  assay  procedure  of  Halow 
and  Lindsay  (1955)  at  250C.  Theoretical  concen- 
trations  in  the  blood  plasma  following  injection 
of  100  mg  succinyldicholine  are  shown  initially 
at  A  and  after  20-30  minutes  at  B. 100 
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Figure  22.  Cholinesterase  phenotype  inhibitions  by  mM 
succinyldielioline  in  the  presence  of  50  VM 
benzoylcholine  in  phosphate  buffer,  p1l  7.4 
at  250C. 32 
for  succiny1dicholine  inhibition  in  this  survey  over  a 
period  of  two  years  are  shown  in  Figure  22.  In  this  illus- 
tration,  the  closed  circles  for  the  usual  phenotype  each 
represent  three  sera,  the  open  circles,  one  specimen. 
Three  anomalous  values  obtained  from  serum  samples  of  two 
sisters  were  assigned  to  the  atypical  homozygote  group 
where  they  are  shown  as  open  circles. 
Figures  23,24  and  25  illustrate  the  correlations 
between  the  distribution  of  Scoline  numbers  and  dibucaine, 
fluoride  and  chloride  numbers  respectively.  The  remaining 
correlations  are  also  illustrated  between  dibucaine  and 
fluoride  numbers  in  Figure  26,  between  dibucaine  and  chloride 
numbers  in  Figure  27  and  between  fluoride  and  chloride  numbers 
in  Figure  28.  A  point  in  the  centre  of  a  symbol  in  these 
diagrams  indicates  two  sera  with  identical  numbers. 
The  phenotype  ranges  for  all  four  inhibitors  derived 
from  this  study  are  shown  in  Figure  29,  (King,  1974).  It 
should  perhaps  be  emphasised  that  in  this  study  whore  a 
result  was  doubtful  or  of  a  controversial  nature  it  was 
confirmed  by  repeated  estimations. 
Pavulon  is  a  solution  of  2  mg  pancuronium  dibromide 
per  ml  that  is  2.63  X  10-3  M.  A  dilution  therefore  of  1  ml 
Pavulon  and  2.29  ml  of  water  gives  a  solution  8X  10-  4M 
with  respect  to  the  drug  and  1  ml  of  this  solution  in  a 
final  assay  mixture  of  4  ml  gives  a  reaction  concentration 
of  2X  10-4  M.  Dilutions  to  give  reaction  concentrations 
down  to  2X  10-8  M  were  prepared  and  the  inhibition  of 
benzoylcholine  hydrolysis  by  a  variety  of  phenotype  sera 
studied.  Typical  results  obtained  are  illutstrated  in 10 
Figurc  23. 
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Figure  25.  Correlation  of  Scoline  Numbers  and  Chloride  Numbers 
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rigure  29.  Phenotype  ranges  of  inhibitor  numbers  (percontage 
inhibition)  by  10  1AI  dibucaine,  50  Vt.  %I  sodium  fluoride, 
500  al  sodium  chloride,  mIM succinyldicholine  in  the 
presence  of  50  11M  benzoy1cholinc  in  phosphate  buffer 
p1l  7.4  and  at  250C. 8117.1. 
Figure  30. 
Similarly  for  tubocurarine  and  gallamine,  concentrations 
of  the  drugs  to  give  reaction  concentrations  from  10-  3M  to 
-5  10  M  were  prepared  and  the  inhibitions  recorded.  These 
are  shown  in  Figure  31. 
Discussion 
Kalow  and  Genest  (1957)  made  the  observation  that  the 
dibucaine  number  of  an  individual  remains  remarkably 
constant  even  when  the  serum  cholinesterase  activity  changes. 
This  fact  implies  a  constant  proportion  of  the  two  enzyme 
variants  in  any  particular  heterozygote.  Furthermore  Kalow 
and  Staron  (1957)  reported  that  even  when  the  cholinesterase 
activity  of  a  serum  sample  decreased  upon  storage,  the  dibu- 
caine  number  remained  unaltered  for  as  long  as  it  could  be 
determined.  rnlis  fact  implies  an  equal  in  vitro  stability 
of  the  cholinesternse  variants.  These  observations  of 
Kalow-and  co-workers  only  applied  to  dibucaine  inhibition 
and  only  knowingly  to  the  usual  and  atypical  variants  but 
the  in  vivo  constancy  of  percentage  inhibition  for  all 
phenotypes  and  inhibitors.  studied  has  been  confirmed  in 
the  present  study  except  in  one  set  of  circumstances  (page  123 
While  it  has  been  noted  that  the  usual  and  atypical 
isoenzymes-are  apparently  equally  stable  to  storage  the 
fluoride-resistant  variant  would  appear  to  be  somewhat  less 
so  under  these  conditions. 
The  finding  that  preincubation  of  dilute  serum  with 
mll  succiny1dicholine  for  one  hour  did  not  alter  the 
percentage  inhibition  is  in  agreement  with  Kalow  (1959a) 
who  showed  that  the  usual  and  atypical  enzymes  at  this 85 
concentration  of  succiny1dicholine  hydrolysed  about  80  jimol 
and  less  than  5  pmol  per  minute  per  litre  respectively  at 
30  0  C.  This  is  equivalent  to  hydrolysis  of  96  nmol  and  less 
than  6  nmol  per  hour  by  20  ul  of  serum  which  from  Figure  21 
would  not  result  in  any  significant  change  in  inhibition. 
The  figures  given  by  Goedde,  Held  and  Altland  (1968)  for 
the  spontaneous  hydrolysis  of  succiny1dicholine  are  of  the 
same  order  as  that  for  the  atypical  enzyme.  These  workers 
studied  the  inhibition  by  succiny1dicholine  of  benzoyl- 
choline  hydrolysis  by  the  usual  and  atypical  enzymes-and 
the  curves  they  obtained  are  almost  identical  with  those 
reported  here  (Figure  21).  The  literature  does  not  appear 
to  contain  any  similar.  study  relating  to  the  other  cholin- 
esterase  phenotypes. 
The  technical  advantages  to  tho  use  of  suecinyldicholiDe 
in  differentiating  the  serum  ChOliDCStorase  variants  are 
limite 
. 
d.  Less  skill  is  required  in  preparing  the  reingent. 
For  a  litre  of  solution  an  error  of  a  few  milligrams  in  the 
required  397  mg  of  succiny1dicholine  chloride  dihydrate 
will  not  significantly  alter  the  results,  whereas  with 
dibucaine  and  sodium  fluoride,  13.7  mg  and  8.4  mg  respectively 
must'be  accurately  weighed  for  one  litre  of  solution.  This 
robustness  of  the  reagent  does  not  extend  to  storage  however 
where  it  was  found  to  be  no  more  stable  than  the  dibucaine 
solution  and,  not  unexpectedly,  much  less  than  the  fluoride 
and  chloride  reagents. 
Lehmann  and  Liddell  (1969)  indicated  that  about  one 
in  3,200  of  the  usual  homozygote  population  is  found  to  be 
moderately  sensitive  to  suxamethonium  and  that  this  accounted nc 
for  371,  lo  of  suxamethonium  apnoeas.  It  had  been  hoped, 
rather  than  confidently  expected,  that  employing  the,  actual 
causative  agent  as  inhibitor  might  demonstrate  a  new  pheno- 
type  and  permit  differentiation  of  sensitive  usual  homozygotes. 
Eleven  such  individuals  were  tested  during  this  survey  and 
did  not  exhibit  any  difference  to  succiny1dicholine  inhibition 
from  the  other  usual  homozygotes. 
There  is  nevertheless  an  undoubted  advantage  in  inter- 
preting  results  from  succiny1dicholine  inhibition  in  that 
the  difference  between  the  means  of  the  usual  homozygotes 
(907o)  and  the  atypical  homozygotes  (187o)  is  greater  than 
that  obtained  with  dibucaine.  Figure  23  however  indicates 
that  there  is  a  close  correlation  between  the  two  inhibitor 
numbers. 
It  is  only  a  comparison  of  Figures  24  and  26  which 
shows  any  divergence  of  interpretation.  Three  of  the 
specimens  classified  as  EaEf  by  Scoline  and  fluoride  number  11 
combination  (Figure  24)  would  probably  be  classed  as  EuEa  11 
by  dibucaine  and  fluoride  numbers  (Figure  26).  It  is  not 
possible  by  family  studies  to  decide  this  matter,  although 
in  one  case  involved  in  an  apnoeic  episode,  it  may  be 
possible  at  a  later  date  if  there  are  any  children.  The 
wide  range  of  inhibitor  numbers  which  is  found  particularly 
in  heterozygotes,  has  been  the  cause  of  much  speculation 
and  some  experimental  work. 
Apart  from  experimental  error,  there  would  appear  to 
be  two  possible  causes,  either  the  synthesis  of  enzyme  due 
to  each  gene  is  separately  controlled,  that  is,  the 
proportions  of  variants  in  heterozygous  sera  varies,  or 87 
there  are  numerous  cholinesterase  variants  with  different 
enzymic  properties,  mainly  turnover  number,  but  also  possibly, 
relative  stabilities. 
With  regard  to  the  experimental  error,  the  assay  of 
cholinesterase  activity  in  these  studies  has  an  error  of 
2.47o  and  replicate  estimates  of  dibucaine  number  around 
20  and  80  have  maximum  variations  of  ±3  and  ±1  respectively. 
The  scatter  of  results  due  to  experimental  error  can  be 
readily  calculated.  Assuming  a  higher,  rounded  figure  of 
37o  for  the  coefficient  of  variation  the  ratio  is  independent 
of  the  actual  level  of  cholinesterase  activity  which  again 
for  ease  may  be  taken  as  the  rounded  figure  of  1000  mU/ml- 
Then  for  the  usual  homozygote  with  80%  inhibition  by 
dibucaine  the  outside  limits  of  error  are: 
2070  activity  ±C.  V.  206 
to  194 
-1  OT01/0  7,  ýC-'  tivityT.  C-V-  970  1030 
that  is,  79  to  81 
For  the  atypical  homozygote  inhibited  207  the  limits  of 
dibucaine  number  are: 
80%  activity  ±C.  V.  824 
to 
776 
100%  a  tivity  TC.  V.  970  1030 
that  is,  15  to  25 
The  fluoride-resistant  homozygote  with  65%  inhibition  by 
dibucaine  will  have  limits: 
1 
3579  activity  ±C.  V.  360.5 
to 
339.5 
1007o  activity  : TC.  V.  970  1030 
that  is  63  to  67 
The  theoretical  limits  of  dibucaine  number  due  to  experi- 
mental  error  so  calculated  and  the  actual  ranges  encountered 
(Figure  29)  are  shown  in  Table  11.  The  conclusion  to  be Table  11 
Dibucaine  Numbers 
Phenotype  Theoretical  Range  Experimental  Range 
Eu  Eu  80  ±1  77  -  83 
1  1 
Eu  1  Ef  1 
75  ±  1.5  70  -  80 
Eu  Ea  60  ±  2.5  54  -  69 
1  1 
Ef  1  Ef  1 
65  ±2  64  -  67 
Ea  Ef  50  ±3  41  -  56 
E  Ea  1 
20  ±5  15  28 8413 
derived  from  this  is  that,  apart  from  the  fluoride-resistant 
homozygote  where  only  three  values  have  been  obtained  to 
establish  the  actual  range,  the  ranges  of  inhibitor  numbers 
are  real  and  not  a  result  of  lack  of  precision  in  the  assay. 
Accuracy  of  activity  measurement  does  not  enter  into  these 
calculations  since  the  inhibitor  number  is  independent  of 
the  absolute  level  of  activity.  Accordingly  the  scatter 
of  results  due  to  experimental  error  in  other  inhibitor 
numbers  follows  the  same  pattern,  being  least  (±l)  at 
highest  percentage  inhibitions  (80%)  and  greatest  (±5)  at 
lowest  inhibitions  (20'/0)  with  intermediate  gradations. 
That  different  amounts  of  enzyme  are  synthesised 
through  each  gene  was.  postulated  by  Kalow  and  Staroll  (1957) 
and  Kalow  (1959a).  These  workers  noted  that  the  distrIbIlLion 
curve  of  dibucaine  numbers  in  what  they  termod  the  inter- 
mediate  group  was  negatively  skewed,  th;  tt  is,  the  tall 
extended  towards  the  lower  numbers,  and  also  that  the 
position  was  asymmetric  between  the  atypical  and  utsmal 
homozygote  distributions.  This  observation  has  been  amply 
confirmed  in  the  present  study  (Figure  29).  Kalow  and 
Staron  (1957)  then  mixed  equal  volumes  of  usual  homozygous 
and  atypical  homozygous  sera  and  both  by  calculation  from 
means  and  by  experiment  found  the  dibucaine  number  to  be 
61.5.  When  the  mixture  contained  two  parts  of  usual  serum 
to  one  part  of  atypical  serum  the  percentage  dibucaine 
inhibition  was  68.8.  By  this  means  they  considered  it 
possible  to  translate  each  dibucaine  number  of  the  inter- 
mediate  group  into  a  "percentage  of  atypical  esterase"  and 
found  the  mean  to  be  50.2  with  a  standard  deviation  of  9.0. The  distribution  curve  obtained  from  these  calculations  was 
superimposed  on  the  numbers  determined  experimentally  but 
I 
it  was  found  that  "the  fit  of  the  data  to  this  curve  is 
imperfect".  This  is  not  surprising  since  from  the  data 
presented  by  Kalow  and  Staron  (1957)  and  enlarged  later 
Kalow  (1959b)  the  series  contained  sera  from  atypical/ 
fluoride-resistant  heterozygotes,  the  existence  of  which 
was  not  known  at  that  time  (Lehmann,  Silk,  Harris  and 
Whittaker,  1960)  and  the  existence  of  which  they  were 
endeavouring  to  disprove. 
The  basic  argument  is  unsupportable  since  in  mixing 
equal  parts  of  the  two  sera  they  assumed  that  they  were 
mixing  equal  amounts  of  the  two  enzymes.  In  other  words 
the  argument  was  based  on  the  premise  that  the  genes  in 
the  atypical  homozygote  brought  about  the  synthesis  of  enzyme 
molecules  at  the  same  rate  as  the  genes  in  the  usual 
homozygote  and  this  was  then  used  to  prove  that  the  genes 
in  each  individual  mediated  different  rates  of  synthesis. 
On  the  contrary  if  the  fact  that  the  mean  value  obtained 
from  their  calculations  of  50.2  is  accepted  as  proof  that 
the  original  assumption  was  correct  (and  the  concordance 
with  the  values  obtained  in  this  study  from  thermodynamic 
data  lends  confirmation)  then  this  in  turn  provides  evidence 
that  there  is  no  genetic  control  of  the  number  of  enzyme 
molecules  only  of  the  type  of  enzyme  molecule. 
Despite  this  apparently  unappreciated  argument  in 
favour  of  genetic  control  of  qualitative  but  not  quantitative 
enzyme  synthesis,  Kalow  (1959a)  presented  interpretation 
of  some  of  the  data  of  Kalow  and  Staron  (1957)  "assuming 90 
genetical  control  of  type  and  activity  of  cholinesterase" 
but  concluded  "while  it  is  necessary  to  postulate  a  control 
of  activity,  the  observed  values  do  not  conform  rigidly". 
A  study  of  the  presentation  reveals  that  even  with  an 
unexplained  juggling  of  supposed  proportions  of  activity 
due  to  each  gene  any  semblance  of  conformity  is  only  achieved 
in  two  members  of  the  second  generation  and  none  at  all  in 
the  third  generation. 
Kalow  (1959b)  concluded  his  discussion: 
"However  the  total  blood  of  a  person 
contains  nearly  a  kilogram  of  haema- 
globin  and  perhaps  20  mg  of  serum 
cholinesterase:  the  assumption  is 
inescapable  that  the  levels  of 
proteins  are  under  genetical  control". 
This  argument  could  readily  be  reworded  to  the  alternative 
proposition  and  say  that  in  the  blood  of  adult  humans  there 
occur  more  than  100  variants  of  haemoglobin  and  to  date  only 
four  of  serum  cholinesterase:  the  assumption  is  inescapable 
that  numberous  cholinesterase  variants  are  as  yet  unidentified. 
I 
Certainly  among  the  "silent  gene"  homozygotes  hetero- 
geneity  has  been  conclusively  demonstrated  (Goedde  and 
Altland,  1968;  Rubinstein,  Dietz,  Hodges,  Lubrano  and 
Czebotor,  1970)  and  either  explicitly  or  implicitly  the 
presence  of  subtypes  has  been  suggested  by  chloride  inhibition 
(Whittaker,  1968b;  King  and  Dixon,  1970)  by  the  effect  of 
n-butyl  alcohol  (Whittaker,  1968a)  or  by  substrate  affinities 
(Irwin  and  Hein,  1966). 
The  three  sera  of  controversial  phenotype  (Figures  24 
and  26)  can  readily  be  explained  on  either  premise  but  the 
concept  that  there  may  be  numerous  subtypes  of  cholinesterase 
gains  support  from  the  three  anomalous  results  from  two sisters  who  were  classified  as  atypical  homozygotes  despite 
the  unusually  high  inhibition  values  (Figure  22).  This 
in  turn  could  suggest  that  there  is  not  a  single  entity 
at  present  classed  as  "usual",  "atypical"  or  "fluoride- 
resistant"  enzyme  but  that  each  of  these  designations 
embraces  a  heterogeneous  population.  There  may  well  be 
therefore  a  continuous  range  of  cholinesterases  within 
that  which  is  presently  termed  a  phenotype  and  characterised 
by  the  enzymic  properties  of  the  molecular  species. 
Unlike  succinyldicholine,  pancuronium  is  reputedly 
not  hydrolysed  by  cholinesterase  and  its  molecular  structure 
would  tend  to  support  this.  Under  these  circumstances  any 
inhibition  observed  with  pancuronium  would  not  be  an  index 
of  its  rate  of  enzymic  hydrolysis  but  of  a  simple  blocking 
of  the  active  site.  From  Figure  30  it  can  be  soon  that  the 
effect  of  pancuronium  on  benzoylcholine  hydrolysis  is  In 
general  very  similar  to  that  of  succinyldl.  clioline. 
Pancuronium  could  therefore  readily  be  employed  for  differ- 
entiating  the  allelic  variants  but  for  the  lack  of  contrast 
in  effect  between  the  usual  and  fluoridc-resistant  enzymes. 
The  plasma  levels  of  most  injected  substances  show  a 
biphasic,  reduction,  the  first  rapid  followed  by  a  more 
gradual  decline.  The  half-life  of  the  first  phase  is 
generally  of  the  order  4-7  minutes.  Five  circulation  times 
or  about  7J  minutes  is  usually  accepted  as  necessary  for 
even  distribution  of  injected  substances  throughout  the 
plasma  and  therefore  it  is  inferred  that  the  first  rapid 
phase  represents  a  transfer  from  the  plasma  to  the  inter- 
stitial  fluid  (Kalow,  1959b).  Taking  the  circulating  plasma C 
C 
I 
oll 
Figure  30.  Inhibition  of  serum  cbolinesteraso  activities  by 
pancuro-nium  in  the  assay  procedure  of  Nalow  nnd 
Lindsay  (1955)  at  251C.  Theoretical  concentrations 
in  the  blood  plasma  following  injection  of  -4  mg 
pancuronium  are  shown  initially  at  A  and  after 
20-30  minutes  at  B. 
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Figure  31.  Comparative  inhibitions  of  serum  cholinesternse 
activities  by  some  depolarisinG  and  non-ftpolarising 
muscle  relaxants. 92 
as  5%  of  body  weight  and  extraccllular  fluid  as  20-25%  or 
3.5  litres  and  14-18  litres.  respectively  in  a  70  Kg  person 
it  can  generally  be  assumed  that  20-30  minutes  after 
injection  only  207b  Of  the  calculated  initial  concentration 
will  remain  in  the  plasma. 
This  highlights  another  difference  between  the  inhibitions 
by  succiny1dicholine  and  pancuronium.  The  maximal  dose  of 
100  mg  succiny1dicholine  assuming  immediate  even  distribution 
would  give  a  plasma  level  of  100  vM  and  after  20-30  minutes, 
assuming  no  hydrolysis,  the  concentration  would  be  20  1A.  A. 
Neither  assumption  of  course  is  justified  but  even  at  these 
maximal  possible  levels  of  10  -4  M  and  2X  10-  5M  (A  and  B  in 
Figure  21)  barely  come  into  the  range-of  concentrations  at 
which  succinyldielioline  inhibits  benzoylcholine  hydrolysis 
in  vitro.  On  the  other  hand  a  full  dose  of  pancuronium  of 
7  mg  would  result  in  an  initial  plasma  level  of  about  2.5  till 
and  after  20-30  minutes  0.5  VM.  Both  of  those  levels  (A  and 
B  respectively,  Figure  30)  are  well  within  the  effoctive 
range  of  in  vitro  Pavulon  inhibition  of  benzoylcllolJ.  ne 
hydrolysis,  the  initial  level  representing  near  maximum 
inhibition  of  the  usual  homozygote. 
As  far  as  the  writer  is  aware  this  is  the  first 
recording  of  anticholinesterase  activity  in  a  non-depolarising 
muscle  relaxant  at  in  vivo  concentrations.  Neither  gallamine 
nor  tubocurarine  exhibit  inhibition  at  such  concentration 
(Figure  31).  A  dose  of  15  mg  of  Tubarine  gives  an  initial 
plasma  concentration  of  5  vM  and  120  mg  of  gallamine  about 
40  pM. 2.  (d)  Effect  of  Temperature  on  Inhibition. fl') 
Introduction 
That  the  inhibitory  action  of.  some  compounds  on  serum 
cholinesterase  activity  alters  with  temperature  has  been 
known  for  some  time.  Thus  King  (1965)  reported  that  the 
phenotype  ranges  of  fluoride  numbers  which  lie  presented 
were  only  valid  if  the  assays  were  performed  in  the 
neighbourhood  of  25  0  C.  Heilbronn  (1965)  also  recorded  an 
increased  inhibition  by  fluoride  with  decrease  in  reaction 
temperature  as  did  McComb,  La  Motta  and  Wetstone  (1965) 
who  found  the  dibucaine  and  succiny1dicholine  inhibition 
of  o-nitrophenylbutyrate  hydrolysis  to  be  less  affected. 
In  making  a  plea  for  the  adoption  of  a  standard  temperature, 
King  (1967)  illustrated  the  variation  with  temperature  of 
dibucainc  and  fluoride  inhibition  which  showed  that  these 
alterations  were  also  dependent  upon  the  enzyme  variant. 
These  early  observations  are  confirmed  and  extended  in  the 
present  studies  (King  and  Dixon,  1970;  King,  McQtieen  and 
Morgaiý,  1971). 
Instrumentation,  Methods  and  Materials 
These  were  the  same  as  described  in  the  previous 
section  except  that  a  fourth  inhibitor  solution,  4  mM 
succiny1dicholine  (King  and  Griffin,  1973)  was  included 
in  some  of  the  later  experiments. 
The  studies  on  the  effect  of  heat  on  the  inhibition 
of  benzoylcholine  hydrolysis  followed  the  same  protocol 
as  previously  in,  that  no  allowance  was  made  for  change  in 
optimum  substrate  or  hydrogen  ion  concentrations  with 
temperature,  but  the  same  concentrations  of  reactants  and 
inhibitors  were  employed  over  the  temperature  range  studied, 94 
15  0C  to  550C. 
Serum  specimens  from  seven  usual  homozygotes,  three 
usual/fluoride-resistant  heterozygotes,  seven  usual/atypical 
heterozygotes,  two  fluoride-resistant  homozygotes,..  three 
atypical/fluoride-resistant  heterozygotes  and  seven  atypical 
homozygotes  were  studied. 
Experimental  Results 
The  variation  with  reaction  temperature  of  the  per- 
centage  inhibition  (inhibitor  number)  of  dibucaine,  fluoride, 
chloride  and  Scoline  (succinyldicholine)  are  shown  for  each 
phenotype  in  Figures  32  to  37.  Although  in  some  cases, 
because  of  paucity  of  numbers,  the  mean  values  are  barely 
meaningful,  these  were  calculated  and  are  also  shown  in 
these  diagrams.  The  phenotype  mean  inhibitor  numbers  were 
Collected  for  each  inhibitor  and  these  are  illustrated  in 
Figures  38  to  41.  The  ranges  of  inhibitor  numbers 
established  in  this  study  for  25  0C  (Fig.  29)  are  also 
shown  in  these  latter  diagrams  as  are  also  the  expected 
ranges  at  37  0  C. 
.  The  mean  variations  in  the  four  inhibitor  numbers 
for  each  50C  temperature  range  are  listed  according  to 
cholinesterase  phenotype  in  Tables  12  to  15. 
Discussion 
Although  in  the  description  of  their  assay  procedure 
Kalow  and  Lindsay  (1955)  corrected  activities  to  26  0C 
and 
'reported  them  at  this  temperature,  for  the  determination 
of  dibucaine  numbers.,  Kalow  and  Genest  (1957)  used  a 
forced  circulation  of  air  to  stabilise  the  reaction  temperature uu 
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between  210  and  250.  Only  if  there  was  a  difference  in 
reaction  temperature  between  the  inhibited  and  uninhibited 
assays  were  the  reaction  rates  corrected  to  26  0  C.  This 
obviously  would  not  correct  for  any  variation  in  inhibition 
with  temperature  and  the  earlier  figures  at  least  for 
dibucaine  numbers  given  by  Kalow  and  co-workers  are  suspect 
on  these  grounds.  However,  Kalow  and  Genest  did  state  that 
"the  influence  of  temperature  on  the  intensity  of  inhibition 
was  negligible  within  the  narrow  range  from  21-25  ocit 
) 
indicating  that  they  were  aware  of  the  phenomenon.  On  the 
other  hand,  Harris  and  Whittaker  (1961)  in  introducing  the 
fluoride  number  did  not  mention  any  reaction  temperature 
merely  stating  that  it.  was  determined  "in  exactly  the  same 
way  as  dibucaine  number  determination".  It  was  assumed 
therefore  by  some  workers  (Lee  and  Robinson,  1967)  that 
the  phenotype  ranges  of  fluoride  number  were  determined 
0  .0  at  2  -25  C,  as  they  well  may  have  been  although  Whittaker 
(19G4,1967)  did  stipulate  a  reaction  ternperaturo  of 
26.5  OC.  This  was  also  the  temperature  at  which  she  deter- 
mined  chloride  numbers  (Whittakor,  1968a,  b)  while  King  arid 
Griffin  (1973)  estimated  succinyldicholine  inhibition  at  250C. 
In  general,  in  the  temperature  range  studied,  all 
inhibitions  were  highest  at  the  lower  temperatures,  except 
for  the  anomalous  chloride  inhibition  of  the  family  reported 
by  King  and  Dixon  (1970)  as  having  low  or  zero  chloride 
0  numbers  at  25  C.  These  individuals  were  classified  as 
either  usual  homozygotes  or  usual/fluoride-resistant 
heterozygotes  and  the  loci  of  chloride  numbers  are  shown 
in  Figures  32  and  33  respectively.  It  was  noted  in  these inhibition  experiments,  as  in  the  previous  benzoylcholine 
hydrolysis  studies,  that  the  presence  of  a  silent  gone 
did  not  alter  phenotype  behaviour. 
I 
Chloride  inhibition  was  the  least  affected  by  change 
in  reaction  temperature  and  showed  a  similar  pattern  for 
all  variants.  As  the  temperature  increases  there  is  a 
small  decrease  in  inhibition  reaching  minima  about  35  0C 
for  the  usual  enzyme,  20  0-  300C  for  ihe  fluoride-resistant 
variant  and  400-45  0C  for  the  atypical  isoenzyme  after 
which  the  inhibitor  numbers  increase.  It  is  interesting 
to  note  that  the  heterozygous  sera  demonstrate  intermediate 
minima  and  although  it  would  be  foolhardy  to  draw  any 
conclusions  from  two  experiments,  the-erratic  behaviour  of 
the  chloride  number  with  the  atypical/fluoride-resistant 
sera  could  possibly  be  construed  as  mirroring  the  widely- 
divergent  minima  of  th6  two  constituent  variants  (Figure  40). 
Variation  with  temperature  of  chloride  inhibition  of 
cholinesterase  activity  does  not  appear  to  be  recorded  in 
the  literature. 
For  all  phenotypes,  dibucaine  and  succinyldicholine 
inhibitions  follow  fairly  similar  patterns  (Figures  32  to 
37).  There  is,  in  general,  except  for  the  fluoride-resistant 
enzyme  a  tendency  to  show  a  maximum  about  200C,  followed 
by  a  moderate  decline  in  number  to  about  35  0-  40  0C  and  then, 
except  for  the  atypical  variant  which  shows  an  increase, 
a  more  rapid  decrease  in  inhibition.  It  is  difficult  to 
explain  the  anomalous  behaviour  of  the  succiny1dicholine 
inhibition  of  the  usual/atypical  heterozygous  sera  except 
that  these  three  specimens  came  from  siblings  and  may  not 97 
be  representative  of  the  general  atypical  hetcrozygote 
population. 
Between  25  0C 
and  37  0C  the  dibucaine  number  falls  by 
11  in  the  usual  homozygote,  by  15  for  phenotype  EfEf  and  11 
by  7  for  the  atypical  homozygote  with  generally  intermediate 
values  for  heterozygotes  (Figure  24  and  Table  10).  Between 
20  0C  and  40  0C  the  average  dibucaine  inhibition  of  the  usual 
enzyme  decreases  from  817o  to  66%  or  a  fall  of  0.75  per 
degree  in  the  dibucaine  number.  Over  the  same  temperature 
range,  Lee  and  Robinson  (1967)  reported  a  reasonably  similar 
figure  of  0.6  for  what  they  termed  the  AD,  '.  Except  for 
At 
this  study  (King  and  Dixon,  1970)  the  literature  does  not 
appear  to  record  any  information  regarding  the  variation 
with  temperature  of  dibucaine  inhibition  of  cholinestorase 
activity  for  any  of  the  other  genetic  variants. 
Over  the  range  25  0  to  37QC  the  mean  scoline  number 
decreases  by  4  for  the  usual  homozygote,  by  11  for  the 
fluoride  resistant  homozygote  and  by  6  for  the  atypical 
homozygote,  values  which  are  less  than,  but  follow  a 
similar  trend  to.,  the  dibucaine  number  (Figure  41  and 
Table  15).  For  the  usual  homozygote-the  change  in  scoline 
number  is  less  than  0.3  per  degree  between  20  0C  and  40  0  C. 
The  picture  for  fluoride  inhibition  differs  from  the 
others,  qualitatively  in  that  there  are  no  maxima  or  minima 
and,  quantitatively  in  that  there  are  greater  changes 
amounting  to  reductions  in  the  mean  fluoride  number  of  25, 
21  and  15  for  the  phenotypes  EuEu,  EfEf  and  E  a.  Ea  111111 
respectively  between  25  0  and  37  0  C.  The  heterozygotes  show 
the  appropriate  intermediate  changes  (Figure  39  and  Table  1.3)). 98 
For  the  usual  homozygote  over  the  temperature  range  200-40  0C 
there  is  a  change  of  2.2  in  the  fluoride  number  per  degree. 
This  is  the  identical  value  given  by  Lee  and  Robinson  (1967) 
but  is  less  than  the  3.1  found  by  McComb,  La  Motta  and 
Wetstone  (1965).  The  latter  authors  employed  o-nitrophenyl- 
butyrate  as  substrate  however  and  the  values  are  therefore 
not  truly  comparable. 
The  values  given  in  the.  preceding  paragraphs, 
particularly  those  referring  to  the  fluoride  number,  tend 
to  give  the  superficial  impression  that  the  inhibition  of 
the  atypical  enzyme  is  least  affected  by  temperature  change. 
This  results  from  the  fact  that,  except  for  chloride,  the 
inhibition  of  the  atypical  enzyme  is  much  lower  than  tho 
other  variants  at  200-25  0  C.  Perhaps  the  most  valid  index 
of  sensitivity  by  phenotype  is  to  take  the  inhibition  at 
250C  as  standard  and  record  the  increase  in  tomporaturo 
necessary  to  reduce  the  inhibition  by  half.  Expressed  in 
this  manner,  fluoride  inhibition  is  reduced  to  50%  at  34  0  CS 
350C  and  390C  for  the  phenotypes  EaEa$EfEf  and  Ell  E"' 
respectively  (Figure  39).  By  the  same  procedure  the 
dibucaine  number  at  25  0C  of  the  fluoride-resistant  homozy- 
gote  is  reduced  by  half  at  460C  but  this  does  not  occur 
with  any  other  phenotype  at  less  than  500C  (Figure  38). 
Harris,  Lehmann  and  Silk  (1960)  reported  that  there 
was  "significant  correlation  between  the  dibucaine  numbers 
and  cholinesterase  levels  within  the  'intermediate'  group", 
that  is  the  atypical  heterozygote  group,  and  indeed  there 
is  in  general  a  correlation  between  the  dibucaine  number 
and  the  cholinesterase  activity  between  the  groups.  The (Z)o  I 
phenotypes  with  lowest  dibucaine  numbers  tend  to  have 
lowest  serum  activities  (Figures  14  and  15)  and  there  is 
a  distinct  correlation  between  dibucaine  number  and 
suxamethonium  sensitivity  (Figures  2  and  29)  with  duration 
of  apnoea  under  standardised  conditions.  This  general 
precept  only  fails  in  the  case  of  the  fluoride-resistant 
homozygote  with  which  dibucaine  inhibition  is  similar  to 
that  of  the  atypical  heterozygote,  although  the  EfEf  11 
phenotype  is  invariably  sensitive  but  EuEa  individuals 
11 
are  rarely  and  unpredictably  so.  Again  however  this  anomaly 
is  resolved  by  a  study  of  Figure  38  where  it  is  seen  that 
the  dibucaine  inhibition  of  the  fluoride-resistant  homozy- 
gote  is  more  severely  affected  by  increase  in  temperature 
than  any  other  phenotype  and  at  370C  the  dibucaine  number 
is  sensibly  that  of  the  Ea  Ef  genotype  which  is  invariably 
suxamethonium  sensitive.  The  same  applies  to  the  other 
inhibitors,  fluoride  (Figure  39),  chloride  (Figure  40)  and 
scoline  (Figure  41)  and  Tables  12-15. 
Once  more  therefore  this  study  has  indicated  the 
inadequacy  of  measurements  at  lower  reaction  temperatures 
to  predict  that  which  will  happen  at  the  functional 
temperature  of  the  enzyme,  37  0  C,  and  for  a  true  comparability 
between  inhibitor  number  and  sensitivity  to  suxamethonium 
the  inhibition  assays  should  be  performed  at  370C. 
In  the  absence  of  a  thermostatically  controlled 
spectrophotometer  it  is  the  ambient  temperature  which 
dictates  the  reaction  temperature  of  cholinesterase  assays. 
Schneider  and  Willis  (1958)  and  Henry,  Chiamori,  Golub  and 
Berkman  (1960)  found  the  temperature  in  the  cell  compartment Table  12  Variation  of  Percentage  Inhibition  with  Temperature 
DIBUCAINE  NUMBER 
Temperature 
Range  0  C) 
uu  E1E  uf  E1E1  u  EIE1  ff  EIEI  af  EIE1  a  a.  E1E 
15  20  +2.5  -1.5  +1.5  -3.0  0  -3.5 
20  25  -1.0  -1.5  -0.5  -4.0  -0.5  -3.5 
25  30  -4.0  -1.0  -2.0  -6.0  -0.5  -3.0 
30  35  -4.0  -4.0  -1.0  16.5  -2.0  -3.5 
35  40  -6.5  -6.0  -0..  5  -7.0  -7.0  -0.5 
40  45  -7.0  -7.5  -4.0  -9.5  -3.0  -0.5 
45  50  -7.  o  -7.5  -3.5  -11.5  -6.0  +2.0 
50  55  -12.5  -6.5  -8.0  -8.5  -7.0  +6.0 Table  13  Variation  of  Percentage  Inhibition  with  Temperature 
FLUORIDE  NUMBER 
Temperature 
Range  0  C) 
uu  E1E1.  uf  EIE1  ua  E1E1  ff  EIEI  f  E1E1  E1E1 
15  20  -9.0  -11.5  -8.5  -13.5  -9.0  -13.0 
20  25  -  10.5  -10.5  -6.0  -12.5  -9.0  -11.5 
25  30  -10.0  -7.0  -9.0  -10.5  -7.5  -6.5 
30  35  -10.5  -12.0  -9.0  -7.5  -10.0  -7.0 
35  40  -12.5  -9.0  -9.5  -6.0  -6.0  -4.0 
40  45  -8.0  -8.5  -7.0  -5.0  -0.5  -3.0 
45  50  -  7.0  -6.0  -6.0  -4.5  -2.5  -0.5 
50  55  -6.5  -4.0  -5.5  -1.0  0  -0.5 Table  14  Variation  of  Percentage  Inhibition  with  Temperature 
CHLORIDE  NUMBER 
Temperature 
Range  0c  Uu  E1E1  uf  EIE1  ua  EIE1  ff  E1EI  af  E1E1  aa  EIE1 
15  -  20  -4.0  -2.0  -1.0  -3.0  +1.1  -1.5 
20  -  25  -  3.0  -2.0  -3.5  +0.5  -4.0  0 
25  -  30  -1.5  -2.0  -2.5  -0.5  +1.0  +0.5 
30  -  35  -0.5  -0.5  -1.5  +2.0  0  +0.5 
35  -  40  +1.0  +0.5  -1.5  +1.0  -3.0  -0.5 
40  -  45  +1.5  +0.5  -0.5  +1.0  +1.5  +0.5 
45  -  50  +3.0  +1.0  +1.5  -0.5  -1.0,  +2.5 
50  -  55  +2.0  +1.5  +0.5  -2.0  0  -2.0 Table  15  Variation  of  Percentage  Inhibition  with  Temperature 
SCOLINE  NUMBER 
Temperature 
Range  (0  C) 
uu  E1E1  uf  EIEI  ua  EIEI  ,ff  E1E1  af  EIE1  aa  EjE  I 
15  -  20  -0.5  -2.0  -  -3.0  -  -1.5 
20  -  25  +1.0  -1.5  +2.0  -4.0  -2.5  0 
25  -  30  -2.0  -3.0  +1.5  -4.5  -3.0  +0.5 
30  -  35  -1.0  -3.5  +1.5  -5.0  -5.0  +0.5 
35  -  40  -2.5  -3.5  +0.5  -5.5  -5.5  0 
40  -  45  -3.5  -4.0  +1.0  -G.  0  -5.5  0 
45  -  50  -5.0  -5.0  -2.5  -7.0  -5.5  +2.5 
50  -  55  -6.5  -6.0  -5.0  -8.5  -7.5  -2.0 10  Cl 
of  their  spectrophotometers  to  be  50  to  70C  above  the 
ambient  room  temperature.  In  these  laboratories  in 
Glasgow  Royal  Infirmary,  the  bench  temperature,  out  of 
direct  sunlight,  has  been  found  to  fluctuate  between  18  0C 
and  32  0C  during  the  year.  This  is  probably  a  general  range 
in  these  islands  but  is  probably  wider  elsewhere.  It  was 
doubtless  an  appreciation  of  such  high  ambient  temperatures 
which  prompted  the  International  Union  of  Biochemistry 
(1965)  to  reject  the  earlier  advocacy  of  250C  by  its  Commission 
on  Enzymes  (I.  U.  B.  1961)  and  to  recommend  that  300C  be 
used  as  the  standard  temperature.  In  many  parts  of  the 
world  however,  even  in  these  northern  latitudes  in  summer- 
time,  to  maintain  a  euvette  temperature  of  30  0C  requires 
thermostatic  cooling  of  the  instrument.  This  difficulty, 
the  fact  that  a  valid  index  of  some  enzymes  is  only  obtained 
by  assay  at  their  physiological  temperature  (King  and  Dixon, 
1969;  King  and  Morgan,  1970)  and  the  desirability  of 
exploiting  the  increased  activity,  and  honce  better  precislon, 
at  higher  temperatures  in  the  automation  of  enzyme  assays, 
compellingly  suggest  the  universal  adoption  of  370C  as  tho 
standard  temperature  for  enzyme  assays  at  least  in  clinical 
biochemistry  (King,  1972). 
The  variation  with  temperature  in  the  inhibition  of 
the  allelic  serum  cholinesterase  isoenzymes  would  appear 
to  be  a  counter-argument  to  this  proposal.  This  only 
applies  to  fluoride  however  under  the  assay  conditions 
employed  in  this  study  since  Figures  38,40  and  41  show 
that  dibucaine,  chloride  and  succiny1dicholine  respectively 
can  still  provide  a  means  of  differentiating  the  cholin- 
esterase  phenotypes  at  37  0  C.  With  fluoride  on  the  other I  ol 
hand  (Figure  39)  the  inhibition  is  extremely  sensitive  to. 
temperature  change  so  that  even  at  30  0  C,  far  less  37  0C  it 
cannot  provide  a  reliable  means  of  distinguishing  the 
cholinesterase  variants. 
As  it  is,  even  with  current  practices,  the  revelation 
that  between  180C  and  32  0  C,  the  ambient  temperature  range 
in  these  laboratories,  the  fluoride  number  alters  by  1.4 
to  2.2  per  degree  change  in  reaction  temperature,  emphasises 
the  need  for  strict  temperature  control  of  the  reaction. 
From  Figure  39  it  can  readily  be  seen  that  an  alteration 
in  reaction  temperature  of  2  0-  40C  suffices  to  change  the 
fluoride  number  from  one  phenotype  range  to  that  of  the 
next.  It  has  been  recorded  (King,  McQueen  and  Morgan,  1971) 
that  if  the  assays  were  performed  at  20  0  C,  the  fluoride- 
resistant  homozygote  would  give  values  for  inhibitor 
numbers  except  scoline,  which  could  lead  to  a  classification 
uauf 
of  E1EI  or  even  E1E  It  was  even  speculated  that  the 
ff 
rarity  of  the  phenotype  El  El  (Lehmann  and  Liddell,  1969) 
might  in  part  be  due  to  a  general  failure  to  appreciate 
the  necessity  for  strict  temperature  control. 
Kalow  and  Davies  (1958)  postulated  that  the  structural 
difference  between  the  usual  and  atypical  enzymes  involved 
an  alteration  in  the  so-called  "anionic  site"  at  which  the 
positively  charged  grouping  of  some  substrates  and  inhibitors 
(Figures  1  and  20)  finds  attachment.  To  check  this  hypothesis 
Bamford  and  Harris  (1964)  used  the  'neutral'  substrate 
a-naphthyl  acetate  with  which  it  was  argued  that  the  anionic 
state  would  play  little  part  while  the  postulated  esteratic 
site  would  be  the  same  for  both  enzymes.  These  later ioi 
workers  found  that  with  the  Positively-charged  inhibitors, 
dibucaine  and  R02-0683  (Kalow  and  Davies,  1958),  at 
appropriate  concentrations,  differential  inhibitions  were 
obtained  with  a-naphthyl  acetate  similar  to  those  with 
benzoylcholine.  However  they  found  the  differential 
inhibition  of  the  enzymes,  with  fluoride  was  minimal  with 
a-naphthyl  acetate  in  contrast  to  that  obtained  with  a 
benzoylcholine  substrate  and  concluded 
"However,  some  difference  in  the  degree  of 
inhibition  of  the  two  enzymes  by  fluoride 
does  appear  to  be  present  even  when  naph- 
thyl  acetate  is  used  as  substrate,  and 
when  therefore  neither  substrate  not 
inhibitor  is  positively  charged.  This 
observation  is  not  readily  explained  by 
the  hypothesis  in  its  simplest  form,  and 
it  will  clearly  be  difficult  to  assess  its 
significance  until  more  is  known  about  the 
mode  of  action  of  the  F-  ion  on  the  enzyme". 
Bamford  and  Harris  (1964)  followed  the  hydrolysis  of  the 
a-naphthyl  acetate  substrate  at  37  0C 
and  the  reduction  in 
the  obsorved  differential  inhibition  by  fluoride  was 
probably  entirely  due  to  the  reaction  temperature  and  little 
influenced  by  the  substrate. 3.  Thiocholine  Ester  Hydrolysis, , 7"", 
Thiocholine'  Ester  Ilydr'olysis 
Koelle  (1957)  used  acetylthioclioline  as  a  substrate 
for  histochemical  localisation  of  cholinesterase.  The 
sulphur  analogues  of  aliphatic  choline  esters  have  also 
been  widely  used  in  cholinesterase  assays  employing  various 
indicator  reactions  to  follow  the  liberation  of  thiocholine 
(Page  8).  The  most  successful  of  these  has  been  the  reaction 
(Ellman,  1959)  with  5,51-dithiobis-(2-nitrobenzoic)  in  which 
the  liberation  of  the  yellow  anion  of  5-thio-2-nitrobonzoic 
acid  (Figure  42)  is  used  to  follow  the  enzymic  hydrolysis 
at  wavelengths  405-420  nm.  Ellman,  Courtney,  Andres  and 
Featherstone  (1961)  were  the  first  to  employ  this  principle 
for  assay  of  acetyleholinesterase  and  Garry  and  Routh  (1965) 
for  human  serum  cholinesterase.  Since  then  numorous  modifi- 
cations  (Augustinsson,  1971)  havo  appeared,  all  employing 
acetylthiocholine  or  butyrylthiocholino  as  substrate,  except 
for  the  recently  published  Selected  Method  of  the  American 
Association  of  Clinical  Chemists  which  uses  prop  Iony  1  thio- 
choline  (Dietz,  Rubinstein  and  Lubrano,  1973). 
The  validity  of  using  thiocholine  esters  as  substrates 
has  been  established  therefore  and  the  kinetics  of  the 
reactions  apparently  well  investigated,  certainly  for  the 
acetyl  and  butyryl  esters.  Augustinsson  (1971)  concluded 
that  "the  principle  described  by  Ellman  and  his  co-workers 
represents  one  of  the  most  straightforward  methods  developed 
for___cholinesterase  experiments".  Only  one  disadvantage  can 
be  attributed  to  the  principle.  Unlike  benzoyleholine  for 
which  Kalow,  Genest  and  Staron  (1956)  estimated  a  half-life 
at  bench  temperature  of  21  years,  the  thiocholine  ester +  -, 
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Figure  42.  The  reactions  involved  in  estimating  thiocholine 
aster  hydrolysis. solutions  are  not  very  stable  and  non-enzymic  hydrolysis 
cannot  be  ignored. 
Initially  it  had  been  thought  that  succiny1dicholine 
would  be  an  excellent  substrate  for  differentiating  the 
suxamethonium  sensitive  individuals  by  cholinesterase  activity 
alone.  However  preliminary  experiments  in  following  the 
change  in  pII  by  means  of  the  Astrup  micro-equipment  (Johnson 
and  Whitehead,  1965)  revealed  this  to  be  too  insensitive. 
This  did  lead  to  the  studies  of  succiny1dicholine  as  a 
differential  inhibitor  however  (p.  80  et  seq.  )  and  the  search 
for  a  commercial  source  of  succinyldithiocholine.  This 
substrate  has  only  recently  become  commercially  available 
(Boehringer  Corporation)  following  the  studies  of  Gibson 
and  Brown  (1972). 
Instrumentation,  Methods  and  Materials 
Initially,  studies  with  thiocholine  esters  were 
carried  out  at  410  nm  on  a  Unicam  SP800  recording  spectro- 
photometer  with  scale  expansion  to  a  Servoscribe  recorder 
and  temperature  control  given  by  a  Shandon  circulating 
heater  and  waterbath.  The  major  part  of  the  work  herein 
reported  however  was  carried  out  on  an  LKB  8600  Reaction 
Rate  Analyzer  with  410  nm  filter  system.  This  is  a  fixed- 
temperature  instrument,  operating  at  37  0C 
and  therefore  not 
capable  of  accomodating  temperature  studies.  It  was  modified 
however  by  Mr.  J.  Gilchrist,  the  LKB  Scottish  Region  Engineer 
to  have  a  variable  temperature  control  (Figure  43)  between*20  0C 
and  500C  in  steps  of  50C  (King  and  Ritchie,  1974).  At  first,  for 
temperatures  below  ambient,  this  instrument  was  operated  in 
the  cold  room,  but  was  more  conveniently  employed  in  con- Figure  43.  Temperature  modification  to  the  LKB  8600  Reaction 
Rate  Analyzer. 
Figure  44.  Complete  instrumentation  for  reaction  rate  analysis 
of  thiocholine  ester  hydrolysis  comprising  modified 
LKB  8600  analyzer,  LKB  8610  cooling  stage,  LKB  6500 
flat  bed  recorder,  LKB  8200  calculator  and  Data 
Dynamics  390  ASR  teletype. 01.  I 
r- 
junction  with  an  LKB  8610  Cooling  Stage  for  which  the  generous 
support  of  the  New  Medical  Developments  Committee  of  the 
Scottish  Home  and  Health  Department  is  gratefully  acknowledged. 
This  last  apparatus  holds  the  reaction  temperature  at 
25  0C  against  an  ambient  temperature  of  32.5  0  C,  the  highest 
experienced  during  its  period  of  operation.  As  a  cooling 
device  it  is  very  slow  however,  taking  2  hours  to  cool  the 
reaction  tunnel  of  the  analyzer  from  450C  to  250C  at  ambient 
temperatures  around  30  0  C.  It  was  found  that  keeping  the 
cuvette  racks  in  the  deep  freeze  (-20  0  C)  and  processing 
these  through  the  tunnel  reduced  the  temperature  in  a  matter 
of  minutes.  The  same  result  was  obtained  more  conveniently 
by  a  solid  brass  block  of  identical  dimensions  to  the  euvette 
rack  which  was  manufactured  to  order  by  Watson-Balgray 
Engineering  of  Glasgow.  Latterly,  the  instrumentation  was 
largely  automated  by  the  addition  of  an  LKB  8200  Calculator 
and  Data  Dynamics  390  ASR  teletype  (Figure  44).  The  LKB 
8600  Reaction  Rate  Analyzer  was  further  modified  in  that  the 
timing-cam  was  cut  for  a  30-second  differential.  For  the 
,  experiments  described  it  was  found  that  a  30-second  scan  was 
sufficient  for  precise,  accurate  results  and  the  reduced 
pre-incubation  time  of  71  minutes  was  just  sufficient  for 
the  rack,  cuvette  and  contents  to  reach  the  selected  reaction 
temperature  (King,  1973).  Initially  temperature  control 
was  checked  by  means  of  a  Wayne  Kerr  contact  thermometer  and 
latterly  by  a  Light  Laboratories  3GID  Temperature  11onitor 
with  an  IRM  probe. 
In  addition  to  the  reagents  previously  employed  (p.  43 
and  p.  82)  acetylthiocholine  iodide  was  obtained  from 106 
Boehringer  Corporation  (London)  and  DDII  Chemicals,  propionyl- 
thiocholine  iodide  from  Sigma  Chemical  Corporation,  butyryl- 
thiocholine  iodide  from  BDH  Chemicals,  succiny1dithiocholine 
iodide  from  Boehringer  Corporation  (London)  and  Ellman's 
reagent,  5,5'-dithio-bis(2-nitrobenzoic  acid)  from  Boehringer 
Corporation  (London)  and  BDII  Chemicals.  'No  significant 
difference  was  found  between  reagents  from  alternative  sources. 
For  these  studies  the  following  solutions  were 
prepared: 
(i)  50  mg  DTNB  (5,51-dithiobis-(2-nitrobenzoic  acid) 
dissolved  in  50  ml  67  mM  Sbrensen  phosphate 
buffer,  pH  7.4. 
(ii)  160  mg  acetylthiocholine  iodide  dissolved  in 
10  ml  of  reagent  (i). 
165  mg  propionylthiocholine  iodide  dissolved 
in  10  ml  of  reagent  (1). 
(iv)  105  mg  butyryltliioelioline  iodide  dissolved  In 
10  ml  of  reagnet  (i). 
(v)  60  mg  succinyldithiocholine  iodide  dissolved 
in  10  ml  of  reagent  (i). 
Addition  of  100  Q  of  these  substrate-DTNB  solutions  to  give 
a  reaction  volume  of  1.1  ml  produced  final  substrate  concen- 
trations  of  5W  acetylthiocholine,  5  mM  propionylthyocholine, 
3  0.1  butyrylthiocholine  and  I  mM  succiny1dithiocholine. 
The  enzyme  sources  for  these  studies  were  human  sera, 
the  phenotypes  of  which  had  been  determined  as  detailed  in 
the  preceding  sections.  For  assay  of  cholinesterase  activity 
on  the  LKB  8600,20  pl  of  the  reqiiired  serum  was  diluted 
with  20  ml  of  67  mM  phosphate  buf  'r,  pH  7.4.  One  millilitre 107 
of  this  diluted  serum  was  then  placed  in  a  euvetto  and  the 
reaction  started  by  the  automatic  priming  with  100  V1  of 
substrate-DTNB  solution.  For  the  inhibition  studios,  20  P1 
of  serum  was  diluted  with  10  ml  of  buffer;  0.5  ml  of  this 
dilution  and  0.5  ml  of  inhibitor  in  buffer  were  then  placed 
in  the  euvette  and  the  assay  continued  as  above. 
For  the  acety1cholinesterase  experimcnts  human  erythro- 
cytes  were  twice  washed  in  0.9%  saline  and  then  haemolysed 
by  adding  100  vl  of  packed  cells  to  10  ml  of  distilled  water. 
After  centrifugation  this  preparation  was  employed  as  the 
source  of  human  acetylcholinestorase.  To  1  ml  of  buffer 
containing  varying  concentrations  of  inhibitor,  200  pl  of 
haemolysate  was  added  and  the  reaction  started  as  indicated 
above  by  priming  with  100  V1  of  ace-tylthiocholine.  F  or 
these  experiments  the  acetylthiocholine-DTNB  (roagent  (ii), 
p.  1OG  )  was  diluted  I  in  10  with  phosphate  buffer  to  Vivo 
a  final  substrate  concentration  of  0.5  mM,  optimal  for 
acetyleliolinesterase. 
Although  the  level  of  non-enzymic  hydrolysis  was 
constant  for  each  series  of  experiments  a  blank  to  monitor 
this  was  included  in  each  raci-ý  of  ton  cuvettes. 
Experimental  Results 
Preliminary  experiments  to  establish  optimal  assay 
conditions  by  investigating  the  variation  of  enzyme  activity 
with  substrate  concentration,  buffer  and  pH,  confirmed  the 
lability  of  the  thiocholine  esters.  The  non-enzymic  or 
spontaneous  hydrolysis  obviously  increased  in  the  order 
butyryl-,  propionyl-,  acetyl-,  succinyl-,  and  while  the 
percentage  rate  of  hydrolysis  remained  sensibly  constant 10  20 
the  absolute  amount  of  product  obviously  increased  with 
substrate  concentration  (Figure  65).  The  spontaneous 
hydrolysis  also  increased  with  p1l  (Figure  45).  An 
observation  from  standard  cysteine  curves  prepared  at  dif- 
ferent  pH  values  appeared  to  indicate  that  the  absorption 
at  410  nm  of  the  5-thio-2-nitrobenzoate  anion  I increased 
with  pH.  To  check  this  0.5  ml  each  of  aqueous  cysteine 
solution  and  DTNB  solution  were  added  to  3  ml  of  different 
buffers  of  varying  pH  values.  Blanks  with  water  substituted 
for  cysteine  solution  were  also  prepared.  Absorptions  were 
recorded  at  different  temperatures  and  at  various  time 
intervals.  Typical  results  are  illustrated  in  Figure  46. 
These  results  confirmed  the  original  observation  and 
indicated  that  tile  increase  in  spontaneous  hydrolysis  with 
p1l  was  in  part  due  to  the  increased  absorption  of  tile. 
indicator  ion  with  p1l.  This  also  meant  that  the  obsei,  ved 
variation  in  enzyme  activity  with  hydrogen  ion  concentration 
was  similarly  affected.  '  This  latter  phenomenon  and  the  iioli- 
enzymic  hydrolysis  of  the  thiocholine  esters  were  largely 
the  determinants  in  deciding  to  retain  tile  buffer  msed  in 
previous  experiments,  that  is,  67  mll  Sbrensen  phosphate 
buffer,  p1l  7.4  and  substrate  concentrations  of  5  mM,  5  mM 
and  3  mAl  for  acetyl,  propionyl-  and  butyrylthiocholine 
respectively  at  37  0  C.  ese  were  the  standard  assay  con- 
ditions  employed  in  all  later  experiments.  The  correctness 
of  this  decision  gained  Support  from  the  work  of  Szasz  (1968a) 
who,  at  250C,  used  50  mM  tris  buffer  and  2  mIT  butyrylthiocholine. 
This  worker  also  recorded  that  the  optimum  for  acetylthio- 
choline  was  "only  reached  at  a  concentration  of '"C' 
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at  least  5  n2M.  This  increase  in 
concentration  does  however  raise 
conside'rably  the  autolysis  of  the 
substrate". 
Consequently  Szasz  used  a2  mM  concentration  of  acetyl- 
thiocholine  at  25  0  C,  thereby  indicating  similar  experiences 
to  those  described  above. 
Experiments  with  succiny1dithiocholine  were  disap- 
pointing  due  to  the  spontaneous  hydrolysis  at  37  0C  (Figure 
65).  In  many  cases  particularly  with  sera  from  suxamethonium- 
sensitive  phenotypes  or  with  low  normal  activities,  907o  or 
more  of  the  recorded  change  in  absorption  was  due  to  non- 
enzymic  factors.  Studies  with  succiny  ldithiocholine  were 
not  continued  because  of  this  lack  of  sensitivity  in  the 
assay. 
Inhibition  of  the  cholinesterase  hydrolysis  of  the 
thiocholine  esters  was  only  examined  with  %  view  to  establish- 
ing  that  the  characteristics  of  the  variants  exhibited  with 
. 
benzoyleholine  were  also  shown  with  these  substrates. 
Figures  47,48  and  49  illustrate  the  effects  of  increasing 
dibucaine  concentration  of  the  hydrolysis  at  37  0C  of  5  mAl 
acetylthiocholine.  5  mM  propionylthiocholine  and  3  mll 
butyrylthiocholine  respectively  by  the  six  cholinesterase 
phenotypes  studied.  Similar  curves  were  obtained  using 
succiny1dicholine,  chloride  and  with  certain  anomalies, 
fluoride  as  shown  in  Figures  50  to  58. 
To  complete  studies  reported  earlier  (p.  83  et  seq.  ) 
the  inhibition  of  erythrocyte  acetylcholinesterase  hydrolysis 
of  acetylthiocholine  was  also  examined  and  the  results  with 
pancuronium  and  tubocurarine  are  shown  in  Figures  59  and  60 
respectively.  Gallamine  inhibition  was  also  attempted  in ilo 
these  acety1cholinesterase  experiments  but  addition  of  the 
substrate-DTNB  solution  produced  such  an  intense  yellow 
colour  that  recording  of  reaction  rates  was  not  possible. 
Although  the  May  and  Baker  leaflet  on  Flaxedil  gave  no 
indication  as  to  the  possible  cause  of  this  phenomenon  the 
British  Pharmacopoeia  (p.  334)  indicates,  that  for  injection, 
gallamine  triethiodide  is  dissolved  in  0.27o  w/v  sodium 
sulphite. 
It  was  evident  at  an  early  stage  of  preliminary 
studies  that  the  relative  rates  of  hydrolysis  of  the  different 
substrates  varied  with  the  serum  phenotype.  This  had  also 
been  observed  with  a  wide  range  of  choline  esters  (Davies, 
Marton  and  Kalow,  1960)  with  acetylcholine  and  benzoylcholine 
(Rubinstein  and  Dietz,  1963)  and  with  acetylcholine,  benzoyl- 
cholinc,  procaine  and  tetracaine  (Smith  and  Foldes,  1972). 
At  most  these  studies  only  compared  the  usual  and  atypical 
homozygotes  and  the  heterozygote.  To  extend  these  observations 
sera  from  34  usual  homozygotcs,  5  usual/fluoride-resistant 
heterozygotes,  21  usual/atypical  heterozygotes,  2  fluoride- 
resistant  homozygotes,  4  atypical/fluoride-resistant  heterozy- 
gotes-and  11  atypical  homozygotes  were  assayed  under  the 
prescribed  conditions  at  37  0  C.  The  best  differentiation  was 
obtained  with  acetylthiocholine  and  butyrylthiocholine  and 
is  shown  in  Figure  61. 
The  results  of  the  temperature  studies  with  t'he  three 
thiocholine  ester  substrates  and  six  phenotypes  are 
illustrated  in  Figures  62,63  and  64.  In  these  figures  the 
spontaneous  hydrolysis  (Figure  65)  is  allowed  for  but  no 
account  is  taken  of  the  increase  in  absorption  with  tempera- Sol-  Acetylthioclioline  (37  0  C) 
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hydrolysis  by  cholinesterase  phenotypes  at  370C 
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hydrolysis  by  cholinesterase  phenotypos  at  370C 
with  a  reaction  concentration  of  5  WA  propionyl- 
thiocholine  in  67  mM  Sbrensen  phosphate  buffer, 
p1l  7.4. 
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Figure  55.  Sodium  chloride  inhibition  of  butyrylthiocholine 
hydrolysis  by  cholinesterase  phenotypes  at  37oC 
with  a  reaction  concentration  of  3  mM  butyryl- 
thiocholine  in  67  mM  SUrensen  phosphate  buffer, 
pll  7.4. C 
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Figure  56.  Fluoride  inhibition  of  acetylthiocholino  hydrolysis 
by  cholinesterase  phenotypes  at  370C  with  a  reaction 
c,  oncentration  of  5  mM  acetylthiocholine  in  G7  mM 
SUrensen  phosphate  buffer,  pill  7.4.  The  curves  for 
the  other  phenotypes  lie  between  those  extremes 
shown  and  are  omitted  for  clarity  of  presentation. 
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Figure  57.  Fluoride  inhibition  of  propionylthiocholine  hydrolysis 
by  cholinesterase  phenotypes  at  370C  with  a  reaction 
concentration  of  5  mM  propionylthiocholine  in  67  el 
SUrensen  phosphate  buffer,  pli  7.4. Butyrylihiocholine 
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Figure  - 58.  Fluoride  inhibition  of  butyrylthiocholine  hydrolysis 
by  cholinesterase  phenotypes  at  370C  with  a  reaction 
concentration  of  3  mM  butyrylthiocboline  in  67  Al 
SUrensen  phosphate  buffer,  pH  7.4. Acetylthiocholine  37  0C 
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Figure  59.  Pancuronium  inhibition  of  acetylthiocholino  hydrolysin 
by  serum  cholinesterases  and  erythrocyte  acetyl- 
cholinesterase  at  370C.  For  the  cholinesterase  assays 
a  reaction  concentration  of  5  mlla  acetylthiocholine  and 
for  the  acetylcholinesterase  studies  of  500  1AI 
acetylthiocholine  in  67  mAl  Sbrensen  phosphate  buffer, 
p1l  7.4  were  employed. 
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Figure  60.  Tubocurarine  inhibition  of  acetylthiocholine  hydrolynis 
by  serum  cholinesterases  and  erytbrocyto  neutyl- 
thiocholinesterase  at  370C.  For  the  cholinesteraso 
assays  a  reaction  concentration  of  5  mM  acetylthlocholine 
and  for  the  acety1cholinesterase  estimations  of  500  VIA 
acetylthiocholine  in  67  M  Sbrensen  phosphate  buffer, 
pH  7.4  were  employed.. 
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Figure  61.  Ratios  of  activities  at  370C  with  3  mM  butyrylthiocholine 
and  5W  acetylthiocholine  for  serum  cholinesterase 
phenotypes. AcetylfhicKholine 
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Figure  62.  Temperature/activity  curves  of  serum  cholinesteraso 
pbenotypes  with  a5  mM  acetylthiocholine  substrate 
and  referred  to  unity  at  250C. Propionyllhiocholine 
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Figure  63.  Temperature/activity  curves  of  serum  cholinosterase 
phenotypes  with  a5  mM  propionylthiocholine  substrate 
and  referred  to  unity  at  250C. 2.2  - 
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Figure  64.  Temperature/activity  curves  of  serum  cholinestorase 
phenotypes  with  a3  iyM  butyrylthiocholino  substrate 
and  referred  to  unity  at  250C. Im)  Succinyidithiocholine 
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Figure  65.  Variation  of  the  non-enzymic  hydrolysis  of 
thiocholine  esters  with  reaction  temperature. om 
ture  of  the  indicator  ion  (Figure  46). 
Discussion 
The  non-enzymic  hydrolysis  of  the  thiocholine  esters 
varies  with  the  hydrogen  ion  concentration  (Figure  45), 
substrate  concentration  and  reaction  temperature  (Figure  65) 
and  even  the  absorption  of  the  indicator  ion,  5-thio-2- 
nitrobenzoate,  varies  with  pH  and  temperature  (Figure  46). 
These  facts,  some  apparently  unappreciated  by  other  workers, 
make  this  assay  less  ideal  and  reliable  than  that  based  on 
benzoylcholine  hydrolysis. 
Interpretation  of  results  from  benzoyleholine  hydrolysis 
however  must  always  be  viewed  from  the  background  knowledge 
that  this  ester  is  hardly  acceptable  as-  a  physiological 
substrate.  Nonetheless  if  similar  behaviour  is  exhibited 
by  other  substrates  with  close  chemical  affinity  to  naturally 
occurring  esters  then  it  may  be  concluded  that  these  inter- 
pretations  are  real  and  valid.  Therefore  despite  the  doubts 
engendered  by  the  preliminary  investigations  into  the  assay 
principle,  the  study  was  continued  albeit  bearing  in  mind 
that  all  that  was  sought  or  expected  was  generally  confirm- 
atory  evidence.  As  a  consequence  no  absolute  values  were 
recorded  in  these  studies,  only  relative  figures  such  as 
percentages  and  ratios. 
The  inhibition  studies  with  dibucaine.,  succinyl- 
dicholine  and  chloride  amply  provided  the  confirmation  that 
these  substances  reacted  with  the  enzyme  protein.  For 
dibucaine  the  concentration  giving  optimal  differentiation 
between  the  phenotypes  was  10-  4 
if  with  all  three  substrates. 
For  acetylthiocholine  and  propionylthiocholine  this  gave 112 
inhibitions  about  657o,  307o  and  >10,,  ýo'  for  the  homozygous 
phenotypes  EuEu*EfEf  and  EaEa  respectively  (Figures  47 
111111 
and  48.  With  butyrylthiocholine  (Figure  49)  these  values 
become  757o,  407o  and  107o.  The  difference  in  these  inhibitions 
does  not  necessarily  betoken  a  contrast  in  the  handling  of 
the  substrates  but  is  probably  related  to  their  concentrations, 
5  mM  for  the  acetyl  and  propionyl  esters,  3  mM  for  butyryl- 
thiocholine.  When  the  dibucaine  concentration  is  reduced 
proportionally  to  6X  10-  5  1.1  the  inhibitions  obtained  with 
butyrylthiocholine  are  identical  to  those  obtained  at  10- 
4  hi 
with  the  other  two  substrates.  This  is  the  expected 
behaviour  of  a  simple  competitive  inhibitor. 
The  improved  differentiation  of-'the  fluoride-resistant 
homozygote  from  other  phenotypes  is  probably  not  a  reflection 
of  its  behaviour  in  the  presence  of  thiocholine  ester 
substrates  but  rather  of  the  reaction*temperature,  37  0  C.  it 
was  noted  earlier  (Figure  35)  that  the  inhibitions  of  the  - 
fluoride-resistant  homozygote  were  more  sensitive  to  tempera- 
ture  change  than  the  other  phenotypes  and  at  37  0C  yielded 
inhibitions  more  consistent  with  its  known  suxamethonium 
sensitivity  (p.  99). 
Succiny1dicholine  is  also  a  competitive  inhibitor 
and  its  bohaviour  is  therefore  unexpected.  The  inhibitor 
concentration  giving  maximum  differentiation  is  10  mM  at 
which  the  atypical  homozygote  is  inhibited  107o  irrespective 
of  substrate.  Under  the  same  conditions  the  usual  homozygote 
is  inhibited  70',  10  with  acetylthiocholine,  557o  with  propionyl- 
thiocholine  and  657o  with  butyrylthiocholine.  Proportional 
adjustment  of  succiny1dicholine  concentration  to  6  rrM  reduces 11 
113 
the  butyrylthiocholine  inhibition  to  551,  lo.  It  is  interesting 
to  note  that  the  optimal  differentiating  concentrations  for 
both  dibucaine  and  succinyldicholine  are  tenfold  greater 
than  those  employed  with  benzoylcholine.  Although  not 
directly  comparable  because  of  the  different  substrate 
concentrations  employed  and  the  use  of  tris  buffer  of  pIl  7.2 
similar  results  to  those  described  here  for  dibucaine  and 
succinyldicholinc  were  reported  by  Garry  (1971). 
With  sodium  chloride  the  differential  inhibition  of 
phenotypes  is  much  reduced  and  is  fairly  constant  between 
0.01  and  1.5M.  Again  the  loci  for  the  propionyl  and 
butyryl  esters  are  very  similar  with  acetylthiocholine 
giving  a  slightly  different  picture  and  better  segregation. 
Nonetheless  at  0.01  sodium  chloride  the  usual  homozygote  is 
inhibited  about  207o  and  the  atypical  homozygote  about  45% 
with  all  three  substrates. 
With  sodium  fluoride  the  most  bizarre  results  are 
obtained  with  distinct  progressive  variations  depending  upon 
the  substrate.  The  degree  of  inhibition  for  all  phenotypes 
increases  with  substrate  chain  length.  At  lower  inhibitor 
concentrations  the  relative  phenotype  inhibitions  are  the 
reverse  of  that  found  with  a  benzoylcholine  substrate  but 
with  increasing  concentration  of  fluoride  this  becomes 
inverted.  The  first  part  of  these  curves  with  the  atypical 
variant  more  inhibited  than  the  usual  enzyme  is  illustrated 
by  Garry  (1971)  using  a  butyrylthiocholine  substrate.  This 
worker  did  not  continue  the  fluoride  concentration  beyond 
5X  10-  4M 
at  which  he  was  obtaining  almost  complete 
inhibition  of  all  phenotypes.  The  effect  of  other  inhibitors 114 
were  examined  by  Garry  at  37  0C  but  strangely  the  fluoride 
experiments  were  conducted  at  25  0  C.  Heilbronn  (1965)  had 
already  noted  that  fluoride  inhibition  of  butyryleholine 
hydrolysis  increased  with  lowering  of  temperature  as  noted 
in  this  study  with  a  benzoylcholine  substrate  (Figure  39). 
Garry  (1971)  did  employ  higher  concentrations  of 
4 
fluoride  up  to  10-  2 
14  but  in  these  experiments  in  tris  buffer. 
At  these  higher  concentrations  the  usual  enzyme  was  inhibited 
to  a  greater  extent  than  the  atypical  variant,  the  inversion 
to  the  situation  found  with  benzoylcholine  substrate.  This 
inversion  was  attributed  to  the  effect  of  the  change  in 
buffe  r  from  phosphate  to  tris.  Certainly  in  tris  buffer  the 
inhibitory  effect  of  fluoride  is  much  reduced  as  well  as 
the  relative  phenotype  inhibitions  inverted  to  that  found 
in  phosphate  buffer.  This  phenomenon  is  made  use  of  by 
Garry,  Owen  and  Lubin  (1972)  to  differentiate  the  fluoride- 
resistant  variants  by  duplicate  assays  at  215  0C  in  phosphate 
and  tris  buffer,  with  and  without  addition  of  fluoride. 
Obviously  from  the  results  obtained  in  this  study  (Figure  58) 
the  same  differentiation  could  be  obtained  at  37  0C  in 
phosphate  buffer  alone  at  two  fluoride  concentrations,  say 
10- 
4 
11  and  10-  2M 
with  a  butyrylthiocholino  substrate. 
In  the  Selected  Method  of  the  American  Association  of 
Clinical  Chemists  (Dietz,  Rubinstein  and  Lubrano,  1973)  a 
2  mM  propionylthiocholine  substrate,  with  4  mll  sodium 
fluoride,  phosphate  buffer,  )?  H  7.6  and  reaction  temperature 
of  37  0C  is  recommended.  These  conditions  yield  highest 
percentage  inhibitions  with  overlapping  ranges  for  the  usual 
(78-81%)  and  atypical  homozygotes  (82-867o)  and  the  heterozyLgote 115 
(78-827o),  lowest  values  of  54  and  657o  for  the  fluoride- 
resistant  homozygote  and  67-697o  for  the  atypical/fluorido- 
resistant  heterozygote.  Obviously  the  conditions  chosen 
are  close  to  the  point  of  inhibition  inversion  and  incredibly 
in  an  official  Selected  Method  this  would  appear  not  to 
have  been  appreciated. 
In  unrecorded  experiments  on  benzoylcholine  hydrolysis 
it  was  found  that  at  the  inhibitor  concentrations  routinely 
employed  (page  43)  increasing  the  substrate  concentration 
from  50  vII  to  100  vM  reduced  the  inhibition  by  the  competitive 
inhibitors,  dibucaine  and  succiny1dicholine  by  about  10%, 
but  increased  the  fluoride  number  by  about  10.  The  complexity 
of  fluoride.  inhibition  had  been  appreciated  therefore  before 
these  thiocholine  ester  studies.  The  increase  in  inhibition 
with  increase  in  substrate  concentration  had  given  rise  to 
the  idea  that  fluoride  acted  by  forming  a  complex  with  the 
substrate.  That  this  complex  might  be  thermolabile  would 
be  in  accord  with  the  pronounced  decrease  in  inhibition  with 
increase  in  reaction  temperature  (Figure  39).  This  simple 
hypothesis  might  also  be  in  keeping  with  the  difference  in 
degree  of  inhibition  experienced  with  the  different  thiocholine 
substrates  (Figures  56,57,58).  This  last  phenomenon  had 
already  been  reported  by  Heilbronn  (1965)  who  noted  that 
sensitivity  to  fluoride  inhibition  decreased  in  the  order, 
benzoylcholine,  butyrylcholine,  acetylcholine.  Cimasoni 
(1966)  also  recorded  that  'human  serum  pseudocholinesterasel 
was  less  readily  inhibited  by  fluoride  with  an  acetylthio-7 
choline  substrate  than  with  butyrylthiocholine. 
Inhibition  by  fluoride  is  reversible  both  by  dilution 116 
and  by  dialysis  against  0.97o  sodium  chloride  (Heilbronn, 
1965)  and  phosphate  buffer  (Cimasoni,  1966).  Garry  (1971) 
explained  the  differences  in  inhibition  in  tris  and 
phosphate  buffers  by  postulating  that  in  the  former  the 
inhibitor  was  the  fluoride  ion  and  in  the  latter  the. 
fluorophosphate  ion.  However  Cimasoni  (1966)  obtained 
comparable  inhibitions  of  thiocholino  ester  hydrolysis  in 
phosphate  and  veronal  buffers.  He  concluded  that  the 
inhibition 
"does  not  take  place  through  the 
formation  of  complexes  of  fluoride 
with  magnesium,  phosphate  or  calcium; 
nor  does  the  substrate  play  a  role  in 
the  mechanism  of  inhibition.  It  can 
therefore  be  postulated  that  the 
enzyme  molecules  themselves-are  directly 
affected  by  the  halide  ions.  " 
The  statement  that  the  substrate  does  not  play  a  role 
is  difficult  to  understand  since  the  only  experiments  under- 
taken  on  this  point  did  show  different  inhibitions  with 
different  substrates.  Heilbronn  (1965)  considered  many 
possible  mechanisms  including  the  hypothesis  that  trans- 
acylation  occurred  to  fluoride  rather  than  the  hydroxyl 
ion  and  that  the  acyl  fluoride  was  then  the  inhibitor. 
This  could  account  for  the  more  potent  inhibitions  found 
with  the  longer  (butyryl)  and  bulkier  (benzoyl)  esters'. 
She  also  considered  inhibition  of  acylation  due  to  a  reaction 
of  the  inhibitor  with  the  enzyme-substrate  complex  but 
finally  recorded  that  an  "interaction  with  a  group  in  the 
active  site,  necessary  for  the  acylation  of  the  enzyme, 
seems  indicated.  " 
None  of  these  postulated  mechanisms  however  would 117 
appear  to  account  for  the  inversion  of  the  phenotypic 
inhibitions.  This  occurs  with  all  three  substrates  examined 
in  this  study  at  roughly  the  sane  fluoride  concentration 
between  5X  10-  4 
and  10-  3 
and  is  due  to  inhibition  of  the 
atypical  variant  reaching  a  plateau  about  this  concentration. 
A  possible  explanation  could  be  the  presence  of  two 
inhibitory  species,  one  a  readily-formed  fluoride  complex 
and  the  other  free  fluoride  ions,  both  equally  inhibitory 
to  the  usual  enzyme  but  only  one  a  potent  inhibitor  of  the 
atypical  variant. 
Speculations  regarding  these  inhibitions  far  less  their 
mechanisms  must  be  tempered  by  the  recent  report  (Brownson 
and  Watts,  1973)  that.  5,5'-dithiobis-(2-nitrobenzoic  acid) 
has  an  activating  effect  on  cholinesteraso.  This  activation 
is  abolished  at  saturating  concentrations  of  acetylthio- 
choline  although  it  is  still  found  with  butyrylthiocholine 
under  such  conditions.  Indeed  it  is  even  possible  that  this 
activation  may  be  phenotype-dependent  but  this  was  not 
recorded. 
This  complication  and  that  concerning  the  variation 
in  absorpt.  ion  of  the  indicator  ion  with  temperature  were 
not  taken  into  account  in  the'temperature  studies  with  the 
thiocholine  esters.  Only  the  non-enzymic  hydrolysis  of  the 
substrate  was  allowed  for  in  these  experiments  by  including 
a  control  for  each  substrate  at  each  temperature.  The 
uncompensated  complexities  of  this  assay  make  calculation 
of  temperature-activity  constants  a  meaningless  exercise. 
I 
Even  expressed  as  ratios  referred  to  unity  at  250C  as  in 
Figures  62  to  64  probably  yields  erroneously  high  values "I  I  ý131 
at  the  higher  temperatures.  However  even  without  the 
I 
necessary  compensatory  adjustments  the  temperature-activity 
relationships  found  for  all  three  thiocholine  ester  substrates 
is  sufficient  to  confirm  that  the  phenotypic  thermal  responses 
found  with  a  benzoylcholine  substrate  result  from  character- 
istic  molecuiar  alterations  in  the  allelic  cholinesterase 
isoenzymes. 
Apart  from  this  general  confirmatory  evidence  any 
meaningfulness  to  be  attached  to  these  experiments  can  only 
be  considered  approximations,  and  that  under  the  specific 
conditions  employed.  This  does  not  invalidate  these  results 
from  being  used  for  screening  purposes  however  (King  and 
Ritchie,  1974).  It  would  be  quite  valid  by  assays  at  25  0C 
0  and  45  C  to  infer  that  ratios  of  activity  less  than  1.5 
with  5  mM  acetylthiocholine  (Figure  62),  less  than  1.55 
with  5  mM  propionylthiocholine  (Figure  63)  and  less  than 
1.7  with  3  W1  butyrylthiocholino  (Figure  64)  indicate  a 
suxamethonium-sensitive  phenotype.  With  the  modified 
LKB  8600  Reaction  Rate  AnalYser  used  in  those  studies,  100 
cholinestorase  assays  can  be  performed  in  one  hour.  A 
realistic  figure  might  be  600  assays  per  day,  say  300  at 
25  0C  in  the  morning  then  repeated  at  450C  in  the  afternoon. 
This  number  of  specimens  could  be  processed  readily  using 
the  LKB  2071  or  the  Hook  and  Tucker  K40  sample-diluters  and 
processing  the  teletype  tape  through  a  modest  computer  to 
obtain  the  ratios.  The  recently  introduced  Vitatron  AKES 
which  has  a  variable  temperature  control,  a  sampling- 
dispensing  system  and  produces  a  print-out  of  results  can 
increase  the  number  of  specimens  screened  to  400  per  day 00-1  00 
(McQueen  and  King,  1974). 
The  action  of  inhibitors  may  be  used  also  to  screen 
for  suxamethonium-sensitive  phenotypes.  With  10  -4  it 
dibucaine  an  inhibition  of  less  than  4079,3876  or  507o  with 
acetylthiocholine  (Figure  47),  propionylthiocholine 
(Figure  48)  or  butyrylehiocholine  (Figure  49)  respectively 
would  indicate  a  sensitive  phenotype.  Less  reliably, 
succiny1dicholine  at  10-  2M 
sensitive  phenotypes  would  give 
inhibitions  less  than  60%,  34cilo  or  45/10  with  acetyl-  (Figure 
50),  propionyl-  (Figure  51)  or  butyrylthiocholine  (Figure 
52)  respectively.  Chloride  and  fluoride  do  not  provide 
sufficient  differentiation  to  be  of  use  even  for  screening. 
Yet  again  the  ratio  of  hydrolysis  rates  with  two  sub- 
strates  may  be  employed  although  here  the  differentiation 
is  less  precise.  However  with  3  mM  butyrylthiOChOlIDO  Und 
5  mM  acetylthiocholine  an  activity  ratio  of  less  than  1.65 
(Figure  61)  would  suggest  the  need  for  further  investigatton 
of  the  specimen. 
The  experiments  into  the  effect  of  the  non-depolarising 
relaxants  on  the  hydrolysis  of  acetylthiocholine  by  usual 
and  atypical  homozygous  sera  confirm  the  inhibitory  action 
of  pancuronium  and  tubocurarine  noted  earlier  with  a 
benzoylcholine  substrate  (page  92).  There  is  however  a 
relative  difference  in  that  an  initial  plasma  level  of 
2.5  1  pancuronium  is  too  low  to  have  any  effect  on  either 
variant  (Figure  59)  while  an  initial  plasma  level  of  5  vM 
tubocurarine  would  slightly  inhibit  the  usual  enzyme 
(Figure  60). 
0 
Particularly  interesting  is  the  inhibition  of  erythrocyte 120 
acetyleholinesterase  which  with  both  pancuronium  and  tubo- 
curarine  closely  resembles  the  behaviour  of  the  atypical 
cholinesterase.  Although  both  non-depolarising  relaxants 
have  an  anti-acetylcholinesterase  action  this  does  not 
occur  at  concentrations  achieved  in  the  blood. 4.  Population  Surveys 12  1) 
During  the  course  of  the  biochemical  investigations 
reported  herein,  two  extensive  population  studies  were  made, 
the  first  on  a  family  or  geographical  basis,  the  second  in 
a  selected  clinical  setting. 
Scalpay  Survey 
A  patient  admitted  to  the  Lewis  Hospital,  Stornoway, 
suffered  a  "suxamethonium  apnoeall  and  assay  of  his  serum 
indicated  cholinesterase  activity  of  260  mU/ml  at  25  0  C, 
dibucaine  number  19,  fluoride  number  22,  chloride  number 
57  and  scoline  number  17.  Ile  was  accordingly  classified 
as  phenotype  EaEa 
11  although  in  view  of  the  low  activity 
the  presence  of  a  silent  gene  was  possible. 
Family  studies  were  suggested  but  this  was  difficult 
since  the  patient  resided  on  a  small,  fairly  remote  island, 
Scalpay,  off  the  Island  of  Lewis.  His  father  was  the 
"Elder"  of  the  island  which  was  the  home  of  most  members 
of  his  family.  However,  Dr.  J.  H.  Burton,  Surgical  House 
Officer  at  the  Lewis  Hospital  and  Dr.  J.  W.  Robertson,  the 
local  General.  Medical  Practitioner  took  blood  samples  from 
109  members  of  the  family.  As  a  result  one  brother  and 
two  sisters  of  the  propositus  were  also  classified  as 
atypical  homozygotes,  two  brothers  as  heterozygotes  and  one 
brother  a  usual  homozygote.  One  further  brother  was  at  sea 
and  no  specimen  was  obtained  and  one  sister  was  dead.  The 
mother  was  also  dead  but  the  father  was  identified  as  a 
usual/atypical  heterozygote. 
Two  neices  of  the  propositus,  daughters  of  a  heterozygote 
brother,  were  classified  phenotype  EaEf  although  in  the  11 
absence  of  a  blood  sample  from  their  mother,  their  certain 12 
'11ý1. 
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phenotype  must  remain  in  some  doubt  (p.  86  and  Figures  24 
and  26).  A  second-cousin  was  found  to  be  phenotype  EuEu  11 
with  a  serum  cholinesterase  of  280  mU/ml  which  in  a  healthy 
individual  again  raises  the  possibility  of  the  presence  of 
a  silent  gene  although  there  was  no  evidence  for  this  in 
the  immediate  family  and  indeed  the  usual  homozygote  brother 
had  serum  cholinesterase  activity  of  1000  mU/ml.  The 
phenotype  relationship  of  the  immediate  family  is  shown  in 
Figure  66. 
-  Outside  the  immediate  family  of  the  propositus  the 
relationship  data  received  was  somewhat  less  than  satisfactory 
but  a  possible  maternal  aunt,  a  usual  homozygote  had  serum 
ebolinesterase  activity  of  2100  W/ml,  and  twenty  of  the 
sera  assayed  had  activities  greater  than  the  normal  range 
of  600  to  1350  mU/ml.  This  might  suggest  segregation  within 
the  family  of  the  A  variant  but  no  attempt  was  made  to 
confirm  this.  Although  deriving  from  a  second  cholinestorase 
locus  it  has  been  shown  that  the  A  variant  apparently  adopts 
the  same  inhibition  characteristics  as  the  variants  at  the 
first  locus  (Harris,  1970). 
Despite  the  possible  presence  of  these  other  variants 
in  the  population  studied,  in  which  incidentally  there  was 
no  evidence  of  consanguineous  matings,  it  had  been  hoped 
that  in  such  an  extensive  family  study  the  scatter  of 
inhibitor  numbers  would  be  less  than  in  the  general  population. 
Such  a  finding  would  lend  support  to  the  thesis  (p.  86  et  seq.  ) 
. 
that  the  atypical  gene,  as  currently  accepted,  is  not  a 
single  entity  but  embraces  several  mutations.  However  the 
figures  obtained  and  summarised  in  Table  16  were  disappointing 1..,,.., 
1.6 
..  b 
Figure  66.  Phenotype  relationship  of  the  immediate  family  of 
the  Scalpay  propositus. Table  16 
Summary  of  Results  from  Scalpay  Survey 
Phenotype  Number  Cholinesterase 
Dibucaine  Fluoride  Chloride  Scoline 
Number  Number  Number  Number 
(280  -  2100) 
EuEu  73  520  -  1740  79  -  83  56  -  66  .9- 
19  88  -  93 
11 
EuEa  28  340  -  1320  54  -  69  45  -  52  21  -  30  63  -  70 
11 
aEa4  260  -  395  15  -  22  19  -  24  48  -  57  14  -  17 
11 
The  values  in  parenthesis  for  cholinesterase  activity  of  the  usual 
homozygotes  represent  the  true  limits  found.  When  these  two  values  are 
deleted  the  narrower  unbracketted  range  is  obtained. 123 
in  this  respect.  The  inhibitor  numbers  for  the  atypical 
homozygotes  certainly  show  less  scatter  than  the  general 
population  but  this  was  from  only  four  individuals. 
Pregnancy  Survey 
The  first  patient  suffered  a  "Scoline  apnoeall  at 
term  in  Glasgow  Royal  Maternity  Hospital  and  a  blood  sample 
was  sent  for  analysis.  The  results  of  cholinesterase 
130  mU/ml,  dibucaine  number  29,  fluroide  number  31  and 
chloride  number  40  did  not  fit  with  any  phenotype  (Figures  2 
and  29).  The  sample  was  haemolysed  and  although  it  was 
known  that  this  did  not  invalidate  the  results  a  repeat 
specimen  was  requested.  Analysis  of  this  second  specimen 
gave  results  for  serum  cholinesterase  105  mU/ml,  dibucaine 
nijmber  33,  fluoride  number  31  and  chloride  numbe-r  42.  TIio 
second  values  were  still  anomalous  but  a  provisional  pheno- 
type  of  EEa  Nvas  given.  A  third  blood  sample  Nvas  received 
five  weeks  later  when  the  results  of  sentin  cholincsternso 
435  mU/ml,  DN  =--  44,  FN  =  35  and  Cl  N=  30  were  obtained  and 
1.1  f 
ater  indicated  that  the  patient's  phenotype  was  El  E1L, 
assays  confirmed  this  phenotype  just  as,  repeated  assays  of 
the  first  two  specimens  yielded  the  original  anomalous 
results.  The  change  in  inhibitor  numbers  was  paralleled 
by  alterations  in  the  temperature-activity  relationships 
(Figure  67). 
The  second  case  originated  in  identical  circumstances 
and  the  first  determinations  gave  serum  cholinesterase 
175  mU/ml,  DN  =  30,  FN  =  34  and  Cl  N=  39  figures  which 
did  not  correlate  with  any  phenotype  but  most  closely 
resembled  those  of  EaEa  As  before  a  later  specimen  11 M.  McF. 
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Figure  67.  Temperature/activitY  curves  for  the  serum  cholinesterase 
of  the  first  pregnancy  case  (page  123)  at  different 
times.  The  specimen  dated  5.3.69  was  taken  on  the  day 
of  delivery. 124 
indicated  a  phenotype  EaEf  with  cholinesterase  activity  11 
375  mU/ml,  DN  =  45,  FN  =  37,  Cl  N=  31  and  Scoline  number  50. 
Chloroform  had  been  part  of  the  anaesthetic  regime  in 
the  first  case  and  without  any  real  conviction  had  been 
postulated  as  the  cause  of  the  anomalous  inhibitor  numbers. 
Chloroform  was  not  employed  with  the  second  patient  and 
the  anomalous  inhibitions  were  attributed  generally  to  term 
pregnancy. 
It  was  this  background  which  gave  rise  to  the  comment 
(King,  McQueen  and  Morgan,  1971)  when  the  third  case 
(patient  M  of  Case  4,  page  49)  was  presented  that  "assay 
of  her  serum  at  this  time  yielded  the  usual  anomalous 
results  associated  with  late  pregnancy".  These  restilts 
were  serum  cholinesterase  365  mU/ml,  DN  =  54,  FN  =  32  and 
C1  N=  27  which  corresponded  most  closely  to  phenotype 
Ea  Ef.  However  later,  post-partum  figures  for  cholinesterase  11 
activity  of  480  mU/ml  and  dibucaine,  fluoride  and  chloride 
numbers  of  64,36  and  28  respectively  indicated  that  she 
was  in  fact  a  fluoride-resistant  homozygote,  Ef  Ef  1  1* 
It  was  recalled  (King,  1965)  that  the  activity  of 
oxytocinase,  an  aminopeptidase,  increased  in  the  blood 
plasma  in  pregnancy,  reaching  very  high  levels  in  the  last 
trimester.  It  is  the  presence  of  this  enzyme,  which  has 
overlapping  substrate  specificities  with  leucine  amino- 
peptidase,  which  results  in  high  activities  of  the  latter 
enzyme'being  measured  in  blood  serum  in  pregnancy  (Green, 
Tsou,  Bressler  and  Seligman,  1955;  Bressler  and  Forsyth, 
1959;  Miller  and  Worsley,  1960). 
It  seemed  possible  that  the  aminopeptidase  action 125 
might  be  modifying  the  molecular  structure  of  cholincsterase 
resulting  in  the  anomalous  inhibitions.  Dr.  L.  Murray  of 
the  Glasgow  Royal  Maternity  Hospital  was  therefore  approached 
with  the  project  of  obtaining  blood  samples  at  various  times 
during  pregnancy  for  assay  of  leucine  aminopeptidase  activity, 
cholinesterase  activity  and  inhibitor  number  to  determine 
whether  and  at  what  point  these  last  altered  during  pregnancy. 
Four  hundred  and  fifteen  blood  samples  from  148  patients 
were  obtained  over  a  period  of  fourteen  months  . 
Many  of  the 
specimens  were  single  samples  and  from  other  patients  only 
two  blood  specimens  were  received.  However  from  26  patients, 
five  or  more  blood  samples  were  obtained  during  pregnancy 
and  in  13  cases  post-partum  specimens  were  also  obtained. 
While  analysis  of  the  sera  confirmed  the  pronounced  increase 
in  aminopeptidase  activity  already  mentioned  and  the  more 
modest  decrease  in  cholinesterase  activity  (Friedman,  Lapan 
and  Taylor,  1961;  Schnider,  1965;  Robertson,  1966)  in 
pregnancy,  no  change  in  inhibitor  numbers  was  found.  This 
was  in  agreement  with  the  report  by  Hazel  and  Monier  (1971) 
published  about  this  time. 
.  During  this  survey  however  a  fourth  term  pregnancy 
apnoea  with  anomalous  results  was  referred  from  Stobhill 
Hospital.  The  serum  cholinesterase  was  395  mU/ml,  DN  =  65, 
FN  =  50,  C1  N=  24  and  SN  =  78  which  suggested  a  phenotype 
uaff  of  EIEI  or  less  likely  EIE1  Arrangements  were  made  to 
phenotype  close  relatives  and  on  this  occasion  the  patient's 
sera  gave  values  for  cholinesterase  of  570  mU/ml  and  of  76, 
54,21  and  86  for  dibucaine,  fluoride,  chloride  and  scoline 
numbers  respectively  which  indicated  a  usual/fluoride- 126 
uf 
resistant  heterozygote  EIE1  This  Phenotype  agreed  with 
those  of  parents  and  siblings. 
It  then  became  clear  that  the  anomalies  occurred  in 
individuals  possessing  the  fluoride-resistant  gene.  This 
accounted  for  the  negative  findings  in  the  pregnancy  survey 
in  which  only  the  usual  and  atypical  variants  had  been 
encountered. 
Attempts  were  later  made  with  sera  containing  the 
fluoride-resistant  cholinesterase  to  simulate  the  proposed 
mechanism  in  vitro  by  adding  crystalline  leucine  amino- 
peptidase  (Boehringer  Corporation,  leucine  arylamidase). 
It  was  found  however  that  addition  of  the  enzyme  caused  an 
immediate  alteration  in  all  inhibitor  numbers  which  did  not 
further  change  significantly  on  prolonged  incubation.  The 
crystalline  enzyme  is  supplied  as  a  suspension  in  3.2  1.1 
ammonium  sulphate  and  it  was  found  that  addition  of  a  simple 
3.2  M  ammonium  sulphate  solution  resulted  in  the  observed 
change  in  inhibitions. 
Dialysis  or  ultrafiltration  of  the  crystalline  enzyme 
and  subsequent  solution  in  say  50%  glycerol  may  remove  this 
last  effect  but  obviously  a  purification  of  cholinesterase 
as  achieved  by  Das  and  Liddell  (1970)  would  also  seem  indicated. 
Then,  if  changes  in  inhibitor  numbers  were  noted  on  incubation 
with  aminopeptidase  or  other  proteolytic  enzyme,  an  amino- 
acid  analysis  of  the  reaction  mixture  might  give  some  insight 
into  the  alteration  in  the  molecular  structure  of  cholinestcr- 
ase  which  brought  about  this  change  in  kinetic  behaviour. 5.  Discussion.  Conclusions  and  ProspectS. 127 
Discussion,  Conclusicins  and  Prospects 
The  studies  undertaken  in  this  project  have  produccd 
results  with  applications  and  meaningfulness  in  the  diverse 
but  connected  spheres  of  technology,  biochemistry,  physiology, 
pharmacology  and  genetics. 
Technical  and  Clinical 
For  precise  identification  of  sensitive  cholinesterase 
phenotypes  the  assay  method  of  Kalow  and  Lindsay  (1955) 
employing  a  50  VM  benzoyleholine  substrate  with  inhibition 
by  10  VII  dibucaine  (Kalow  and  Genest,  1957)  and  50  pM  sodium 
fluoride  (Harris  and  Whittaker,  1961)  at  25  0C  has  been  shown 
to  be  adequate  and  indeed  apparently  essential.  As  King  and 
Griffin  (1974)  have  pointed  out  retention  of  this  technJque 
is  certainly  not  on  the  grounds  of  case  or  speed.  The  rate 
of  hydrolysis  is  monitored  at  240  nm  which  requires  a  fairly 
sophisticated  ultraviolet  recording  spectrophotometer  with 
temperature  control,  while  the  procedure  is  somewhat  time- 
consuming  and,  by  routine  clinical  biochemistry  standards, 
demands  more  than  the  usual  technical  ability.  However  the 
studies  on  the  variation  of  benzoylcholinesterase  activity 
and  the  studies  with  other  substrates  have  not  revealed  an 
alternative  procedure  capable  of  yielding  precise  categorisation 
of  the  phenKype.  Nevertheless  these  investigations  have 
disclosed  means  of  screening  for  individuals  at  risk  to  the 
muscle-relaxant,  suxamethonium. 
By  the  use  of  thiocholine  esters  and  the  LKB  8600 
Reaction  Rate  Analyzer  it  has  been  shown  to  be  possible  to 
screen  300  patients  per  day  using  the  relative  hydrolysis 128 
rates  of  two.  substrates,  dibucaine  inhibition,  or  the  ratio 
of  hydrolysis  rates  at  two  temperatures.  The  first  two  of 
these  techniques  do  not  require  the  ability  to  alter  the 
reaction  temperature  and  can  be  achieved  by  the  standard 
instrumentation,  automated  to  a  degree  and  performed  quickly, 
simply  and  cheaply.  These  are  the  requirements  for  population 
screening. 
The  modifications  carried  out  on  the  LKB  instrumentation 
serve  to  underline  the  concept  that  the  limits  of  endeavour 
in  laboratory  medicine  must  never  be  circumscribed  by 
manufacturers.  Only  the  laboratory  worker  knows  what  is 
required  of  him  and  only  he  knows  what  he  must  have  to  carry 
this  out.  The  fact  that  the  manufacturers  of  this  instrument, 
following  publicity  attached  to  our  modificatlons,  now  offer 
a  variable  temperature  device  as  an  optional  extra,  emphasises, 
this  point  of  view.  As  it  is,  recently  introduced  alte-rnativo 
analysers  such  as  the  Vitatron  AKES  system,  the  Union- 
Carbide  Centrifichem  and  Aminco  Rotachem,  which  have  variable 
temperature  capabilities,  can  be  employed  for  chollnesterase 
screening  using  procedures  based  on  any  of  the  three  principles 
outlined  above. 
However  it  is  too  easy  to  be  blinded  by  dedication  to 
a  single  goal.  The  ability  to  carry  out  population  screening 
for  cýolinesterase  variants  would  appear  to  be  possible  as 
a  result  of  these  studies.  The  question  to  be  considered 
now  and  which  should  have  been  posed  at  the  outset,  is 
whether  screening  for  suxamethonium  sensitivity  is  desirable 
and  worthwhile.  Obviously  it  is  desirable  to  have  information 
concerning  the  sensitivity  of  a  patient  to  a  drug.  At 12S. 
present  biochemical  investigations  are  only  undertaken  after 
the  apnoeic  episode  has  occurred  and  in  a  few  laboratories 
such  as  these,  close  relatives  are  subsequently  offered 
phenotyping.  This  is  a  very  limited  screening.  As  it  is, 
the  ability  to  screen  300  patients  per  day  would  cover  all 
surgical  patients  in  the  Glasgow  Royal  Infirmary  group  of 
hospitals.  Indeed  it  can  be  estimated  that  if  screening 
were  to  be  limited  to  patients  receiving  suxamethonium, 
300  per  day  would  provide  such  discriminatory  cover  to  the 
whole  West  of  Scotland  Region,  embracing  a  population  of 
some  three  million.  Since  about  one  in  three  thousand  of 
the  population  is  of  a  predictably  sensitive  phenotype 
(Lehmann  and  Liddell,  1969)  then  on  the  average  the  proposed 
screening  programme  would  reveal  one  such  patient  every 
ten  days  of  operation.  During  this  same  period  however  one 
other  pationt  would  suffer  a  suxamethonium  apnoca  which  in 
our  present  state  of  biochemical  knowledge  and  anaesthetic 
practice  could  not  have  been  predicted  (Lehmann  and  Liddell, 
1969).  At  its  very  best  then  a  fifty  per  cent  success  rate 
is  all  that  can  be  expected  from  a  screening  programme 
for  8uxamethonium  sensitive  individuals.  Were  the  apnoeic 
episodes  to  carry  a  similar  percentage  of  fatal  outcomes, 
indeed  any  significant  percentage  of  fatalities,  then  the 
answer  to  whether  screening  is  worthwhile  would  never  have 
to  be  given  for  the  question  would  not  be  asked.  However 
today  the  phenomenon  is  well  understood  by  all  practising 
anaesthetists  and  while  it  is  the  cause  of  some  inconvenience 
and  even  prolonged,  intensive  attention  it  does  not  con- 
stitute  a  serious  major  problem  either  to  patient  or 1301 
anaesthetist..  Under  these  circumstances  it  is  debatable 
whether  mass  screening  is  more  desirable  and  worthwhile 
than  the  limited  selective  screening  currently  undertaken 
in  these  laboýatories. 
It  has  been  amply  shown  above  that  in  the  clinical 
setting  under  discussion,  that  of  suxamethonium  apnoca, 
the  standard  procedure  for  identifying  the  serum  cholinest- 
erase  variants  has  little  to  recommend  it  to  the  analyst. 
That  it  does  precisely  define  the  cholinesterase  phenotype 
is  the  sole  reason  for  its  retention  because  the  results 
obtained  are  not  always  readily  correlated  by  the  anaesthetist 
with  the  degree  of  sensitivity.  Generally  it  can  be  accepted 
that  the  lower  the  cholinesterase  activity  and  the  lower 
the  dibucaine  and  fluoride  numbers  the  longer  will  be  the 
period  of  paralysis.  However,  oven  excluding  the  507o  of 
all  apnocas  which  occur  in  the  usual  homozygote  or  heterozy- 
gotes  and  hence  are  not  predictable,  as  was  seen  from 
Figure  14  the  serum  activity  of  many  suxamethonium-sensitive 
individuals  is  in  the  normal  range  of  this  standard 
procedure  at  25  0  C.  The  studies  herein  recorded  have 
indicated  that  a  false  impression  is  obtained  of  the 
activities  of  the  most  sensitive  phenotypes  by  assay  at 
25  0C  and  a  true  index  is  only  obtained  at  37  0C  as  shown  in 
Figure  15. 
The  second  lack  of  correlation  between  enzymic  para- 
meters  and  apnoeic  response  occurs  with  the  fluoride- 
ff 
resistant  homozygote,  E1E1  This  sensitive  phenotype  is 
categorised  by  a  dibucaine  number,  and  also  chloride  and 
scoline  numbers,  of  the  same  order  as  the  non-sensitive 131 
ua  usual/atypical  heterozygote,  E,  E,  Again  the  explanation 
lies  with  the  assay  temperature  used.  Figure  35  showed 
that  the  response  to  temperature  of  the  dibucainc  inhibition 
of  the  EfEf  phenotype  is  more  pronounced  than  the  others.  11 
At  37  0  C,  the  temperature  which  the  Patient  exhibits  the 
sensitivity,  the  dibucaine  number  is  similar  to  that  of  the 
af 
predictably  sensitive  E,  E,  phenotype. 
These  temperature  studies  on  the  inhibition  of  bonzoyl- 
choline  hydrolysis  have  clearly  shown  that  accurate  tempera- 
ture  control  is  essential  for  precise  phenotype  categorisation, 
which_only  adds  to  the  technical  strictures  of  the  method. 
On  a  more  general  topic  the  finding  of  the  different 
temperature-activity  relationships  of  the  allelic  cholin, 
esterase  isoenzymes  provides  important  factual  evidonco  on 
the  vexed  problem  of  a  standard  temperature  for  clinical 
enzyme  assays  (King,  1972).  In  this  controversy  one  of  the 
first  questions  to  be  considered  is  whether  the  actual 
assay  temperature  and  the  standard  temperature  need  be  one 
and  the  same.  If  there  is  no  compulsion  for  this  then  it 
is  possible  to  conduct  an  assay  at  the  temperature  giving 
greatest  advantages  for  each  individual  enzyme  and  then 
convert  to  the  standard  temperature.  This  reduces  to  the 
question  of  whether  temperature  correction  factors  are 
feasible  and  valid.  In  the  present  instance,  although 
lengthy  and  cumbersome,  following  determination  of  the 
phenotype,  the  appropriate  correction  factors  can  be  used. 
This  however  could  not  be  done  for  varying  proportions  of 
isoenzymes  as  encountered  with  lactate  dehydrogenase  or 
alkaline  phosphatases.  The  studies  with  the  thiocholine 132 
esterd,  also  show  that  the  correction  factors  vary  with  the 
substrate  employed.  From  these  facts  it  was  concluded  that 
at  best  temperature  conversion  factors  can  only  give 
approximations  and  their  present  indiscriminate  use  should 
be  avoided.  As  a  necessary  consequence  of  this,  the  assay 
and  standard  temperatures  must  be  the  same. 
The  principle  has  been  applied  further  and  on  the 
temperature-activity  differences  between  human  serum  enzymes 
and  the  enzymes  in  commercial  quality  control  sera,  limits 
of  valid  use  of  the  latter  have  been  described  (King, 
Henderson  and  Morgan,  1972). 
The  failure  to  precisely  classify  the  allelic  variants 
at  any  tcmperattire  other  than  25  0C 
raises  questions  apart 
from  those  already  discussed  under  the  appropriate  sections, 
and  in  particular  the  basic  question  of  defining  the  variants. 
Gonetics 
I  As  the  work  of  Lehmann  and  co-workers  on  haemoglobin 
(Lehmann  and  Huntsman,  1966;  Lehmann  and  Carrell,  1969)  and 
Harris  and  colleagues  on  enzymes  (Harris,  1970)  has  shown, 
protein  polymorphism  is  the  rule  rather  than  the  exception. 
A  non-lethal-mutation  occurs,  is  passed  on  and  a  balance 
is  eventually  achieved  with  the  remainder  of  the  population. 
Such  mutations  occurring  initially  in  the  DNA  coding  may 
result  in  a  simple  substitution  of  a  single  amino-acid  at 
any  point  in  the  polypeptide  chain  with  variations  down  to 
an  incomplete  or  nonsense  chain.  The  latter  possibilities 
of  course  are  examples  of  "silent  genes".  Depending  upon 
the  change  in  properties  attending  upon  the  simple  sub- 
stitution  and  its  point  in  the  chain  diverse  alterations 1331 
in  the-three-dimensional  protein  conformation  will  result 
with  consequent  alterations  in  stability  and  enzymic 
characteristics.  In  our  present  state  of  knowledge  of 
enzymes,  unlike  haemoglobin,  we  are  not  capable  generally 
of  differentiating  such  mutations  by  specifying  the  actual 
change  in  molecular  structure.  Instead  such  variants  are 
differentiated  by  relatively  crude  procedures  such  as 
electrophoresis  or  by  precipitation,  inactivation  or 
inhibition  by  reagents,  antibodies  or  physical  means  such 
as  heat.  The  means  by  which  the  mutations  are  differentiated 
is  of  necessity  therefore  the  terms  in  which  the  mutations 
are  defined.  In  the  present  instance  the  first  allolic 
cholinesterase  isoenzyme  to  be  differentiated  from  the 
usual  was  termed  the  "atypical"  and  was  def  ined  by  its 
relative  resistance  to  inhibition  by  dibucaine  under  specific 
assay  conditions.  Sodium  fluoride  not  only  achieved  the  s-,  ime 
but  revealed  a  further  sub-differentiation  (Harris  and 
jVhittaker,  1961)  attributable  to  another  allelic  variant 
and  for  obvious  reasons  termed  the  fluoride-resistant  enzyme. 
These  mutations  were  therefore  defined  in  terms  of  the 
inhibition  of  50  pll  benzoylcholine  hydrolysis.  in  phosphate 
buffer  of  pIl  7.4  at,  or  near,  25  0C  by  10  11M  dibticaine  or 
50  VM  fluoride.  In  view  of  the  interdependence  of  all 
factors  influencing  enzyme  activity  it  would  be  most  unlikely 
therefore  if  the  definition  of  the  allelic  isoenzymes  were 
retained  when  the  conditions  of  determination  were  altered. 
Since  dibucaine  and  succiny1dicholine  act  as  simple 
competitive  inhibitors  it  is  possible  by  manipulating 
substrate  and  inhibitor  concentrations  to  maintain  the 1341 
definit-ive  inhibitions  at  other  temperatures  and  with  other 
substrates.  However  these  studies  have  shown  (Figures  56  - 
58)  that  the  inhibition  by  fluoride  is  complex  and  this  in 
conjunction  with  the  profound  effect  of  temperature  on  the 
I 
inhibition  (Figure  39)  is  responsible  for  the  failure  to 
precisely  differentiate  the  mutations  other  than  under  the 
definition  conditions. 
By  the  use  of  other  inhibitors  such  as  chloride 
(Whittaker,  1968b;  King  and  Dixon,  1970),  formaldehyde 
(Whittaker,  1969)  and  n-butyl  alcohol  (Whittaker,  1968a) 
the  presence  of  further  variants  has  been  postulated.  From 
these  present  investigations  the  correlations  between 
succinyldicholine  inhibition  and  others  (Figures  23  to  28) 
tend  to  support  this  and  reasoning  from  other  similar  protein 
mutations  strongly  advises  that  a  large  number  of  structurally 
similar  cholinesterases  exist.  This  proposition  did  not  gain 
any  support  from  the  family  survey  on  the  Jsland  of  Scalpay. 
However  if  the  original  postulate  is  correct  then  starting 
with  the  mother  and  father  it  is  possible  that  two  different 
usual  and  two  different  atypical  genes  were  segregating 
between  the  propositus  and  his  siblings.  Only  in  the  homozy- 
gote,  usual  or  atypical,  can  the  genetic  compositions  be 
identical  but  the  numbers,  four  atypical  homozygotes  is  too 
small  to  draw  any  conclusions  from  the  narrow  scatter  of 
inhibitor  numbers  obtained  (Table  16). 
The  postulate  that  there  is  a  quantitative  genetic 
control  of  serum  cholinesterase  (Wetstone,  11oneyman  and 
McComb,  1965)  in  addition  to  the  well  established  qualitative 
I 
control  receives  no  support  from  these  investigations. 13  r,, 
I 
Certainly  the  mechanisms  which  control  type  need  not  control 
amount  but  if  the  mechanism  controlling  quantitative  pro- 
duction  is  uncoupled  from  that  controlling  type  then  it  is 
to  be  expected  that  the  rate  of  syntheis  of  the  two  allelic 
proteins  will  be  separately  affected.  The  thermodynamic 
data  herein  derived  suggests  that  quantitatively  there  is 
equal  gene  synthesis.  This  can  only  be  accepted  as  a  mean 
or  average  assessment  however  since  the  values  used  in  the 
calculations  were  such  themselves.  Reasoned  extrapolation 
from  other  enzymes  would  make  it  seem  more  likely  that  the 
quantitative  differences  observed  in  serum  cholinesterase 
activities  in  a  normal  population  are  mediated  by  environ- 
mental  and  hormonal  rather  than  genetic  influences.  As 
discussed  earlier  the  numerically  large  values  attached  to 
serum  cholinesterase  activity  are  a  reflection  of  its,  11serum 
specificity"  and  the  relative  range  span,  that  is,  the  ratio 
of  upper  to  lower  limits  of  normal  actiity,  is  small  compared 
to  other  enzymes. 
Pharmacology 
The  problems  associated  with  the  mixing  of  depolarising, 
and  non-depolarising  relaxants  are  well  surmnarised  by  Wylie 
and  Churchill-Davidson  (1972).  However  the  literature  does 
not  appear  to  contain  any  report  of  the  inhibition  of  cholin- 
esterase  by  the  non-depolarising  relaxant,  pancuronium,  and 
thus  finding  would  theoretically  appear  to  further  Complicate 
anaesthetic  practice. 
This  initial  finding  of  cholinesterase  inhibition  by 
pancuronium  related  to  benzoylcholine  hydrolysis  but  was 
also  found  with  an  acetylthiocholine  substrate  and  would 136 
therefore  appear  to  be  a  true  anti  cholinesterase  action. 
While  an  ant  iacetylchol  inest  erase  activity  has  also  been 
shown  (Figure  59)  this  effect  only  occurred  in  vitro  at 
concentrations  not  likely  to  be  obtained  in  blood.  However 
it  is  stated  that  a  concentration  of  10- 
5M 
pancuronium  is 
required  at  the  neuromuscular  junction  for  blockade  (Goodman 
and  Gilman,  1970)  and  at  this  concentration  there  is  some 
inhibition  of  acety1cholinesterase  with  consequent  depolaris- 
ing  action.  The  manufacturer's  data  (Organon  Laboratories) 
states  that  the  maximum  effect  is  evident  after  2-21  minutes 
and,  depending  upon  dosage  and  anaesthetic  techniques,  lasts 
about  45  minutes.  On  the  results  of  the  experiments 
described  herein  it  would  certainly  seem  ill-advised  to 
administer  pancuronium  before  suxamethonium  since  the 
pancuronium  inhibition,  particularly  of  the  usual  homozygote, 
would  reduce  the  hydrolysis  of  the  suxamethonium.  Even 
administration  of  pancuronium  after  suxamethonium  but  before 
-the  effects  of  the  latter  had  passed  off,  would  seem  to  be 
less  than  ideal. 
On  these  in  vitro  experiments  it  is  difficult  to 
understand  why  a  partial  "dual  block"  is  not  obtained  by 
administration  of  pancuronium  alone.  When  both  relaxants 
are  administered  it  is  apparently  standard  anaesthetic 
practice  to  give  suxamethonium  first  and  one  is  assured  that 
no  untoward  reactions  are  obtained  under  these  circumstances. 
In  only  two  cases  of  "Scoline  apnoeall  among  the  many  which 
are  of  non-predictably  sensitive  phenotype,  one  a  usual 
homozygote  and  one  an  atypical  heteroxygote  was  it  found 
that  pancuronium  had  been  administered  and  in  the  accepted 
sequence. 1371 
Bioclýemlstry  and  Physiolog 
Paigen  (1971)  stated  "The  most  sensitive  and  accurate 
test  for  changes  in  protein 
structure  is  relative  thermo- 
stability.  The  probability  that 
a  random  aminoacid  substitution 
produces  a  protein  with  altered 
thermolability  is  more  than  50c,,  o 
This  probability  is  higher  than 
for  any  other  test,  and  the 
necessary  measurements  can 
generally  be  made  with  consider- 
able  accuracy  in  dilute  solutions 
of  crude  enzyme". 
By  "thermolability"  Paigen  obviously  referred  to 
denaturation  by  incubation  at  a  set  temperature  and  the 
sensitivity  of  this  has  been  demonstrated  by  Walsh,  Lowell 
and  Neurath  (1966)  in  two  carboxypeptidase  A  allelomorphs 
differing  only  in  the  antepenultimate  C-terminal  aminoacid 
residue  and  by  Langridge  (1968)  in  induced  muttations  of  the 
0-galactosidase  of  E.  Coli.  However  as  far  as  the  writor  is 
aware  the  experiments  described  herein  are  the  first  in 
which  differential  temperature  analysis  has  been  employed 
in  the  recognition  of  enzyme  molecular  forms.  The  principle 
has  considerable  potential.  King  (1972)  has  suggested  that 
it  could  be  applied  to  other  enzyme  species  and  in  fact  har. 
used  it  in  differentiating  human  macroamylase  from  the 
normal  a-amylase  (Henderson,  King  and  Imrie,  1973;  Imrie, 
King  and  Henderson,  1973). 
The  studies  on  the  hydrolysis  rates  of  the  thiocholin- 
esters  would  indicate  that  the  relative  affinity  for  butyryl- 
thiocholine  shown  by  the  usual  enzyme  is  not  shared  by  the 
fluoride-resistant  variant  and  less  so  by  the  atypical 
isoenzyme.  Indeed  the  last  shows  almost  equal  activity  with 
acetylthiocholine  and  butyrylthiocholine  (Figure  61)  almost 1381 
a  tendency  towards  the  substrate  specificities  of  acetyl- 
cholinesterase.  The  similarity  in  the  inhibition  by 
pancuronium  of  the  atypical  homozygote  and  erythrocyte 
acetyleholinesterase  (Figure  59)  offers  support  to  this 
premise.  If  therefore  as  has  been  suggested  (Jamieson, 
1963;  Koelle,  1963)  the  phy.  §iological  role  of  cholinesterase 
is  not  dissimilar  to  that  of  acety1cholinesterase  then  the 
atypical  homozygote  is  at'no  disadvantage  in  normal  circim- 
stances.  Indeed  the  enzyme  will  function  at  substrate 
concentrations  not  only  inhibitory  to  acetylcholinesterase 
but  even  to  the  usual  varianý  although  it  is  highly  improbable 
that  such  concentrations  will  be  found  in  vivo. 
The  principle  of  differential  substrate  analysis 
illustrated  by  the  above  thiocholine  ester  studies  (Figure 
61)  has  been  employed  with  pyruvate  and  2-oxobutyrate  as 
substrates  for  lactate  dehydrogenase  (Wilkinson,  1972).  In 
these  laboratories  this  has  been  extended  by  the  use  of 
hydroxypyruvate  (McQueen  and  King,  1971a,  b)  and  glyoxylate 
(King,  Young  and  Naghizadeh,  1973;  Young,  Naghizadeh,  King 
and  Morgan,  1973). 
_Speculations 
and  Prospects 
In  their  erudite  review  of  the  mechanism  of  hydrolysis 
by  cholinesterase  Davies  and  Green  (1958)  critically  examined 
the  kinetic  evidence  available  and  convincingly  concluded 
that  histidine  was  present  in  the  anionic  active  site  of 
cholinesterase. 
With  regard  to  the  allelic  cholinesterase  isoenzymes 
the  difference  in  substrate  and  inhibitor  specificities  is 
most  evident  with  positively  charged  compounds  (Kalow  and 13 
Davies,  1958;  Davies,  Marton  and  Kalow,  1960) 
differences  in  the  anionic  sites.  Harris  and 
(1963)  have  pointed  out  that  the  differe  . ntial 
fluoride  and  high  concentrations  of  chloride 
necessarily  conflict  with  this  view. 
Most  mutations  result  from  single-point 
indicating 
Whittaker 
inhibition  by 
does  not 
DNA  transitions 
or  transversions  and  Epstein  (1967)  has  pointed  out  that 
this  generally  results  in  an  aminoacid  substitution  which 
conserves  the  properties  of  the  polypeptide.  In  this  particular 
instance  this  proposition  gains  support  from  the  lack  of 
difference  in  electrophoretic  mobilities  of  the  variants 
which  in  itself  could  suggest  the  substitution  of  an  aminoacid 
with  unionised  side  chain  being  substituted  by  another  or 
by  one  the  side  chain  of  which  is  uncharged  at  p1I  8.6.  The 
imidazole  side  chain  of  histidine  is  uncharged  at  p1l  S.  6 
the  p1l  at  which  protein  electrophoresis  is  usually  performed. 
Equally  well  the  substitution  could  be  for  histidino  and  the 
clectrophoretic  separation  of  the  variants  at  p1l  9.7  (Liddell, 
Lehmann,  Davies  and  Shank,  1962)  would  require  the  substituent 
side  chain  to  have  a  less  negative  charge  than  imidazole  at 
this  p1I. 
Photo-oxidation  in  the  presence  of  methylene  blue 
which  specifically  decomposes  histidine  and  tryptophan  was 
used  in  demonstrating  a  functional  role  for  imidazole  groups 
in  chymotrypsin,  (Cohen  and  Oosterbaan,  1963).  This  pro- 
cedare  or  the  blocking  of  the  imidazole  ring  by  selective 
sulphonylation  below  pIl  5  should  elucidate  this  possibility. 
If  histidine  has  a  function  in  the  cholinesterase  active 
site  then  photo-oxidation  or  sulphonylation  would  destroy I 
or  impair  the  activity  of  usual  homo:,  ýygote  sera.  If 
substitution  of  the  histidine  i.  --;  the  mutation  which  results 
in  the  inhibitor-resistant  varinnts  then  such  homozygous 
sera  would  be  unaffected,  unless  of  course  using  the  photo- 
oxidation  process,  tryptophan  were  the  substituent. 
Accepting  the  above  circumstantial  evidence  that 
histidine  is  a  functional  component  of  the  active  site  of 
cholinesterase  and  further  that  the  allelic  variants  arise 
from  its  substitution  there  are  seven  possible  one-point 
transitions  and  transversions  which  could  occur  in  its 
genetic  coding  (CA  -  C/U).  These  mutations  could  result  in 
substitutions  by  aspartic  acid  (GA  -  C/U),  tyrosine  (UA  -  C/U), 
arginine  (CG  -  C/U),  proline  (CC  -  C/U),  'Ieucine  (CU  -  C/U), 
asparagine  (AA  -  C/U)  and  glutamine  (CA  -  G/A).  Tryptophan 
is  not  a  possible  substitution  from  a  single-point  mutation. 
Of  the  possible  substituents  it  can  be  reasoned  that  the  first 
four  would  not  have  uncharged  side-chains  at  pH  8.6  and  less 
negative  dharges  than  imidazole  at  pil  9.7.  Tile  al:  Lphatic 
side  chain  of  leucine  and  the  amides  of  asparagine  and 
glutamine  do  fulfill  both  conditions. 
The  finding  of  anomalous  inhibitor  numbers  at  term 
pregnancy  in  patients  possessing  the  fluoride-resistant 
gene  is  important  as  this  constitutes  the  first  recording 
of  a  cholinesteraso  mutation  outside  the  control  of  the 
structural  gene.  Since  this  modification  apparently  only 
occurs  in  the  fluoride-resistant  enzyme  this  is  further  proof 
that  there  is  a  structural  differenco  between  this  variant 
and  the  others.  Further  if  the  po.,;  tulate  is  correct  that  the 
fluoride-resistant  molecule  is  modtfiod  by  the  action  of 141 
oxytocinase  then  since  the  aminopeptidase  only  splits  off 
N-terminal  residues  it  is  in  this  position  that  the  fluoride- 
resistant  variant  differs  from  the  usual  and  atypical  iso- 
enzymes. 
Again,  oxytocinase  has  a  high  affinity  for  N-terminal 
cystine;  leucine  aminopeptidase  for  leucine  but  also  for 
phenylalanine,  tyrosine,  histidine  and  tryptophan.  If 
therefore  the  future  studies  proposed  with  leucine  amino- 
peptidase  (page  126)  do  not  yield  similar  alterations  in 
inhibition  characteristics  as  found  in  term-pregnancy  this 
could  constitute  evidence  that  the  N-terminal  residue  was 
not  an  amino-acid  readily  attacked  by  leucine  aminopeptidase. 6.  References. 142 
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